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A B S T R A C T
Background
Non-absorbable disaccharides (lactulose and lactitol) are recommended as first-line treatment for hepatic encephalopathy. The previous
(second) version of this review included 10 randomised clinical trials (RCTs) evaluating non-absorbable disaccharides versus placebo/
no intervention and eight RCTs evaluating lactulose versus lactitol for people with cirrhosis and hepatic encephalopathy. The review
found no evidence to either support or refute the use of the non-absorbable disaccharides and no differences between lactulose versus
lactitol.
Objectives
To assess the beneficial and harmful effects of i) non-absorbable disaccharides versus placebo/no intervention and ii) lactulose versus
lactitol in people with cirrhosis and hepatic encephalopathy.
Search methods
We carried out electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register
of Controlled Trials (CENTRAL 2015, Issue 10), MEDLINE, EMBASE, and Science Citation Index Expanded to 19 October
2015; manual searches of meetings and conference proceedings; checks of bibliographies; and correspondence with investigators and
pharmaceutical companies.
Selection criteria
We included RCTs, irrespective of publication status, language, or blinding.
Data collection and analysis
Two review authors, working independently, retrieved data from published reports and correspondence with investigators. The primary
outcomes were mortality, hepatic encephalopathy, and serious adverse events. We presented the results of meta-analyses as risk ratios
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(RR) and mean differences (MD) with 95% confidence intervals (CI). We assessed the quality of the evidence using ’Grading of
Recommendations Assessment Development and Evaluation’ (GRADE) and bias control using the Cochrane Hepato-Biliary Group
domains. Our analyses included regression analyses of publication bias and other small study effects, Trial Sequential Analyses to detect
type 1 and type 2 errors, and subgroup and sensitivity analyses.
Main results
We included 38 RCTs with a total of 1828 participants. Eight RCTs had a low risk of bias in the assessment of mortality. All trials
had a high risk of bias in the assessment of the remaining outcomes. Random-effects meta-analysis showed a beneficial effect of non-
absorbable disaccharides versus placebo/no intervention on mortality when including all RCTs with extractable data (RR 0.59, 95%
CI 0.40 to 0.87; 1487 participants; 24 RCTs; I2 = 0%; moderate quality evidence) and in the eight RCTs with a low risk of bias (RR
0.63, 95% CI 0.41 to 0.97; 705 participants). The Trial Sequential Analysis with the relative risk reduction (RRR) reduced to 30%
confirmed the findings when including all RCTs, but not when including only RCTs with a low risk of bias or when we reduced the
RRR to 22%. Compared with placebo/no intervention, the non-absorbable disaccharides were associated with beneficial effects on
hepatic encephalopathy (RR 0.58, 95% CI 0.50 to 0.69; 1415 participants; 22 RCTs; I2 = 32%; moderate quality evidence). Additional
analyses showed that non-absorbable disaccharides can help to reduce serious adverse events associated with the underlying liver disease
including liver failure, hepatorenal syndrome, and variceal bleeding (RR 0.47, 95% CI 0.36 to 0.60; 1487 participants; 24 RCTs; I
2 = 0%; moderate quality evidence). We confirmed the results in Trial Sequential Analysis. Tests for subgroup differences showed no
statistical differences between RCTs evaluating prevention, overt, or minimal hepatic encephalopathy. The evaluation of secondary
outcomes showed a potential beneficial effect of the non-absorbable disaccharides on quality of life, but we were not able to include
the data in an overall meta-analysis (very low quality evidence). Non-absorbable disaccharides were associated with non-serious (mainly
gastrointestinal) adverse events (very low quality evidence). None of the RCTs comparing lactulose versus lactitol evaluated quality of
life. The review found no differences between lactulose and lactitol for the remaining outcomes (very low quality evidence).
Authors’ conclusions
This review includes a large number of RCTs evaluating the prevention or treatment of hepatic encephalopathy. The analyses found
evidence that non-absorbable disaccharides may be associated with a beneficial effect on clinically relevant outcomes compared with
placebo/no intervention.
P L A I N L A N G U A G E S U M M A R Y
Are non-absorbable disaccharides associated with beneficial or harmful effects in people with cirrhosis and hepatic encephalopa-
thy?
Background
Cirrhosis is a chronic disorder of the liver. People with cirrhosis may develop hepatic encephalopathy, a condition that results in poor
brain functioning. Hepatic encephalopathy may be clinically obvious (overt) with changes including poor concentration, tremor, and
alterations in consciousness. Others have no obvious clinical changes (minimal) but, when tested, some aspects of brain function such
as attention and the ability to perform complex tasks are impaired.
The reason why people develop hepatic encephalopathy is complex. The accumulation of ammonia plays a key role. The non-absorbable
disaccharides, lactulose and lactitol, are indigestible sugars that reduce the levels of ammonia in the blood.
Review question
We investigated the use of non-absorbable disaccharides for the prevention and treatment of hepatic encephalopathy in people with
cirrhosis by reviewing randomised clinical trials (RCTs).
Search date
The search date was October 2015.
Study funding sources
Seven RCTs received financial support and 11 RCTs received lactitol or inactive placebo free of charge from a pharmaceutical company.
Study characteristics
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We included 29 RCTs comparing non-absorbable disaccharides with inactive placebo or no intervention and nine RCTs comparing
lactulose with lactitol. Seven of the included RCTs evaluated the prevention of hepatic encephalopathy and 31 evaluated the treatment
of hepatic encephalopathy. Sixteen of the treatment RCTs included people with overt hepatic encephalopathy while 15 included people
with minimal hepatic encephalopathy. The duration of treatment varied depending on the type of hepatic encephalopathy from five
days to one year.
Key results
People who received non-absorbable disaccharides were less likely to die than people given a placebo or no treatment. They were also
less likely to develop serious complications of their liver disease such as liver failure, bleeding, and infections. The non-absorbable
disaccharides were also effective in preventing the development of hepatic encephalopathy and increased the number of participants
who recovered from hepatic encephalopathy. There was some evidence from a small number of trials that lactulose has a beneficial effect
on the quality of life, but we were unable to include the data in an overall analysis. The non-absorbable disaccharides were associated
with adverse events including diarrhoea, nausea, bloating, and flatulence. None of the RCTs comparing lactulose versus lactitol reported
quality of life. The analyses showed no differences between the two interventions for the remaining outcomes.
Quality of the evidence
In the comparison of non-absorbable disaccharides versus placebo/no intervention, we found moderate quality evidence of benefit for
the outcomes of death, hepatic encephalopathy, and serious complications. The evidence for the remaining outcomes was of very low
quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Non-absorbable disaccharides versus placebo/ no intervention for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
Population: prevent ion and treatment of hepat ic encephalopathy in people with cirrhosis
Intervention: non-absorbable disaccharides (lactulose and lact itol)
Control: placebo/ no intervent ion
Setting: in-hospital (overt hepat ic encephalopathy) and outpat ient (m inimal hepat ic encephalopathy and prevent ion trials)
Duration of follow-up: the durat ion depended on the type of encephalopathy with 5 days for acute, 74 days for chronic, 70 days for m inimal, and 207 days for prevent ion of
hepat ic encephalopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Non-absorbable disac-
charides
versus placebo/ no in-
tervention
M ortality Study population RR 0.59 (0.40 to 0.
87) when including all
RCTs; RR 0.63 (0.41
to 0.97) when including
RCTs with a low risk of
bias
1487
(24 studies)
⊕⊕⊕©
moderate1
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found a ben-
ef icial ef fect of the in-
tervent ion including all
RCTs, but when the
analysis only included
RCTs with a low risk of
bias
Assessment method:
Assessed based on the
total number of part ici-
pants who died
88 per 1000 49 per 1000
(32 to 75)
M oderate
20 per 1000 11 per 1000
(7 to 17)
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Hepatic encephalopa-
thy
Study population RR 0.58
(0.5 to 0.69)
1415
(22 studies)
⊕⊕⊕©
moderate2
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found a ben-
ef icial ef fect of the in-
tervent ion including all
RCTs, but when the
analysis only included
RCTs with a low risk of
bias
Assessment method:
Assessed based on the
def init ions in included
RCTs (number of par-
t icipants without a clin-
ically relevant improve-
ment of hepat ic en-
cephalopathy)
469 per 1000 272 per 1000
(234 to 323)
M oderate
423 per 1000 245 per 1000
(211 to 292)
Serious adverse events Study population RR 0.47
(0.36 to 0.6)
1487
(24 studies)
⊕⊕⊕©
moderate3
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found a ben-
ef icial ef fect of the in-
tervent ion including all
RCTs, but when the
analysis only included
RCTs with a low risk of
bias
Assessment method:
Assessed and def ined
as any untoward medi-
cal occurrence that led
to death, was lif e threat-
ening, or required hos-
pitalisat ion or prolon-
5
N
o
n
-a
b
so
rb
a
b
le
d
isa
c
c
h
a
rid
e
s
v
e
rsu
s
p
la
c
e
b
o
/n
o
in
te
r
v
e
n
tio
n
a
n
d
la
c
tu
lo
se
v
e
rsu
s
la
c
tito
l
fo
r
th
e
p
re
v
e
n
tio
n
a
n
d
tre
a
tm
e
n
t
o
f
h
e
p
a
tic
e
n
c
e
p
h
a
lo
p
a
th
y
in
p
e
o
p
le
w
ith
c
irrh
o
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
gat ion of hospitalisa-
t ion (ICH-GCP 2007).
207 per 1000 97 per 1000
(75 to 124)
M oderate
142 per 1000 67 per 1000
(51 to 85)
Quality of life (sec-
ondary outcome)
No overall est imate
available
⊕©©©
very low4
We were unable to com-
bine the data into an
overall analysis due to
unacceptably high het-
erogeneity
Assessment method:
Based on the quality of
lif e quest ionnaires.
Non-serious adverse
events (secondary out-
come)
Study population RR 2.47
(1.24 to 4.93)
739
(9 studies)
⊕©©©
very low5
Assessment method:
The outcome includes
all adverse events that
do not fulf il the criteria
for ’serious’ (ICH-GCP
2007).
106 per 1000 261 per 1000
(131 to 521)
M oderate
63 per 1000 156 per 1000
(78 to 311)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RCT: randomised clinical trial; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Mortality is downgraded one level to ’moderate quality evidence’ because the Trial Sequent ial Analysis found insuf f icient
evidence when we lim ited the analysis to include only RCTs with a low risk of bias.
2Hepatic encephalopathy is downgraded one level to ’moderate quality evidence’ because none of the RCTs had a low risk of bias
in the overall assessment.
3Serious adverse events is downgraded one level to ’moderate quality evidence’ because none of the RCTs had a low risk of bias
in the overall assessment.
4Quality of lif e is downgraded three levels to ’very low quality evidence’ because i) none of the included RCTs had a low risk of
bias, ii) the heterogeneity was considerable, and iii) we were unable to combine the data in an overall analysis.
5Non-serious adverse events is downgraded three levels to ’very low quality evidence’ because i) none of the included RCTs had
a low risk of bias, ii) the conf idence intervals were wide (uncertainty), and iii) we were only able to include data f rom nine
RCTs in our meta-analysis.
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B A C K G R O U N D
Description of the condition
The term hepatic encephalopathy refers to a spectrum of neu-
ropsychiatric changes occurring in people with liver disease. The
joint guideline from the European and American Associations
for the Study of the Liver defines hepatic encephalopathy as a
brain dysfunction associated with liver insufficiency or portal
systemic shunting (EASL and AASLD guideline 2014a; EASL
and AASLD guideline 2014b). Clinically apparent or overt hep-
atic encephalopathy manifests as a neuropsychiatric syndrome
encompassing a wide spectrum of mental and motor disorders
(Weissenborn 1998; Ferenci 2002). Events such as gastrointesti-
nal bleeding, infection, and alcohol misuse can trigger this so-
called acute or episodic hepatic encephalopathy. Fifty per cent of in-
stances occur with no obvious cause. Episodes may recur. Between
episodes, people may return to their baseline neuropsychiatric sta-
tus or show clinical evidence of impairment (Bajaj 2010b). Less
frequently, people present with persistent neuropsychiatric abnor-
malities, which are always present to some degree, but may vary
in seriousness. Often people with persistent abnormalities have
extensive spontaneous portal-systemic shunting or else a surgically
created or transjugular intrahepatic portosystemic shunt (TIPS).
Changes in mental state range from subtle alterations in personal-
ity, intellectual capacity, and cognitive function to more profound
alterations in consciousness leading to deep coma with decere-
brate posturing. The changes in motor functionmay include rigid-
ity, disorders of speech production, resting- and movement-in-
duced tremor, asterixis, delayed diadochocinetic movements, hy-
perreflexia, hyporeflexia, choreoathetoid movements, Babinsky’s
sign, and transient focal symptoms (Victor 1965; Weissenborn
1998; Cadranel 2001). Asterixis (flapping tremor) is the best
known motor abnormality. Individuals with overt hepatic en-
cephalopathy also show a wide spectrum of other abnormalities,
including impaired psychometric performance (Schomerus 1998),
disturbed neurophysiological function (Parsons-Smith 1957; Chu
1997), altered cerebral neurochemical/neurotransmitter home-
ostasis (Taylor-Robinson 1994), reductions in global and re-
gional cerebral blood flow and metabolism (O’Carroll 1991), and
changes in cerebral fluid homeostasis (Haussinger 2000). In gen-
eral, the degree of impairment in these parameters increases as
the clinical condition worsens. The term minimal hepatic en-
cephalopathy (in the older literature subclinical or latent) refers to
people with cirrhosis who are ’clinically normal’, but who show
abnormalities in neuropsychometric or neurophysiological perfor-
mance (Ferenci 2002).
The diagnosis of hepatic encephalopathy may present no prob-
lems, but without the background information and an obvious
precipitating event, it may go unrecognised. We have no gold stan-
dard for the diagnosis (Montagnese 2004), but techniques that we
can use singly or in combination. The diagnosis or exclusion of
overt hepatic encephalopathy should include a careful and detailed
neuropsychiatric history and examination (Montagnese 2004),
with particular attention paid to changes in memory, concentra-
tion, cognition, and consciousness. Clinicians and researchers of-
ten use the West Haven Criteria to grade mental state (Conn
1977), and the Glasgow Coma Score to grade the level of con-
sciousness (Teasdale 1974). The neurological examination should
be comprehensive, looking particularly for evidence of subtle mo-
tor abnormalities. The assessment should consider and exclude
other potential causes of neuropsychiatric abnormalities including
concomitant neurological disorders and metabolic abnormalities
such as those associated with diabetes, renal failure, drug, or al-
cohol intoxication. People with hepatic encephalopathy have im-
paired psychometric performance (Montagnese 2004; Randolph
2009). Those with minimal hepatic encephalopathy show deficits
in attention, visuo-spatial abilities, fine motor skills, and memory
while their other cognitive functions are relatively well preserved.
People with overt hepatic encephalopathy show additional distur-
bances in psychomotor speed, executive function, and concentra-
tion. Psychometric test batteries to assess cognitive function form
part of the evaluation. The Psychometric Hepatic Encephalopathy
Score has a high specificity for the diagnosis (Schomerus 1998;
Weissenborn 2001). The test employs five paper and pencil tests to
assess attention, visual perception and visuo-constructive abilities.
Test scores have to be normalised to take account of factors such as
age, gender, and educational level. At present, normative databases
are available in Germany, Italy, Denmark, Spain, Mexico, Korea,
India, and Great Britain.
People with hepatic encephalopathy may have a number of neuro-
physiological abnormalities (Guérit 2009). The electroencephalo-
gram, which primarily reflects cortical neuronal activity, may show
progressive slowing of the background activity and abnormal wave
morphology. Recent advances in electroencephalogram analysis
should provide better quantifiable and more informative data.
Other potential diagnostic techniques include the Critical Flicker
Fusion Frequency (Kircheis 2002), and the Inhibitory Control
Test (Bajaj 2008). The tests need further validation. Studies us-
ing structural and functional cerebral imaging techniques have
helped to unravel the pathophysiology of hepatic encephalopathy,
but they currently offer little diagnostically (Grover 2006; Berding
2009).
Description of the intervention
The non-absorbable disaccharides lactulose and lactitol are poorly
absorbed sugars, which act as osmotic laxatives in the treat-
ment of constipation (Johanson 2007; Miller 2014). Lactulose
(Montgomery 1929) is dispensed as a syrup, which is contami-
nated with other sugars; a pure crystalline preparation is also avail-
able. Lactitol, a second-generation disaccharide, is dispensed as a
powder. The mode of administration is generally enteral.
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How the intervention might work
The exact pathogenesis of hepatic encephalopathy is unknown.
Ammonia plays a key role (Butterworth 2014). The main sources
of ammonia include nitrogenous products in the diet, bacterial
metabolism of urea and proteins in the colon, and deamination
of glutamine in the small intestine. Non-absorbable disaccharides
lower ammonia levels through a number of mechanisms: (i) a lax-
ative effect: the colonic metabolism of lactulose and lactitol results
in an increase in intraluminal gas formation, an increase in intra-
luminal osmolality, a reduction in intraluminal pH, and an overall
decrease in transit time; (ii) bacterial uptake of ammonia: the intra-
luminal changes in pH result in a leaching of ammonia from the
circulation into the colon. The colonic bacteria use the released
volatile fatty acids as substrate and proliferate. In doing so, they
use the trapped colonic ammonia as a nitrogen source for protein
synthesis. The increase in bacterial numbers additionally ’bulks’
the stool and contributes to the cathartic effect; (iii) reduction of
intestinal ammonia production: non-absorbable disaccharides in-
hibit glutaminase activity and interfere with the intestinal uptake
of glutamine and its subsequent metabolism to ammonia; (iv)
beneficial effects on the gut microbiome: cirrhosis is associated with
dysbiosis and changes in the colonic mucosal microbiome (Qin
2014). Further changes may be observed in patients with hepatic
encephalopathy(Bajaj 2012). Non-absorbable disaccharides can
beneficially affect microbiota composition (Riggio 1990b; Bajaj
2012).
Why it is important to do this review
The prevalence of hepatic encephalopathy varies. About 10%
to 14% have overt hepatic encephalopathy when first diagnosed
with cirrhosis (Saunders 1981). In studies in people with decom-
pensated cirrhosis, about 20% have overt hepatic encephalopa-
thy (D’Amico 1986; de Jongh 1992; Zipprich 2012). The cu-
mulated incidence of overt hepatic encephalopathy is as high as
40% (Randolph 2009; Bajaj 2011a). The prevalence of minimal
hepatic encephalopathy varies in different studies, but it may be
more than 50% or higher in people with previous overt hepatic
encephalopathy (Sharma 2010; Lauridsen 2011). The presence of
hepatic encephalopathy, whether minimal or overt, is associated
with significant impairment in the performance of complex tasks,
such as driving (Schomerus 1981; Bajaj 2009; Kircheis 2009). The
condition is also associated with a detrimental effect on quality of
life (Groeneweg 1998) and safety (Roman 2011). In addition, the
presence of overt hepatic encephalopathy in people with cirrho-
sis awaiting liver transplantation has a detrimental effect on neu-
rocognitive function following the procedure (Sotil 2009) and on
overall survival (Bustamante 1999; D’Amico 2006; Stewart 2007;
Bajaj 2011a; Patidar 2014). The survival probability in people
with cirrhosis after their first episode of hepatic encephalopathy is
42% at one year and 23% at three years (Bustamante 1999). Thus,
more than 50% die within one year and more than 75% within
three years. Overt hepatic encephalopathy also poses a substantial
burden for the caregivers of affected people (Bajaj 2011b), and a
significant financial burden on healthcare systems (Poordad 2007;
Stepanova 2012).
Since 1966 (Bircher 1966), when lactulose was first introduced
into clinical practice, several RCTs have evaluated non-absorbable
disaccharides for hepatic encephalopathy. Previous meta-analyses
have found that lactitol may be more beneficial than lactulose
(Blanc 1992), or that lactulose and lactitol had comparable ef-
fects (Camma 1993). The previous versions of this review did not
find sufficient evidence to recommend lactulose or lactitol for rou-
tine clinical use in people with cirrhosis and hepatic encephalopa-
thy (Als-Nielsen 2000; Als-Nielsen 2004a; Als-Nielsen 2004b;
Als-Nielsen 2005). Methodological issues including unclear bias
control and lack of statistical power weakened the strength of
the conclusions. A subsequent guideline from the European and
American Association for the Study of Liver Diseases recom-
mended lactulose as the intervention of choice for overt hepatic
encephalopathy and its secondary prevention after an index event
(EASL and AASLD guideline 2014a; EASL and AASLD guideline
2014b). The guideline did not recommend primary prevention
of encephalopathy nor the routine treatment of minimal hepatic
encephalopathy. Clinicians may consider treating minimal hep-
atic encephalopathy on a case by case basis under certain circum-
stances such as impaired driving skills, work performance, quality
of life issues, or cognitive impairment. The original Cochrane re-
view and the current European and American Associations for the
Study of the Liver guidelines provide discrepant views about the
role of lactulose. We therefore conducted this updated review.
O B J E C T I V E S
To assess the beneficial and harmful effects of i) non-absorbable
disaccharides versus placebo/no intervention and ii) lactulose ver-
sus lactitol in people with cirrhosis and hepatic encephalopathy.
To avoid overlap with another planned Cochrane review, we
did not evaluate non-absorbable disaccharides versus antibiotics
(Kimer 2015).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs, regardless of publication status, language, or
blinding.
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Types of participants
We included people with cirrhosis from RCTs on the prevention
(primary or secondary) or treatment of hepatic encephalopathy,
regardless of sex, age, aetiology of the underlying liver disease, type
of hepatic encephalopathy, or precipitating factors.
Types of interventions
The intervention comparisons were i) non-absorbable disaccha-
rides (lactulose or lactitol) versus placebo/no intervention and ii)
lactulose versus lactitol. We included RCTs, irrespective of the
doses, treatment durations, and modes of administration and al-
lowed co-interventions if administered equally to allocation trial
arms.
Types of outcome measures
We assessed all outcomes at the maximum duration of follow-up
(Gluud 2015).
Primary outcomes
1. Mortality.
2. Hepatic encephalopathy. We based our assessment of
hepatic encephalopathy on the definitions in included RCTs.
3. Serious adverse events defined as any untoward medical
occurrence that led to death, was life threatening, or required
hospitalisation or prolongation of hospitalisation (ICH-GCP
2007). We analysed serious adverse events as a composite
outcome (Gluud 2015).
Secondary outcomes
1. Quality of life.
2. Non-serious adverse events: all adverse events that did not
fulfil the criteria for a serious adverse event.
3. Surrogate outcomes: Number Connection Test results and
blood ammonia concentrations.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Hepato-Biliary Group Controlled Tri-
alsRegister, CochraneCentral Register ofControlledTrials (CEN-
TRAL), MEDLINE, EMBASE, and Science Citation Index Ex-
panded using the strategies described in Appendix 1. The last
search update was 19 October 2015.
Searching other resources
We scanned the reference lists of relevant articles and proceed-
ings from meetings of the British Society for Gastroenterology
(BSG), the British Association for the Study of the Liver (BASL),
the European Association for the Study of the Liver (EASL), the
UnitedEuropeanGastroenterologyWeek (UEGW), theAmerican
Gastroenterological Association (AGA), the American Association
for the Study of Liver Diseases (AASLD), and the International
Society for Hepatic Encephalopathy and Nitrogen Metabolism
(ISHEN). We wrote to the principal authors of RCTs and the
pharmaceutical companies involved in the production of non-
absorbable disaccharides for additional information about com-
pleted RCTs and for information about any ongoing RCTs, and
searched the database ClinicalTrials.gov (clinicaltrials.gov/) and
theWorld Health Organization (WHO) online trial meta-register
(apps.who.int/trialsearch/).
Data collection and analysis
Selection of studies
Two review authors (Lise L Gluud and Marsha Y Morgan) read
the electronic searches, performed additionalmanual searches, and
listed potentially eligible RCTs. All authors read the potentially
eligible trial reports and participated in the final selection of those
to be included in the analyses. We reached the final selection
through consensus. For RCTs reported in more than one publica-
tion, we selected the paper reporting the longest duration of fol-
low-up as the primary reference. We listed details of all included
RCTs (Characteristics of included studies) and excluded studies
(Characteristics of excluded studies).
Data extraction and management
Two review authors (Lise L Gluud and Marsha Y Morgan) inde-
pendently collected data and resolved contrary opinions through
discussion. The collected data included information on: i) RCTs:
design (cross-over or parallel), settings (number of clinical sites;
outpatient or inpatient; inclusion period), country of origin; ii)
participants: mean age, proportion of men, aetiology of cirrhosis,
type of hepatic encephalopathy, previous history of hepatic en-
cephalopathy and iii) interventions: type, dose, duration of ther-
apy, mode of administration. We gathered the primary and sec-
ondary outcome data, including the criteria used in the assess-
ment of hepatic encephalopathy, and bias control information.
A commercial translation services or medical personnel fluent
in the language translated foreign language (non-English) papers
(Acknowledgements). We requested missing data and other infor-
mation from authors of included RCTs.
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Assessment of risk of bias in included studies
We assessed bias control using the domains described in the
Cochrane Hepato-Biliary (CHB) module and classified the risk
of bias for each domain as high, unclear, or low and the overall
assessment as high or low (Gluud 2015).
Allocation sequence generation
• Low risk of bias: sequence generation achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, or throwing
dice are adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: the method of sequence generation was
not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (for
example, if the allocation sequence was hidden in sequentially
numbered, opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants, personnel, and outcome assessors
• Low risk of bias: blinding was performed adequately. We
defined lack of blinding (detection and performance bias) as not
likely to affect the assessment of the outcome mortality.
• Unclear risk of bias: there was insufficient information to
assess whether blinding was likely to induce bias in the results.
• High risk of bias: no blinding or incomplete blinding, and
the assessment of outcomes was likely to be influenced by lack of
blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The investigators
used sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses to handle missing
data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data induced bias in the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically relevant
outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we had access to the original trial protocol, the
outcomes selected were those called for in that protocol. If we
obtained information from a trial registry (such as
www.clinicaltrials.gov), we only used that information if the
investigators registered the trial before inclusion of the first
participant.
• Unclear risk of bias: not all pre-defined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial was free of industry sponsorship
or other type of for-profit support that may influence the trial
design, conduct, or results.
• Unclear risk of bias: no information on clinical trial support
or sponsorship was available.
• High risk of bias: the trial was sponsored by industry,
received support in the form of lactulose, lactitol, or placebo, or
received any other type of support.
Other bias
• Low risk of bias: the trial appeared to be free of other biases
including: medicinal dosing problems or follow-up (as defined
below).
• Unclear risk of bias: the trial may or may not have been free
of other domains that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an
inappropriate dose) or follow-up (e.g. the trial included different
follow-up schedules for participants in the allocation groups).
Overall bias assessment
• Low risk of bias: all domains were low risk of bias using the
definitions described above.
• High risk of bias: one or more of the bias domains were of
unclear or high risk of bias.
11Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Measures of treatment effect
We used risk ratios (RR) for dichotomous outcomes and the mean
differences (MD) for continuous outcomes, both with 95% con-
fidence intervals (CI). For primary outcomes, we calculated the
number needed to treat to benefit (NNTB) as 1/ risk difference
(RD) based on the highest quality evidence (RCTs with a low risk
of bias where available).
Unit of analysis issues
We included data from the first treatment period of cross-over
trials (Higgins 2011a).
Dealing with missing data
We extracted data on all randomised participants in order to allow
intention-to-treat analyses. To evaluate the importance of missing
data, we conducted a worst-case scenario analysis with simple im-
putation (Higgins 2008), with inclusion of missing outcomes as
treatment failures. We also conducted an ’extreme’ worst-case sce-
nario analysis in which we includedmissing outcome data as treat-
ment failures (intervention group) or successes (control group).
Assessment of heterogeneity
We expressed heterogeneity as I2 values using the following thresh-
olds: 0% to 40% (unimportant), 40% to 60% (moderate), 60%
to 80% (substantial), and > 80% (considerable). This information
is included in the ’Summary of findings’ tables (GRADEpro).
Assessment of reporting biases
For meta-analyses with at least 10 RCTs, we assessed reporting bi-
ases through regression analyses using the Harbord test (Harbord
2006), which regresses Z/sqrt(V) against sqrt(V), where Z is the
efficient score and V is Fisher’s information (the variance of Z
under the null hypothesis). All meta-analyses of continuous out-
comes included fewer than 10 RCTs.
Data synthesis
We performed the analyses in ReviewManager 5 (RevMan 2014),
STATA (Stata), and Trial Sequential Analysis (Thorlund 2011;
TSA 2011).
Meta-analysis
We undertook random-effects and fixed-effect meta-analyses. Al-
though the conclusion of the two models concurred, the random-
effectsmeta-analysis provides themost conservative estimate of in-
tervention effects. Therefore, we report the random-effects meta-
analyses in our results.
Trial Sequential Analysis
We performed a Trial Sequential Analysis (Higgins 2008;
Thorlund 2011), and defined the required information size (also
known as the heterogeneity adjusted required information size) as the
number of participants needed to detect or reject an intervention
effect based on the relative risk reduction (RRR) and CGR. The
analyses show firm evidence if the Z-curve crosses the monitoring
boundary (also known as the trial sequential monitoring boundary)
before reaching the required information size. We constructed fu-
tility boundaries to evaluate the uncertainty of obtaining a chance
negative finding and performed the analyses with alpha set to 5%,
power to 80%, and model-based diversity. Based on previous evi-
dence (Thorlund 2011; EASLand AASLDguideline 2014a; EASL
and AASLD guideline 2014b), we set the relative risk reduction
(RRR) to 30% and the CGR to 15% (mortality), 45% (hepatic
encephalopathy), and 30% (serious adverse events). In the analy-
sis of mortality, we conducted the analysis with inclusion of i) all
RCTs and ii) RCTs with a low risk of bias (only possible in mor-
tality analyses). We repeated the analyses with the RRR reduced
to 20% and with diversity increased by 20% (from 0% to 20%
in the analyses of mortality and serious adverse events and from
30% to 50% in the analysis of hepatic encephalopathy).
Subgroup analysis and investigation of heterogeneity
We undertook subgroup analyses to investigate the effect of non-
absorbable disaccharides in RCTs evaluating the prevention or
treatment of hepatic encephalopathy. We also evaluated hetero-
geneity based on stratification of RCTs by:
• primary or secondary prevention of hepatic encephalopathy;
• overt or minimal hepatic encephalopathy;
• acute or chronic hepatic encephalopathy.
Sensitivity analysis
Weperformed a sensitivity analysis including onlyRCTswith a low
risk of bias (as described above) and worse-case scenario analysis
as described above.
’Summary of findings’ tables
We used the GRADE system to evaluate the quality of the evi-
dence for outcomes reported in the review considering the within-
study risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimate, and risk of publication
bias (GRADEpro).
R E S U L T S
Description of studies
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We included 38 RCTs in our qualitative analyses (Characteristics
of included studies) and excluded 24 studies (Characteristics of
excluded studies). We were able to gather data for our quantitative
analyses from 34 RCTs.
Results of the search
We identified 1378 potentially relevant references in electronic
databases and 10 additional records through manual searches
(Figure 1). After removing duplicates and references that were
clearly irrelevant, we identified 38 RCTs described in 56 references
that fulfilled our inclusion criteria (Elkington 1969; Simmons
1970; Brown 1971; Germain 1973; Rodgers 1973; Corazza 1982;
McClain 1984; Heredia 1987; Morgan 1987a; Morgan 1987b;
Uribe 1987a; Uribe 1987b; Heredia 1988; Morgan 1989; Riggio
1989; Grandi 1991; Pai 1995; Jankovic 1996; Horsmans 1997;
Quero 1997; Shi 1997; Watanabe 1997; Li 1999; Dhiman 2000;
Xing 2003; Zeng 2003; Raza 2004; Riggio 2005; Prasad 2007;
Sharma 2009; Mittal 2011; Sharma 2011; Agrawal 2012; Sharma
2012; Jain 2013; Wen 2013; Ziada 2013; Yao 2014).
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Figure 1. Trial flow diagram.
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We were unable to obtain outcome data from four RCTs
(Elkington 1969; Brown 1971; Rodgers 1973; Shi 1997), and
we included the remaining 34 RCTs, all published as full paper
articles, in our quantitative analyses (Simmons 1970; Germain
1973; Corazza 1982; McClain 1984; Heredia 1987; Morgan
1987a;Morgan 1987b; Uribe 1987a; Uribe 1987b;Heredia 1988;
Morgan 1989; Riggio 1989; Grandi 1991; Pai 1995; Jankovic
1996; Horsmans 1997; Quero 1997; Watanabe 1997; Li 1999;
Dhiman 2000; Xing 2003; Zeng 2003; Raza 2004; Riggio 2005;
Prasad 2007; Sharma 2009; Mittal 2011; Sharma 2011; Agrawal
2012; Sharma 2012; Jain 2013; Wen 2013; Ziada 2013; Yao
2014).
The countries of origin were India (Dhiman 2000; Prasad 2007;
Sharma 2009; Mittal 2011; Sharma 2011; Agrawal 2012; Sharma
2012; Jain 2013), the USA (Elkington 1969; Simmons 1970;
Brown 1971; Rodgers 1973; McClain 1984), China (Shi 1997;
Xing 2003; Zeng 2003; Wen 2013; Li 1999; Yao 2014), Italy
(Corazza 1982; Riggio 1989; Grandi 1991; Riggio 2005), the
UnitedKingdom (Morgan 1987a;Morgan 1987b;Morgan 1989),
Spain (Heredia 1987; Heredia 1988),Mexico (Uribe 1987a;Uribe
1987b), Belgium (Horsmans 1997), Egypt (Ziada 2013), France
(Germain 1973), Holland (Quero 1997), Pakistan (Raza 2004),
Serbia (Jankovic 1996), and Taiwan (Pai 1995).
Included studies
Participants
The total number of participants was 1828. Theirmean age ranged
from 41 to 67 years and the proportion of men from 11% to
100%. The proportion of participants with cirrhosis secondary to
hepatitis B/C infection ranged from 0% to 81%, while the pro-
portion with alcohol-related cirrhosis ranged from 0% to 100%.
Seven RCTs evaluated the prevention of hepatic encephalopathy.
Three RCTs evaluated primary (Sharma 2012), or secondary pre-
vention of hepatic encephalopathy (Sharma 2009; Agrawal 2012),
in participants with no obvious risks. Four included participants
with an increased risk of hepatic encephalopathy due to gastroin-
testinal bleeding (Sharma 2011; Wen 2013), recent insertion of
a transjugular intrahepatic portosystemic shunt (Riggio 2005), or
portosystemic shunt surgery (Riggio 1989). In 16 RCTs, partici-
pants had overt hepatic encephalopathy (Table 1) classed as acute
(Simmons 1970; Heredia 1987; Morgan 1987a; Uribe 1987a;
Pai 1995; Jankovic 1996; Raza 2004), or chronic (Elkington
1969; Brown 1971; Germain 1973; Rodgers 1973; Corazza 1982;
Morgan 1987b; Uribe 1987b; Heredia 1988; Grandi 1991).
In 15 RCTs, participants had minimal hepatic encephalopathy
(McClain 1984; Morgan 1989; Horsmans 1997; Quero 1997;
Shi 1997; Watanabe 1997; Li 1999; Dhiman 2000; Xing 2003;
Zeng 2003; Prasad 2007; Mittal 2011; Jain 2013; Ziada 2013;
Yao 2014).
Interventions
Twenty-nine RCTs assessed non-absorbable disaccharides versus
placebo/no intervention (Elkington 1969; Simmons 1970; Brown
1971; Germain 1973; Rodgers 1973; Corazza 1982; McClain
1984; Uribe 1987a; Uribe 1987b; Horsmans 1997; Quero 1997;
Shi 1997; Watanabe 1997; Li 1999; Dhiman 2000; Xing 2003;
Zeng 2003; Raza 2004; Riggio 2005; Prasad 2007; Sharma 2009;
Mittal 2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain
2013; Wen 2013; Ziada 2013; Yao 2014). Of these, 25 assessed
lactulose (Elkington 1969; Simmons 1970; Brown 1971;Germain
1973; Rodgers 1973; Corazza 1982; McClain 1984; Horsmans
1997;Quero1997;Watanabe 1997; Li 1999;Dhiman 2000; Xing
2003; Zeng 2003; Raza 2004; Prasad 2007; Sharma 2009; Mittal
2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain 2013;Wen
2013; Ziada 2013; Yao 2014), and four assessed lactitol (Uribe
1987a; Uribe 1987b; Shi 1997; Riggio 2005).
Nine RCTs compared lactulose versus lactitol (Heredia 1987;
Morgan 1987a; Morgan 1987b; Heredia 1988; Morgan 1989;
Riggio 1989; Grandi 1991; Pai 1995; Jankovic 1996).
Outcomes
We were unable to extract outcome data from four RCTs with
64 participants (Elkington 1969; Brown 1971; Rodgers 1973; Shi
1997).
In total, our quantitative analyses included 34 RCTs with 1764
participants (Simmons 1970; Germain 1973; Corazza 1982;
McClain 1984; Heredia 1987; Morgan 1987a; Morgan 1987b;
Uribe 1987a; Uribe 1987b; Heredia 1988; Morgan 1989; Riggio
1989; Grandi 1991; Pai 1995; Jankovic 1996; Horsmans 1997;
Quero1997;Watanabe 1997; Li 1999;Dhiman 2000; Xing 2003;
Zeng 2003; Raza 2004; Riggio 2005; Prasad 2007; Sharma 2009;
Mittal 2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain
2013; Wen 2013; Yao 2014).
Thirty-one RCTs followed participants to the end of the inter-
vention (Simmons 1970; Germain 1973; Corazza 1982; McClain
1984; Heredia 1987; Morgan 1987b; Uribe 1987a; Uribe 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Grandi 1991; Pai
1995; Horsmans 1997; Watanabe 1997; Li 1999; Dhiman 2000;
Xing 2003; Zeng 2003; Raza 2004; Riggio 2005; Prasad 2007;
Sharma 2009; Mittal 2011; Sharma 2011; Agrawal 2012; Sharma
2012; Jain 2013; Wen 2013; Ziada 2013; Yao 2014). Three par-
allel-arm RCTs followed participants for an additional 13 days
(Jankovic 1996), one month (Morgan 1987a), or three months af-
ter the end of treatment (Quero 1997). The duration of the inter-
vention depended on the type of hepatic encephalopathy. Overall,
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the RCTs followed participants for 89 days (range 4 to 360 days)
after randomisation. In prevention RCTs, the duration was 207
days (range 5 to 360 days). For participants with overt hepatic
encephalopathy, the mean duration was 49 days (range 4 to 360)
with a shorter duration in RCTs on acute (mean 5 days; range
4 to 7 days) and chronic hepatic encephalopathy (mean 74 days;
range 10 to 360 days). The mean duration was 70 days in RCTs
on minimal hepatic encephalopathy (range 14 to 180).
Investigators assessed overt (Table 1) and minimal hepatic en-
cephalopathy using several different neuropsychiatric assessments
and variables (Characteristics of included studies). Eight RCTs
used the Portal Systemic Encephalopathy Index and Ratio (
Morgan 1987a; Morgan 1987b; Uribe 1987a; Uribe 1987b;
Heredia 1988; Riggio 1989; Pai 1995; Riggio 2005), which com-
prises mental status (West Haven Criteria), asterixis, Number
Connection Test A results, blood ammonia concentrations, and
the electroencephalogram mean cycle frequency. Two RCTs used
a modified version of the test without the electroencephalogram
(Grandi 1991; Raza 2004), while one additionally replaced Num-
ber Connection Test A with the Digit Symbol test (Raza 2004).
Ten of the remaining RCTs also usedWestHavenCriteria to assess
mental status (Jankovic 1996; Prasad 2007; Sharma 2009; Mittal
2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain 2013;Wen
2013; Ziada 2013). Three RCTs used the Conn Score, which
is similar to the West Haven Criteria (Heredia 1987; Morgan
1989; Watanabe 1997). Thirty-two RCTs employed the Num-
ber Connection Test (Germain 1973; McClain 1984; Heredia
1987;Morgan 1987a;Morgan 1987b;Uribe 1987a; Uribe 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Grandi 1991; Pai
1995; Jankovic 1996; Horsmans 1997; Quero 1997; Shi 1997;
Watanabe 1997; Li 1999; Dhiman 2000; Xing 2003; Zeng 2003;
Raza 2004; Riggio 2005; Prasad 2007; Sharma 2009; Mittal
2011; Agrawal 2012; Sharma 2012; Jain 2013; Wen 2013; Ziada
2013; Yao 2014). Twenty-five RCTs measured blood ammonia
in plasma, venous, or arterial blood (Elkington 1969; Simmons
1970; Brown 1971; Germain 1973; Corazza 1982; Heredia 1987;
Morgan 1987a; Morgan 1987b; Uribe 1987a; Uribe 1987b;
Heredia 1988; Riggio 1989; Grandi 1991; Pai 1995; Quero 1997;
Shi 1997; Xing 2003; Zeng 2003; Raza 2004; Riggio 2005;Mittal
2011; Sharma 2011; Agrawal 2012; Jain 2013; Ziada 2013),
and 22 assessed the electroencephalogram mean cycle frequency
(Elkington 1969; Brown 1971; Germain 1973; Rodgers 1973;
Corazza 1982; Heredia 1987; Morgan 1987a; Morgan 1987b;
Uribe 1987a; Uribe 1987b; Heredia 1988; Morgan 1989; Riggio
1989; Pai 1995; Jankovic 1996; Horsmans 1997; Quero 1997;
Xing 2003; Zeng 2003; Raza 2004; Riggio 2005; Agrawal 2012).
Excluded studies
We excluded four RCTs and 20 observational studies (
Characteristics of excluded studies). Three RCTs compared lac-
tulose versus probiotics (Sharma 2008), polyethylene glycol fol-
lowed by lactulose (Rahimi 2014), or a carbon adsorbent (Pockros
2009), while one RCT compared mannitol lavage versus a com-
bination of lactulose and the antibiotic kanamycin (Quinton
1982). Five case series described the effects of lactulose on mini-
mal (Salerno 1994) or recurrent hepatic encephalopathy (Brown
1970; Rorsman 1970; Zeegen 1970; Bircher 1971). One addi-
tional study looked at the differential effects of lactitol and lac-
tulose on chronic hepatic encephalopathy (Lanthier 1985), while
another looked at the effect of lactulose in preventing hepatic
encephalopathy following insertion of a transjugular intrahepatic
portosystemic shunt (Piotraschke 1996). Three studies of partic-
ipants with cirrhosis described compliance with non-absorbable
disaccharides, the predictors of recurrence of hepatic encephalopa-
thy, and the predictors of response (Bajaj 2010b; Sharma 2009a;
Sharma 2010). Three studies describe the prevalence and charac-
teristics of participantswith overt orminimal hepatic encephalopa-
thy (Schomerus 1993; Sharma 2010a), or young people admitted
with overt hepatic encephalopathy (Sharma2011a). Six studies de-
scribe the effects of non-absorbable disaccharides on cerebral blood
flow and metabolism (James 1971), fat excretion (Merli 1992),
terminal ileal and colonic pH (Patil 1987), blood ammonia, atrial
natriuretic peptide and amino acid concentrations (Trovato 1995),
blood ammonia, Number Connection Test results and lympho-
cyte subpopulations (Vendemiale 1992), and benzodiazepine-like
compounds (Venturini 2005).
Risk of bias in included studies
We based our bias assessment on the published descriptions com-
bined with additional information from investigators (Figure 2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In 26 RCTs, investigators generated the allocation sequence based
on a table of random numbers or computer-generated random
numbers (Simmons 1970;Germain1973;McClain 1984;Heredia
1987;Morgan 1987a;Morgan 1987b;Uribe 1987a; Uribe 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Pai 1995; Horsmans
1997; Quero 1997; Watanabe 1997; Dhiman 2000; Riggio 2005;
Prasad 2007; Sharma 2009; Mittal 2011; Sharma 2011; Agrawal
2012; Sharma 2012; Jain 2013; Wen 2013; Yao 2014).
In 28 RCTs, the allocation concealment involved randomisa-
tion via a central independent unit, serially numbered, opaque,
sealed envelopes, or blinded administration of identically appear-
ing drug containers (Elkington 1969; Simmons 1970; Brown
1971; Germain 1973; Rodgers 1973; Corazza 1982; McClain
1984; Heredia 1987; Morgan 1987a; Morgan 1987b; Uribe
1987a; Uribe 1987b; Heredia 1988; Morgan 1989; Riggio 1989;
Horsmans 1997;Quero1997; Shi1997;Watanabe 1997;Dhiman
2000; Riggio 2005; Prasad 2007; Sharma 2009; Mittal 2011;
Sharma 2011; Agrawal 2012; Sharma 2012; Jain 2013).
We classified 23 RCTs as having low risk of selection bias
(Simmons 1970; Germain 1973; McClain 1984; Heredia 1987;
Morgan 1987a; Morgan 1987b; Uribe 1987a; Uribe 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Horsmans 1997;
Quero 1997;Watanabe 1997; Dhiman 2000; Riggio 2005; Prasad
2007; Sharma 2009; Mittal 2011; Sharma 2011; Agrawal 2012;
Sharma 2012; Jain 2013).
We classified 15 RCTs as having unclear risk of selection bias
(Elkington 1969; Brown 1971; Rodgers 1973; Corazza 1982;
Grandi 1991; Pai 1995; Jankovic 1996; Shi 1997; Li 1999; Xing
2003; Zeng 2003; Raza 2004; Wen 2013; Ziada 2013; Yao 2014).
Blinding
We classified five single-blind RCTs with blinded outcome as-
sessment as having low risk of detection bias (Morgan 1989;
Riggio 1989; Pai 1995; Riggio 2005; Wen 2013), and 14 double-
blind RCTs as having low risk of performance and detection bias
(Elkington 1969; Simmons 1970; Brown 1971; Germain 1973;
Rodgers 1973; Corazza 1982; McClain 1984; Morgan 1987a;
Morgan 1987b; Uribe 1987a; Uribe 1987b; Horsmans 1997;
Quero 1997; Shi 1997).
The remaining 19 RCTs were open and we classified them as
having high risk of performance and detection bias (Heredia 1987;
Heredia 1988; Grandi 1991; Jankovic 1996; Watanabe 1997; Li
1999; Dhiman 2000; Xing 2003; Zeng 2003; Raza 2004; Prasad
2007; Sharma 2009; Mittal 2011; Sharma 2011; Agrawal 2012;
Sharma 2012; Jain 2013; Ziada 2013; Yao 2014).
Incomplete outcome data
In 12 trials, the authors described missing outcome data and
excluded participants who were dropouts or withdrawals from
their analyses (Brown 1971; Rodgers 1973; McClain 1984; Uribe
1987b; Heredia 1988; Pai 1995; Jankovic 1996; Quero 1997;
Watanabe 1997; Jain 2013;Wen 2013; Ziada 2013).We classified
these RCTs as having high risk of attrition bias and four RCTs as
having unclear risk of attrition bias because the trial reports did
not describe dropouts or withdrawals or the handling of missing
outcome data in the analyses (Elkington 1969; Corazza 1982; Shi
1997; Raza 2004).
The remaining 22 RCTs had no missing outcome data and the
analyses included all participants based on the intention-to-treat
principle using adequate methods including last observation car-
ried forward or multiple imputation (Simmons 1970; Germain
1973; Heredia 1987; Morgan 1987a; Morgan 1987b; Uribe
1987a; Morgan 1989; Riggio 1989; Grandi 1991; Horsmans
1997; Li 1999; Dhiman 2000; Xing 2003; Zeng 2003; Riggio
2005; Prasad 2007; Sharma 2009; Mittal 2011; Sharma 2011;
Agrawal 2012; Sharma 2012; Yao 2014).We classified these RCTs
as having low risk of attrition bias.
Selective reporting
Thirty-two RCTs reported predefined, clinically relevant outcome
measures suggesting a low risk of selective reporting (Elkington
1969; Simmons 1970; Germain 1973; Corazza 1982; McClain
1984;Morgan 1987a;Morgan 1987b;Uribe 1987a; Uribe 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Grandi 1991; Pai
1995; Jankovic 1996; Horsmans 1997; Quero 1997; Watanabe
1997; Li 1999;Dhiman 2000; Xing 2003; Zeng 2003; Raza 2004;
Riggio 2005; Prasad 2007; Sharma 2009; Mittal 2011; Sharma
2011; Agrawal 2012; Sharma 2012; Wen 2013; Yao 2014).
One trial reported different primary and secondary outcomes in
the electronic trial register (Jain 2013). The remaining five RCTs
did not report mortality (Brown 1971; Rodgers 1973; Heredia
1988; Shi 1997; Ziada 2013). We therefore classed these six RCTs
as having a high risk of selective reporting.
For-profit funding
Twenty RCTs did not receive funding or had other involvement
with for-profit companies (Corazza 1982;Heredia 1987; Pai 1995;
Jankovic 1996; Shi1997;Watanabe 1997; Li 1999;Dhiman 2000;
Xing 2003; Zeng 2003; Riggio 2005; Prasad 2007; Sharma 2009;
Mittal 2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain
2013; Wen 2013; Ziada 2013).
In 10 RCTs, investigators received lactitol, lactulose, or placebo
from a pharmaceutical company (Simmons 1970; McClain 1984;
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Morgan 1987a; Morgan 1987b; Heredia 1988; Morgan 1989;
Riggio 1989; Grandi 1991; Horsmans 1997; Raza 2004).
Seven RCTs received financial or other support from a pharma-
ceutical company (Brown 1971; Elkington 1969; Germain 1973;
Quero 1997; Rodgers 1973; Uribe 1987a; Uribe 1987b).
One RCT did not report funding (Yao 2014).
Other potential sources of bias
We found no other potential sources of bias and therefore classi-
fied all RCTs as having low risk of bias for this domain (Elkington
1969; Simmons 1970; Brown 1971; Germain 1973; Rodgers
1973; Corazza 1982; McClain 1984; Heredia 1987; Morgan
1987a;Morgan 1987b; Uribe 1987a; Uribe 1987b;Heredia 1988;
Morgan 1989; Riggio 1989; Grandi 1991; Pai 1995; Jankovic
1996;Horsmans 1997;Quero1997; Shi 1997;Watanabe 1997; Li
1999; Dhiman 2000; Xing 2003; Zeng 2003; Raza 2004; Riggio
2005; Prasad 2007; Sharma 2009; Mittal 2011; Sharma 2011;
Agrawal 2012; Sharma 2012; Jain 2013; Wen 2013; Ziada 2013;
Yao 2014).
Overall bias assessment
Weclassified eightRCTs as having low risk of bias in the assessment
of mortality (Dhiman 2000; Riggio 2005; Prasad 2007; Sharma
2009; Mittal 2011; Sharma 2011; Agrawal 2012; Sharma 2012),
and none of the RCTs as having low risk of bias in the assessment
of the remaining outcomes.
Effects of interventions
See: Summary of findings for the main comparison Non-
absorbable disaccharides versus placebo/no intervention for the
prevention and treatment of hepatic encephalopathy in people
with cirrhosis; Summary of findings 2 Lactulose versus lactitol
for the prevention and treatment of hepatic encephalopathy in
people with cirrhosis
Non-absorbable disaccharides versus placebo/no
intervention
Primary outcomes
Our meta-analysis of mortality included 24 RCTs with 1487 par-
ticipants (Analysis 1.1). Compared with placebo/no intervention,
non-absorbable disaccharides were associated with a beneficial ef-
fect onmortality when including all randomised clinical trials (risk
ratio (RR) 0.59, 95% confidence interval (CI) 0.40 to 0.87; I2
= 0%) or the eight RCTs with a low risk of bias (RR 0.63, 95%
CI 0.41 to 0.97; number needed to treat to benefit (NNTB) 19;
Analysis 1.2).
Our meta-analysis of hepatic encephalopathy included 22 RCTs
with 1415 participants (Analysis 1.3) and showed that compared
with placebo/no intervention, non-absorbable disaccharides were
associated with a beneficial effect on hepatic encephalopathy (RR
0.58, 95% CI 0.48 to 0.69; I2 = 43%; NNTB six participants).
Twenty-fourRCTswith 1487participants reported serious adverse
events (Analysis 1.4) that reflected liver-related morbidity such as
liver failure, hepatorenal syndrome, and variceal bleeding (Table
2). Non-absorbable disaccharides had a beneficial effect on serious
adverse events (RR 0.47, 95% CI 0.36 to 0.60; I2 = 0%; Analysis
1.4). None of the RCTs evaluating hepatic encephalopathy or
serious adverse events had a low risk of bias.
We conducted the Trial Sequential Analyses of primary outcomes
with the relative risk reduction (RRR) downgraded to 30%. In
the analysis of mortality, we set the CGR to 15%. When includ-
ing all 24 RCTs (Figure 3), the cumulative Z-curve crossed the
monitoring boundary after 1037 participants before reaching the
heterogeneity adjusted information size. The cumulative Z-curve
did not cross themonitoring boundary when we reduced the RRR
to 20% and increased the diversity to 20%, or when we only in-
cluded RCTs with a low risk of bias (Figure 4). When we con-
ducted the Trial Sequential Analysis for the outcome hepatic en-
cephalopathy, we initially set the CGR to 45% (Figure 5). The
analysis found that the Z-curve crossed the monitoring bound-
ary before reaching the information size of 581 participants and
the analysis was confirmed when we decreased the RRR to 20%
(information size 1337 participants) and increased diversity from
30% (model based) to 50% (information size 814 participants).
Likewise, when analysing serious adverse events with the CGR
set to 30%, the Z-curve crossed the monitoring boundary before
reaching the required information size (737 participants; Figure
6). We confirmed the result in an analysis with RRR of 20% and
diversity 20% (information size 1719 participants).
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Figure 3. Trial Sequential Analysis of mortality in 24 RCTs evaluating non-absorbable disaccharides versus
placebo/no intervention. The primary meta-analysis found a RR of 0.59 (95% CI 0.40 to 0.87). When we set the
RRR to 30% and CGR to 15%, (power 80%, alpha 5%, and diversity 0%), the cumulative Z-curve (the green line)
crossed the monitoring boundary (inward sloping line) after 1037 participants before reaching the
heterogeneity adjusted information size. The cumulative Z-curve did not cross the monitoring boundary when
we increased the diversity to 20% and reduced the RRR to 20%.
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Figure 4. Trial Sequential Analysis of mortality in 8 RCTs with a low risk of bias. The RCTs compare non-
absorbable disaccharides versus placebo/no intervention and the primary meta-analysis found an effect of non-
absorbable disaccharides with a RR of 0.63 (95% CI 0.41 to 0.97). When we set the RRR to 30% and CGR to 45%
(power 80%, alpha 5%, and diversity 0%), the cumulative Z-curve (the green line) did not cross the monitoring
boundary (inward sloping line). The heterogeneity adjusted information size was 1725 participants.
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Figure 5. Trial Sequential Analysis of hepatic encephalopathy in 22 RCTs evaluating non-absorbable
disaccharides versus placebo/no intervention. A meta-analysis including all trials found a RR of 0.58 (95% CI
0.48 to 0.69). The analysis includes a RRR of 30% and CGR of 45% (power 80%, alpha 5%, and diversity 30%).
The analysis found that the Z-curve (green line) crossed the monitoring boundary (inward sloping black line)
before reaching the information size of 581 participants. None of the RCTs were low risk of bias in the overall
assessment. The Z-curve crossed the monitoring boundary before reaching the information size when we
decreased the RRR to 20% (information size 1337 participants) and when we increased diversity to 50% (814
participants).
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Figure 6. Trial Sequential Analysis of serious adverse events including 24 RCTs evaluating non-absorbable
disaccharides versus placebo/no intervention. The primary meta-analysis found a beneficial intervention effect
with a RR of 0.47 (95% CI 0.36 to 0.60). None of the included RCTs had a low risk of bias in the overall
assessment. When conducting the Trial Sequential Analysis with RRR 30%, CGR 30%, power 80%, alpha 5%,
and diversity 0%, the Z-curve crossed the monitoring boundary before reaching the required information size
of 737 participants. The Z-curve also crossed the monitoring boundary before reaching the required
information size when we reduced the RRR to 20% (information size 1719 participants) and when we increased
diversity to 20% (information size 921 participants).
Worst-case scenario analyses (missing outcome data counted as
failures) showed that the non-absorbable disaccharides were asso-
ciated with a beneficial effect on mortality (RR 0.61, 95%CI 0.42
to 0.88; Analysis 1.10), hepatic encephalopathy (RR 0.59, 95%
CI 0.50 to 0.69; Analysis 1.11), and serious adverse events (RR
0.47, 95% CI 0.37 to 0.61; Analysis 1.12). The ’extreme worst-
case scenario’ analyses (missing outcome data counted as failures
in the non-absorbable disaccharide group and successes in the con-
trol group) reached the same conclusions (Analysis 1.10, Analysis
1.11, and Analysis 1.12).
Regression analyses and funnel plots showed no evidence of small
study effects in the analysis of mortality (P value = 0.73), hepatic
encephalopathy (P value = 0.93), or serious adverse events (P value
= 0.96).
Secondary outcomes
Six RCTs included quality of life assessments (McClain 1984;
Quero 1997; Watanabe 1997; Zeng 2003; Prasad 2007; Mittal
2011). Three RCTs, Quero 1997, Prasad 2007 and Mittal 2011,
evaluated 160 participants with minimal hepatic encephalopathy
using the Sickness Impact Profile (Table 3; Table 4; Table 5), which
includes 136 questions about health-related dysfunction (Gilson
1975; SF 36 questionnaire). The responses to these questions are
divided into 12 categories: ambulation, body care/movement,mo-
bility, emotional behaviour, social interaction, alertness behaviour,
communication, work, sleep and rest, eating, home management,
and recreation/pastimes. These, in turn, are used to inform the
two major summative domains physical and psychosocial health.
Two RCTs defined the alteration in the total score after treat-
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ment as the change in the overall quality of life (Prasad 2007;
Mittal 2011). The third trial compared the end of treatment val-
ues (Quero 1997). The three RCTs individually found a beneficial
effect of lactulose. However, the heterogeneity between RCTs was
considerable so we did not conduct a meta-analysis (Analysis 1.5).
One trial, Zeng 2003, used an abbreviated version of the
World Health Organization quality of life 100 questionnaire
(WHOQOL1998), which evaluates the domains: physical health,
psychological health, social relationships, and environment. The
trial report includes a table showing a selection of subscores from
the questionnaire (Table 6). The analyses showed that lactulose
improved the domains of physical and psychological health, and
social relationships (P value < 0.05 for all subscores).
One trial described the effect of lactulose on the quality of life
without specifying the assessment method (Watanabe 1997). The
abstract states that lactulose improved the quality of life without
providing quantitative data. One further trial, McClain 1984, as-
sessed quality of life using the Katz functioning scale (Katz 1963),
which evaluates the adjustment and social behaviour in the com-
munity. The investigators state that there were no differences be-
tween the intervention groups before or after treatment, but do
not provide quantitative data.
The non-absorbable disaccharides increased the risk of gastroin-
testinal non-serious adverse events (RR2.47, 95%CI 1.24 to 4.93;
739 participants; nine RCTs; I2 = 64%; Analysis 1.6), including
diarrhoea, bloating, flatulence, and nausea. Participants allocated
to placebo/no intervention had a higher risk of constipation.
The surrogate outcomes included Number Connection Test re-
sults (mean difference (MD) -5.56, 95% CI -11.59 to 0.47;
Analysis 1.7) and blood ammonia concentrations assessed at the
end of the trials (MD -11.64, 95% CI -21.14 to -2.14; Analysis
1.8) and as the change from baseline to the end of follow-up (MD
18.97, 95%CI 8.86 to 29.09; Analysis 1.9). The analyses included
a small number of participants and considerable heterogeneity.
Prevention RCTs
The meta-analysis evaluating primary or secondary prevention
showed a beneficial effect onmortality when including all six RCTs
(RR 0.63, 95% CI 0.40 to 0.98; 668 participants; Analysis 2.1),
or the five RCTs with a low risk of bias (RR 0.64, 95% CI 0.41 to
0.99; 538 participants; Analysis 2.2). The non-absorbable disac-
charides also had beneficial effects on the prevention of hepatic en-
cephalopathy (RR 0.47, 95% CI 0.33 to 0.68; Analysis 2.3), and
serious adverse events (RR 0.48, 95% CI 0.33 to 0.70, Analysis
2.4). Additional analyses including four RCTs showed that non-
absorbable disaccharides increased the risk of non-serious adverse
events (RR 2.78, 95% CI 1.50 to 5.13; 548 participants; Analysis
2.5).
Treatment RCTs
The meta-analysis evaluating the treatment of overt or minimal
hepatic encephalopathy showed no effect of non-absorbable dis-
accharides on mortality when including all 18 RCTs (RR 0.49,
95% CI 0.23 to 1.05; 819 participants; Analysis 3.1), or the three
RCTs with a low risk of bias (RR 0.56, 95% CI 0.12 to 2.68;
167 participants; three RCTs; Analysis 3.2). The analyses showed
beneficial effect of non-absorbable disaccharides on mortality in
RCTs evaluating acute, overt hepatic encephalopathy (RR 0.36,
95%CI 0.14 to 0.94; 172 participants; six RCTs), but not inRCTs
evaluating minimal hepatic encephalopathy (RR 0.82, 95% CI
0.24 to 2.86; 647 participants; 12 RCTs). No events occurred in
RCTs evaluating chronic hepatic encephalopathy (Analysis 3.3).
The non-absorbable disaccharides had beneficial effects on overt
and minimal hepatic encephalopathy (RR 0.63, 95% CI 0.53 to
0.74; 747 participants; 16 RCTs; Analysis 3.4). The effect was
similar in RCTs evaluating acute or chronic hepatic encephalopa-
thy (Analysis 3.5). Non-absorbable disaccharides had a beneficial
effect on serious adverse events (RR 0.42, 95% CI 0.26 to 0.69;
819 participants; 18 RCTs; Analysis 3.6) with no difference be-
tween the acute and chronic hepatic encephalopathy subgroups
(Analysis 3.7). Non-absorbable disaccharides did not increase the
risk of non-serious adverse events (RR 2.12, 95% CI 0.62 to 7.28;
191 participants; five RCTs; Analysis 3.7).
Lactulose versus lactitol
Meta-analyses showed no difference between lactulose versus lac-
titol in the assessment of mortality (RR 1.30, 95% CI 0.59 to
2.85; 225 participants; eight RCTs; I2 = 0%; Analysis 4.1), hep-
atic encephalopathy (RR 1.00, 95% CI 0.84 to 1.19; Analysis
4.2), or serious adverse events (RR 1.56, 95% CI 0.84 to 2.88;
Analysis 4.3). All Trial Sequential Analyses ignored themonitoring
boundaries because the information size was insufficient. None
of the RCTs assessed the quality of life. The non-serious adverse
events were mainly gastrointestinal (RR 1.55, 95% CI 0.88 to
2.74; Analysis 4.4). We found no differences between interven-
tions for the surrogate outcomes Number Connection Test (end
of treatment Analysis 4.5 or change from baseline Analysis 4.6),
or blood ammonia concentrations (end of treatment Analysis 4.7
or change from baseline Analysis 4.8). We found no differences
between subgroups for any outcomes. We only found evidence of
missing outcome data in two RCTs (Pai 1995; Jankovic 1996).
The trials did not provide information about the number of par-
ticipants in the two groups (lactulose or lactitol) with missing out-
come data. Therefore, we were unable to conduct worst-case sce-
nario or extreme worst-case scenario analyses.
’Summary of findings’ tables
In the analyses comparing non-absorbable disaccharides ver-
sus placebo/no intervention (Summary of findings table 1), we
downgraded the quality of the evidence to ’moderate’ for the out-
comemortality because the Trial Sequential Analysis of RCTs with
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a low risk of bias found no evidence to support or refute an inter-
vention effect. Likewise, we downgraded the quality of evidence for
the outcomes hepatic encephalopathy and serious adverse events
one level to ’moderate’ because none of the included RCTs had a
low risk of bias. We downgraded the outcome quality of life three
levels to ’very low quality evidence’ because none of the included
RCTs had a low risk of bias, the heterogeneity was considerable,
and we were unable to combine the data in an overall analysis. We
also downgraded the outcome non-serious adverse events three
levels to ’very low quality evidence’ because none of the included
RCTs had a low risk of bias, the confidence intervals were wide,
and we were only able to include data from nine RCTs in our
meta-analysis.
In the analyses comparing lactulose versus lactitol (Summary of
findings table 2), we downgraded the evidence three levels to ’very
low quality’ due to imprecision, uncertainty, and a methodological
quality (none of the included RCTs had a low risk of bias).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
Population: prevent ion and treatment of hepat ic encephalopathy in people with cirrhosis
Intervention: lactulose
Control: lact itol
Setting: in-hospital (overt hepat ic encephalopathy) and outpat ient (m inimal hepat ic encephalopathy and prevent ion trials)
Duration of follow-up: the durat ion depended on the type of encephalopathy with 5 days for acute, 74 days for chronic, 70 days for m inimal, and 207 days for prevent ion of
hepat ic encephalopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lactulose versus lacti-
tol
M ortality Study population RR 1.3
(0.59 to 2.85)
225
(8 studies)
⊕©©©
very low1
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found no evi-
dence to support or re-
fute a dif ference be-
tween the 2 interven-
t ions being compared
Assessment method:
Assessed based on the
total number of part ici-
pants who died
71 per 1000 92 per 1000
(42 to 202)
M oderate
0 per 1000 0 per 1000
(0 to 0)
Hepatic encephalopa-
thy
Study population RR 1
(0.84 to 1.19)
194
(7 studies)
⊕©©©
very low1
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found no evi-
dence to support or re-
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f ute a dif ference be-
tween the 2 interven-
t ions being compared
Assessment method:
Assessed based on the
def init ions in included
RCTs (number of par-
t icipants without a clin-
ically relevant improve-
ment of hepat ic en-
cephalopathy)
286 per 1000 286 per 1000
(240 to 340)
M oderate
200 per 1000 200 per 1000
(168 to 238)
Serious adverse events Study population RR 1.56
(0.84 to 2.88)
245
(9 studies)
⊕©©©
very low1
Trial Sequential Analy-
sis:
The Trial Sequent ial
Analysis found no evi-
dence to support or re-
fute a dif ference be-
tween the 2 interven-
t ions being compared
Assessment method:
Assessed based on the
def init ions in included
RCTs (number of par-
t icipants without a clin-
ically relevant improve-
ment of hepat ic en-
cephalopathy
106 per 1000 165 per 1000
(89 to 304)
M oderate
77 per 1000 120 per 1000
(65 to 222)
Quality of life (sec-
ondary outcome)
- No data were available
for this outcome
- - - None of the included
RCTs assessed quality
of lif e.
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Non-serious adverse
events (secondary out-
come)
Study population RR 1.55
(0.88 to 2.74)
169
(6 studies)
⊕©©©
very low2
Assessment method:
The outcome includes
all adverse events that
do not fulf il the criteria
for ’serious’ (ICH-GCP
2007).
247 per 1000 383 per 1000
(217 to 677)
M oderate
246 per 1000 381 per 1000
(216 to 674)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RCT: randomised clinical trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Mortality, hepat ic encephalopathy, and serious adverse events are downgraded three levels to ’very low quality evidence’ because
i) the Trial Sequent ial Analysis found insuf f icient evidence to support or refute a dif ference between the intervent ion and
control group, ii) the conf idence intervals were wide, and ii) none of the included RCTs had a low risk of bias in the overall
assessment of bias control.
2Non-serious adverse events is downgraded three levels to ’very low quality evidence’ because i) none of the included RCTs had
a low risk of bias in the overall assessment of bias control, ii) only six RCTs reported the outcome, and iii) the conf idence
intervals were wide (uncertainty).
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D I S C U S S I O N
Summary of main results
This review includes descriptive information from 38 randomised
clinical trials (RCTs) with 1828 participants and quantitative data
from 34 RCTs with 1764 participants. The primary analyses show
that use of the non-absorbable disaccharides, lactulose and lactitol,
is associated with reduced mortality compared with placebo/no
intervention when including all RCTs and when including the
RCTs with a low risk of bias. In subgroup analyses, we found
no statistical differences between RCTs stratified by the type of
hepatic encephalopathy.We found a beneficial effect on mortality
in RCTs evaluating prevention and RCTs evaluating acute hepatic
encephalopathy, but not in RCTs evaluating chronic or minimal
hepatic encephalopathy (where the mortality rates overall were
extremely low). The quality of the evidence was moderate.
Use of non-absorbable disaccharides is associated with a beneficial
effect on the prevention and treatment of hepatic encephalopathy
(moderate quality evidence). Additional analyses showed that non-
absorbable disaccharides can help to reduce serious adverse events
associated with the underlying liver disease including liver failure,
variceal bleeding, and hepatorenal syndrome (moderate quality evi-
dence). Six RCTs suggested a beneficial effect on quality of life, but
we were unable to combine the results in a meta-analysis (very low
quality evidence). As expected, the non-absorbable disaccharides
increased the risk of non-serious gastrointestinal adverse events
(very low quality evidence). None of the RCTs comparing lactu-
lose versus lactitol assessed quality of life. Analyses of the remain-
ing outcomes found no differences between the two interventions
(very low quality evidence).
Overall completeness and applicability of
evidence
The most important outcomes for people with cirrhosis and hep-
atic encephalopathy are mortality, morbidity, adverse events, and
quality of life (Bajaj 2011a). We included information on all of
these outcomes. The RCTs evaluated improvement in hepatic en-
cephalopathy using a variety of methods. This partly reflects that
fact that the included RCTs were conducted between 1969 and
2014 during which time diagnostic criteria changed on more than
one occasion. The included RCTs often used clinical or composite
scoring systems and a categorical approach to define improvement
(or lack thereof ). The investigators did not use the same thresh-
olds to define improvement, so we chose to use the definitions that
they defined as clinically relevant. The diagnostic classification
of hepatic encephalopathy also changed during the time period
(EASL and AASLD guideline 2014a; EASL and AASLD guideline
2014b). Thus, we made a decision a priori to utilise the individ-
ual primary investigators’ classification of the type of hepatic en-
cephalopathy and the outcome criteria for hepatic encephalopa-
thy, based on the argument that these decisions will have been
made using the criteria that were most clinically relevant when the
investigators conducted the trial.
The olderRCTsoftenused co-interventions such as dietary protein
restriction. Although the RCTs did not use the co-interventions
consistently, participants randomised to experimental or control
groups within a given RCT would have had equal access to them.
This might result in heterogeneity, but not in systematic differ-
ences between groups.
Hepatic encephalopathy varies widely in its manifestations. The
RCTs included in our review represent the entire spectrum of
the syndrome encountered in people with cirrhosis. Thus, RCTs
included people experiencing an acute episode of hepatic en-
cephalopathy, chronic hepatic encephalopathy associated with ad-
vanced liver disease, spontaneous or surgically created portal-sys-
temic shunts, and minimal hepatic encephalopathy. In addition,
the included RCTs explored the use of non-absorbable disac-
charides for primary and secondary prevention of hepatic en-
cephalopathy. The fact that the RCTs address all the objectives
of the review strengthens the completeness of the evidence. We
included all RCTs with extractable data in our primary analyses.
We also conducted subgroup, sensitivity, and regression analyses
to determine the differential effects of intervention on the clinical
variants. Our analyses showed that non-absorbable disaccharides
are associated with stable beneficial effects on clinically important
outcomes across the different groups. This supports the external
validity of our findings.
This review includes the two commercially available disaccha-
rides, lactulose and lactitol. However, only four of the 28 RCTs of
non-absorbable disaccharides versus placebo/no treatment utilised
lactitol (Uribe 1987a; Uribe 1987b; Shi 1997; Riggio 2005).
Nine RCTs with a total of 248 participants compared lactulose
versus lactitol (Heredia 1987; Morgan 1987a; Morgan 1987b;
Heredia 1988; Morgan 1989; Riggio 1989; Grandi 1991; Pai
1995; Jankovic 1996). We found no differences between the two
interventions, but the statistical power was insufficient.
People with non-cirrhotic portal hypertension and those with ful-
minant hepatic failure may also develop hepatic encephalopathy.
They are encountered much less frequently in clinical practice and
were not represented in the included trials. There is no reason to
suppose that our results cannot be extrapolated to people with
hepatic encephalopathy associated with non-cirrhotic portal hy-
pertension, e.g. portal vein block. However, the situation in peo-
ple with fulminant hepatic failure is much more complex and the
result may not be directly applicable.
Episodes of hepatic encephalopathy often develop in response to a
precipitating event such as infection, gastrointestinal bleeding, al-
cohol misuse, or electrolyte disturbances. Identification and treat-
ment of these precipitating factors is key to the management of af-
fected individuals although no obvious precipitating factor is iden-
tified in 50% of instances (EASL and AASLD guideline 2014a;
EASL and AASLD guideline 2014b). Avoiding likely precipitants
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such as constipation, dietary indiscretion, and certain medications
can also reduce the risk of developing hepatic encephalopathy in
the longer term. It is not clear whether use of non-absorbable dis-
accharides provides additional benefit in situations where hepatic
encephalopathy is precipitated by a treatable event. The RCTs in-
cluded in our review do not provide detailed information on pos-
sible precipitating events, on the effects of interventions designed
to ameliorate them, or on the effects, if any, of the addition of
a non-absorbable disaccharide. However, in two of the included
RCTs, non-absorbable disaccharides, used together with measures
to manage upper gastrointestinal haemorrhage, prevented the de-
velopment of hepatic encephalopathy (Sharma 2012; Wen 2013).
Non-adherence to non-absorbable disaccharides is generally as-
cribed to adverse gastrointestinal effects such as unpredictable di-
arrhoea, bloating, flatulence, and abdominal pain (Bajaj 2010c;
Volk 2012). Although we did find that treatment with lactulose
or lactitol was associated with a higher risk of these non-serious
adverse events, none of the RCTs included in our review evalu-
ated compliance in a manner that allowed us to assess the poten-
tial influence of these gastrointestinal effects. Other factors may,
however, be important in determining compliance with treatment
both on the part of the person receiving treatment and the physi-
cian prescribing it. Thus, people with hepatic encephalopathymay
be unaware of the need for long-term treatment, may be unable to
effectively titrate the dosage, andmay find the side effects inconve-
nient especially when away from home. The physician may fail to
explain the multiple ways in which non-absorbable disaccharides
produce their beneficial effects and by placing undue focus on the
need for them to pass two semi-soft stools/day may foster the be-
lief that as long as this is achieved, there is no real need to take the
medication. They may also erroneously assume that people will
comply with treatment and hence fail to check adherence.
Hepatic encephalopathy imposes a significant burden on health-
care systems and the resource utilisation associated with the man-
agement of people with hepatic encephalopathy is increasing
(Poordad 2007). The increased costs do not seem to reflect the
duration of hospitalisation, which has decreased, but a combina-
tion of direct and indirect factors such as the costs of treatment
and rehabilitation after hospitalisation (Neff 2010). None of the
RCTs included in the present review assessed the costs associated
with hospitalisation, but we found a clear beneficial effect of non-
absorbable disaccharides in preventing the development and re-
currence of hepatic encephalopathy that would generally require
hospitalisation. Use of non-absorbable disaccharides is also asso-
ciated with a reduction in the occurrence of serious liver-related
complications. This will also result in reduced hospitalisations and
lengths of hospital stay.
Quality of the evidence
The previous version of this review identified several potential
biases in included RCTs (Als-Nielsen 2004). In this updated re-
view, we identified a larger number of RCTs and additional in-
formation on essential aspects of bias control. As recommended,
we combined the individual bias domains in an overall assess-
ment (Gluud 2015). We also included an assessment of individ-
ual domains, focusing on RCTs with a low risk of selection bias
(Higgins 2011a; Higgins 2011b; Savovic 2012). Based on previ-
ous evidence (Savovic 2012), we definedmortality, but not serious
adverse events, as an outcome that is robust to performance and
detection bias. This decision can be questioned as lack of blinding
is not likely to influence the assessment of events such as variceal
bleeding, hepatorenal syndrome, and liver failure. We included
14 double-blind RCTs and cannot exclude the possibility that our
analyses overestimate the effect of non-absorbable disaccharides
on hepatic encephalopathy due to lack of blinding. In contrast to
the previous version of this review, we included any type of for-
profit funding as a bias domain (Gluud 2015). The decision to
include this domain is debatable (Higgins 2011a; Higgins 2011b).
The fact that we included gratuitous supply of interventions or
placebo was the main reason why we did not identify RCTs com-
paring lactulose versus lactitol with a low risk of bias in the overall
assessment. Based on the revised assessment of bias control com-
bined with the assessment of the directness of evidence, hetero-
geneity, precision of effect estimate, and risk of publication bias we
classified the quality of the evidence asmoderate for the assessment
of our primary outcomes mortality, hepatic encephalopathy, and
serious adverse events.
The included RCTs were conducted world-wide. The country/
continent of origin included India/Pakistan (Dhiman 2000; Raza
2004; Prasad 2007; Sharma 2009; Mittal 2011; Sharma 2011;
Agrawal 2012; Sharma 2012; Jain 2013), the USA (Elkington
1969; Simmons 1970; Brown 1971; Rodgers 1973; McClain
1984), the Far-East (Pai 1995; Shi 1997; Li 1999;Xing 2003;Zeng
2003;Wen2013), Europe (Germain1973;Corazza 1982;Heredia
1987; Morgan 1987a; Morgan 1987b; Heredia 1988; Morgan
1989;Riggio 1989;Grandi 1991; Jankovic 1996;Horsmans 1997;
Quero 1997; Riggio 2005), Mexico (Uribe 1987a; Uribe 1987b),
and Egypt (Ziada 2013). A single centre in India conducted eight
of the RCTs (Dhiman 2000; Prasad 2007; Sharma 2009; Mittal
2011; Sharma 2011; Agrawal 2012; Sharma 2012; Jain 2013).
Four of these RCTs involved participants with minimal hepatic
encephalopathy (Dhiman 2000; Prasad 2007; Mittal 2011; Jain
2013), and four evaluated primary and secondary prophylaxis
(Sharma 2009; Sharma 2011; Agrawal 2012; Sharma 2012). The
results of the RCTs evaluating minimal hepatic encephalopathy
did not differ substantially from those in the similar RCTs under-
taken in centres outside of India.We found no comparable preven-
tion studies undertaken outside of India. Two prevention RCTs
conducted in Italy looked at the effects of non-absorbable disac-
charides following transjugular intrahepatic portosystemic shunt
insertion (Riggio 1989; Riggio 2005). The RCTs found no bene-
fit on mortality, hepatic encephalopathy, or serious adverse events.
However, this is a notoriously difficult situation to manage and
30Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
one that depends more on careful pre-selection of candidates than
on post-hoc exhibition of pharmacotherapy. One RCT conducted
in China looked at the effect of lactulose in the prevention of
hepatic encephalopathy following an acute upper gastrointestinal
bleed and observed significant benefit (Wen 2013). We observed
clinical variation in participant demographics between the preven-
tion RCTs conducted in India and those conducted elsewhere, but
variables such as age, gender, and the aetiology of the cirrhosis did
not confound the results. RCTs evaluating the effects of non-ab-
sorbable disaccharides for primary and secondary prevention con-
ducted in countries outside of India would strengthen the external
validity of our findings.
Potential biases in the review process
A recent methodological review drew attention to outcome re-
porting bias in systematic reviews (Page 2014). Changes between
the outcomes in protocols and published systematic reviews in-
clude the statistical significance of the results for those outcomes.
We updated this review to incorporate current recommendations
(Higgins 2011a; Higgins 2011b; Gluud 2015). The methods used
in this update differ from those in the previous version (Als-Nielsen
2004a; Als-Nielsen 2004b; Als-Nielsen 2005). As part of the up-
date, we changed the definition of our primary outcomes to pro-
vide information on benefits as well as harms. Accordingly, we now
include serious adverse events as a primary rather than a secondary
outcome measure.
The selective publication of RCTs with a positive result increases
the risk of outcome reporting bias (Dwan 2008). The RCTs in-
cluded in the present review were all published as full paper articles
and this might be interpreted as a potential publication bias. How-
ever, we combined our electronic searches with extensive manual
searches of reference lists and conference proceedings. We iden-
tified a large number of abstracts, but all were published subse-
quently as full papers. We found no evidence of publication bias
or other small study effects and very few RCTs showed evidence
of outcome reporting bias. Of the 29 RCTs on non-absorbable
disaccharides versus placebo or no intervention, we were unable
to include data for primary outcomes from four RCTs with 64
participants (Elkington 1969; Brown 1971; Rodgers 1973; Shi
1997). The RCTs are small and the narrative information in the
published reports suggested that the intervention had a beneficial
effect on hepatic encephalopathy. Exclusion of these four RCTs is
unlikely to change our conclusions.
Agreements and disagreements with other
studies or reviews
The previous version of this review assessed the effect of non-
absorbable disaccharides versus placebo/no intervention and lac-
tulose versus lactitol based on a total of 19 RCTs (Als-Nielsen
2004). Eleven RCTs compared lactulose or lactitol versus placebo/
no intervention (Elkington 1969; Simmons 1970; Germain 1973;
Rodgers 1973; Corazza 1982; Uribe 1987a; Uribe 1987b; Shi
1997; Watanabe 1997; Li 1999; Dhiman 2000), and eight RCTs
compared lactulose versus lactitol (Heredia 1987; Morgan 1987a;
Morgan 1987b; Heredia 1988; Morgan 1989; Riggio 1989;
Grandi 1991; Pai 1995). Based on a meta-analyses including four
RCTs with 85 participants, the review found no effect of non-ab-
sorbable disaccharides on mortality compared with placebo/no in-
tervention (Simmons 1970;Germain1973;Uribe 1987a;Dhiman
2000). A meta-analysis including six RCTs with 207 participants
showed a beneficial effect on hepatic encephalopathy (Simmons
1970; Germain 1973; Uribe 1987a; Watanabe 1997; Li 1999;
Dhiman 2000), but the effect was not confirmed in an analysis
that only included RCTs with a low risk of bias. We included
38 RCTs (1828 participants) in our qualitative evaluation and 34
RCTs in our qualitative analyses. Our analyses include several dif-
ferent groups of participants from several countries. In spite of the
clinical differences, our analyses showed negligible or moderate
statistical heterogeneity. Our findings disagree with previous evi-
dence, mainly because previous reviews included fewer RCTs.
The joint guidelines from the European and American Associ-
ations for the Study of the Liver made four recommendations
of relevance to this review (EASL and AASLD guideline 2014a;
EASL and AASLD guideline 2014b). First, that lactulose should
be the first-choice treatment for an acute episode of overt hep-
atic encephalopathy in people with cirrhosis. Second, that lactu-
lose should be used for prevention of recurrent episodes of hepatic
encephalopathy after the initial episode. Third, that minimal hep-
atic encephalopathy should not be treated routinely. Fourth, that
primary prophylaxis for prevention of the development of hepatic
encephalopathy is not required in people with cirrhosis except if
they are known to be at high risk.
In agreement with the guideline recommendations, we found a
beneficial effect of non-absorbable disaccharides on clinical out-
comes in RCTs evaluating secondary prevention and treatment.
The guidelines do not recommend routine treatment of mini-
mal hepatic encephalopathy or primary prevention of hepatic en-
cephalopathy.Our analyses provide a large body of evidence show-
ing that people withminimal hepatic encephalopathy benefit from
non-absorbable disaccharides in relation to cognitive function-
ing and probably quality of life, and some evidence that non-ab-
sorbable disaccharides may be considered in primary prevention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes randomised clinical trials (RCTs) evaluating
the prevention and treatment of hepatic encephalopathy in people
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with cirrhosis. The analyses found that non-absorbable disaccha-
rides are associated with beneficial effects on mortality and hepatic
encephalopathy and that non-absorbable disaccharides can help to
reduce serious adverse events associated with the underlying liver
disease including liver failure, hepatorenal syndrome, and variceal
bleeding. The quality of the evidence was moderate. The inter-
ventions may also have a beneficial effect on quality of life, but
we were unable to combine the data in meta-analyses. The non-
serious gastrointestinal adverse events are well known and include
diarrhoea, bloating, and flatulence. The quality of the evidence
was very low for the secondary outcomes (quality of life and non-
serious adverse events). The mean treatment duration depended
on the type of encephalopathy, with five days for acute, 74 days
for chronic, 70 days for minimal, and 207 days for prevention of
hepatic encephalopathy. None of the RCTs comparing lactulose
versus lactitol evaluated quality of life. The review found no differ-
ences between lactulose and lactitol for the remaining outcomes.
The quality of the evidence was very low.
Implications for research
We used the EPICOT format (Brown 2006) in the definition of
implications for research:
Evidence (what is the current state of the evidence?): this review
includes 38 RCTs and provides moderate quality evidence that
non-absorbable disaccharides have a beneficial effect on clinical
outcomes. Additional research may be needed to further evaluate
the effect of the intervention in specific subgroups.
Participants (what is the population of interest?): the largest body
of evidence evaluated prevention of hepatic encephalopathy and
people with minimal hepatic encephalopathy. Only a relatively
small proportion of participants had chronic hepatic encephalopa-
thy or an acute episode of hepatic encephalopathy. Future research
may address the effect of non-absorbable disaccharides in these
groups.
Interventions (what are the interventions of interest?): the inter-
ventions assessed include lactulose and lactitol.
Comparisons (what are the comparisons of interest?): placebo-
controlledRCTs aswell asRCTs comparing lactulose versus lactitol
seem relevant. Future RCTs should also evaluate the effect of co-
interventions.
Outcomes (what are the outcomes of interest?): RCTs should in-
clude an assessment of mortality, hepatic encephalopathy, and ad-
verse events. Additional evidence evaluating the effect on quality
of life is also needed.
Time stamp (date of literature search): October 2015.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agrawal 2012
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 158 participants (see notes) with cirrhosis and a history, but no current
evidence, of overt hepatic encephalopathy. In total, 71% of participants in the lactulose
group and 73% in the control group had minimal hepatic encephalopathy at inclusion
Age (mean ± SD)
• Lactulose group 41 ± 10.7 years
• Control group 46.0 ± 11.2 years
Proportion of men
• Lactulose group 85.0%
• Control group 78.2%
Aetiology of cirrhosis
• Alcohol 40.0%
• Hepatitis B 20.9%
• Hepatitis C 15.3%
Interventions Lactulose syrup versus no intervention for 12 months
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Block design test
• Digit symbol test
• Critical Flicker Frequency
• Arterial blood ammonia
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and blood ammonia concentrations
assessed after 12 months
Inclusion period October 2008 to December 2009
Country of origin India
Notes • The trial includes 158 participants randomly allocated to lactulose or no
intervention and a third intervention arm with 77 participants allocated to a probiotic.
The probiotic group is not included in our analyses.
• The diagnosis of minimal hepatic encephalopathy was based on the presence of at
least 2 abnormal psychometric tests.
• The primary outcome of the trial was the development of overt hepatic
encephalopathy, graded using the West Haven Criteria, at 12 months.
• Secondary prophylaxis was defined as the prevention of recurrence of hepatic
encephalopathy during the follow-up period in participants who had recovered from a
previous episode of overt hepatic encephalopathy.
41Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Agrawal 2012 (Continued)
• The model of end stage liver disease (MELD) score (mean ± SD) at inclusion was
19.2 ± 5.5 in the lactulose group and 18.5 ± 4.2 in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Numbered, opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of the outcome
assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and report intention-to-
treat analyses that included all participants.
Missing outcome data are unlikely to affect
the analyses or to be associated with the
outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Brown 1971
Methods Double-blind, cross-over, single-centre inpatient/outpatient trial
Participants The trial includes 20 participants with advanced cirrhosis stabilised in hospital on a
low protein diet and then given increasing amounts of protein until they developed
overt hepatic encephalopathy. They were then randomised to treatment with lactulose
or placebo (sorbitol), which they received for prescribed, but not standardised periods
of time in rotation
• Patient characteristics: not reported
Interventions Lactulose syrup versus placebo (sorbitol) for a maximum of 30 months (see notes)
Outcomes Neuropsychiatric assessment
• Clinical status (no specific overall score)
• Subjective improvement e.g. ability to return to work
• Blood ammonia
• Electroencephalogram
• Number of hospitalisations
Outcomes included in meta-analyses No outcomes included in meta-analyses (see notes)
Inclusion period Not reported
Country of origin USA
Notes • The investigators initially evaluated participants in hospital, but continued
follow-up on an outpatient basis. Based on the text, we estimated that the maximum
treatment duration was 30 months.
• The published report excludes 11 participants for the following reasons: i) follow-
up too short (n = 2); ii) non-compliant with treatment (n = 3); iii) managed with
protein restriction alone (n = 3); iv) died due to acute alcoholic hepatitis (n = 2) or
lymphoma (n = 1). The authors report that 9 of the remaining participants responded
well with a reduction in the number of hospitalisations during treatment with
lactulose. Illustrative narrative data are provided on 5 of these 9 participants.
• We were unable to extract qualitative outcome data.
• The investigators did not assess the quality of life directly, but indirectly via the
subjective overall assessment of improvement (e.g. return to work).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of interventions
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
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Brown 1971 (Continued)
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators donot account for all par-
ticipants randomised (see notes)
Selective reporting (reporting bias) High risk Mortality data incomplete
For-profit funding High risk The trial received support in the form of a
grant from a pharmaceutical company
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Corazza 1982
Methods Double-blind, parallel-arm, single-centre inpatient trial
Participants The trial includes 32 participants with cirrhosis and chronic hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 53.7 ± 2.6 years
• Control group 54.1 ± 2.9 years
Proportion of men
• Lactulose group 37.5%
• Control group 50.0%
Aetiology of cirrhosis
• Alcohol 87.5%
• Hepatitis B 12.5%
Interventions Lactulose syrup versus placebo for 10 days
Outcomes Neuropsychiatric assessment
• Mental status (Encephalopathy Intensity Score)
• Blood ammonia
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Corazza 1982 (Continued)
• Electroencephalogram
Outcomes included in meta-analyses Mortality, adverse events, and blood ammonia concentrations assessed after 10 days
Inclusion period Not reported
Country of origin Italy
Notes • The trial includes 32 participants allocated to lactulose or placebo and a third
allocation arm with 20 participants allocated to pyridoxine-alpha-ketoglutarate. The
pyridoxine-alpha-ketoglutarate group is not included in our analyses.
• The trial describes the effects of the interventions on hepatic encephalopathy
based on an overall score, but does not provide an assessment of the changes in the
score from basal (improved or not improved); thus, we were unable to include the post-
intervention scores in our analyses.
• The authors give the impression that none of the included participants died.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded administration of interventions
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear outcome data for participants who
did not complete the trial. The trial does
not appear to have post-randomisation ex-
clusions although this is not specifically
stated
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Corazza 1982 (Continued)
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk Not reported
Other bias Low risk No for-profit funding
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Dhiman 2000
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 26 participants with cirrhosis and minimal hepatic encephalopathy.
None had a past history of overt hepatic encephalopathy (see notes)
Age (mean ± SD)
• Lactulose group 44.1 ± 18.0 years
• Control group 47.8 ± 13.5 years
Proportion of men
• Lactulose group 85.7%
• Control group 33.3%
Aetiology of cirrhosis
• Alcohol 36%
• Hepatitis B 23%
Interventions Lactulose syrup versus no intervention for 3 months
Outcomes Neuropsychiatric assessment
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Block Design Test
• Picture Completion Test
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 3 months
Inclusion period Not reported
Country of origin India
Notes • The investigators screened 40 people with cirrhosis and no past history or current
evidence of overt hepatic encephalopathy using a battery of psychometric tests. The
trial includes the 26 participants diagnosed as having minimal hepatic encephalopathy
on the basis of impaired performance on at least 2 of the 6 psychometric tests
administered. These 26 participants received lactulose (n = 14) or no treatment (n = 12)
. The paper also provides data on the remaining 14 people who did not have minimal
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Dhiman 2000 (Continued)
hepatic encephalopathy (6 of whom were tested at baseline and after 3 months). We
included data for participants with minimal hepatic encephalopathy in our analyses.
• The report provides the mean number of abnormal tests in the lactulose and
control group post intervention.
• The proportion of participants with Child’s Grade B/C at baseline was 71% in
the lactulose group and 67% in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Numbered opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and include all partici-
pants randomised in the analyses. Missing
outcome data unlikely to affect the analyses
or be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Elkington 1969
Methods Double-blind, cross-over, single-centre, outpatient trial
Participants The trial includes 7 participants with cirrhosis and chronic hepatic encephalopathy
(25%) or previous overt hepatic encephalopathy (75%). All participants had advanced
decompensated liver disease
• Participant’s characteristics are not reported (the paper states that participants had
decompensated cirrhosis).
Interventions Lactulose syrup versus placebo (sorbitol) for 15 days
Outcomes Neuropsychiatric assessment
• Mental status (modified Parson-Smith criteria)
• Arterial blood ammonia
• Electroencephalography
Outcomes included in meta-analyses Nooutcomes included in our primarymeta-analyses.Mortality andhepatic encephalopa-
thy assessed after 15 days included in sensitivity analyses
Inclusion period Not reported
Country of origin USA
Notes • The trial describes 7 participants who were randomised to lactulose or placebo
(sorbitol) and then after a wash-out period crossed over to the other treatment. We
were unable to extract data on the individual treatment periods. We therefore excluded
the trial from our analyses.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Blinded allocation of interventions
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
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Elkington 1969 (Continued)
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No losses to follow-up or dropouts seemed
to occur post-randomisation (clinical out-
come data are presented for all participants)
. The trial report does not include informa-
tion about the number of participants allo-
cated to the intervention and control group
during the first period
Selective reporting (reporting bias) Low risk Predefined outcomes described
For-profit funding High risk A pharmaceutical company provided fi-
nancial support
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Germain 1973
Methods Double-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 18 participants with cirrhosis who developed overt hepatic en-
cephalopathy after portal-systemic shunt surgery
Age (mean ± SD)
• Lactulose group 47.0 ± 14.2 years
• Control group 46.2 ± 16.6 years
Proportion of men
• Lactulose group 77.7%
• Control group 66.6%
Aetiology of cirrhosis not reported
Interventions Lactulose syrup versus placebo (saccharose-based) for 15 days
Outcomes Neuropsychiatric assessment
• Mental state (modified Parson-Smith criteria)
• Venous blood ammonia
• Psychometric tests
• Electroencephalography
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 15 days
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Germain 1973 (Continued)
Inclusion period Not reported
Country of origin France
Notes Published in French
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised. There are no missing
outcome data and no dropouts or losses to
follow-up post-randomisation
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical companywas involved in
the trial.
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Grandi 1991
Methods Open, cross-over, single-centre, inpatient trial
Participants The trial includes 40 participants with cirrhosis and chronic hepatic encephalopathy
Age (median)
• Both groups 59.3 years
Proportion of men
• Both groups 62.5%
Aetiology of cirrhosis
• Not reported
Interventions Crystalline lactulose versus lactitol for 60 days
Outcomes Neuropsychiatric assessment
• Modified Portal Systemic Encephalopathy Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events (see notes) assessed after 60 days
Inclusion period Not reported
Country of origin Italy
Notes • Published in Italian
• All participants had Child’s class B or C cirrhosis
• The trial does not describe the number of participants with or without an overall
improvement in manifestations of hepatic encephalopathy, but describes the
intervention effect using the overall score. We were therefore not able to include the
trial in the analyses evaluating hepatic encephalopathy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
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Grandi 1991 (Continued)
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and there are no post-
randomisation dropouts or losses to follow-
up
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk Pharmaceutical companies supplied the in-
terventions, but were not otherwise in-
volved in the trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Heredia 1987
Methods Open, parallel-arm, single-centre, inpatient trial
Participants The trial includes 40 participants with cirrhosis and an acute episode of hepatic en-
cephalopathy. In total, 65% had a previous history of overt hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 59.3 ± 3 years
• Lactitol group 60.0 ± 3 years
Proportion of men
• Lactulose group 55%
• Lactitol group 45%
Aetiology of cirrhosis
• Alcohol 48%
• Hepatitis B/C not reported
Interventions Lactulose syrup versus lactitol for 5 days
Outcomes Neuropsychiatric assessment
• Mental state (modified Conn Scale)
• Number Connection Test A
• Venous blood ammonia
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Heredia 1987 (Continued)
• Electroencephalography
Outcomes included in meta-analyses Mortality, adverse events, and blood ammonia assessed after 5 days
Inclusion period Not reported
Country of origin Spain
Notes 4 participants (10%) had undergone portal systemic shunt surgery
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Unclear risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and there are no post-
randomisation dropouts or losses to follow-
up
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied the
study drugs, but were not otherwise in-
volved in the trial
Other bias Low risk No other biases
53Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Heredia 1987 (Continued)
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Heredia 1988
Methods Open, cross-over, single-centre, outpatient trial
Participants The trial includes 20 participants with cirrhosis and previous portal-systemic shunt
surgery with chronic hepatic encephalopathy
Age (mean ± SD)
• Both groups 54.5 ± 2.1 years
Proportion of men
• Both groups 70%
Aetiology of cirrhosis
• Alcohol 60%
• Hepatitis B/C 24%
Interventions Lactulose syrup versus lactitol for 3 months
Outcomes Neuropsychiatric assessment
• Quantified neurological status
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality and adverse events assessed after 3 months (see notes)
Inclusion period Not reported
Country of origin Spain
Notes • The trial includes 25 participants. 2 died and 3 dropped out of the study. The
trial report does not provide information about the allocation arm (lactulose or lactitol)
of the participants who dropped out.
• The authors reports the effect on hepatic encephalopathy using the overall Portal
Systemic Encephalopathy Sum, but do not describe the number of participants with
(or without) an overall improvement in hepatic encephalopathy.
Risk of bias
Bias Authors’ judgement Support for judgement
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Heredia 1988 (Continued)
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants who died or dropped out are
excluded from the analyses
Selective reporting (reporting bias) High risk Mortality data incomplete
For-profit funding High risk A pharmaceutical company supplied lacti-
tol, but was not otherwise involved in the
trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Horsmans 1997
Methods Double-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 14 participants with cirrhosis and minimal hepatic encephalopathy.
None of the included participants had a history of overt hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 59.0 ± 8.7 years
• Control group 56.1 ± 14.2 years
Proportion of men
• Lactulose group 42.9%
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Horsmans 1997 (Continued)
• Control group 57.1%
Aetiology of cirrhosis
• Alcohol 35.7%
• Hepatitis B/C not reported
Interventions Crystalline lactulose versus placebo (lactose) for 15 days
Outcomes Neuropsychiatric assessment
• Number Connection Test A
• Race Track Test
• Automated sinusoid and psychomotor tests
• Electroencephalography
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results
assessed after 15 days
Inclusion period Not reported
Country of origin Belgium
Notes • Participants were not lactose intolerant
• The criteria for the diagnosis of minimal hepatic encephalopathy were not
specified; all participants were clinically normal and had normal
electroencephalograms, but had impaired psychometric performance.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Numbered sealed envelopes.
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
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Horsmans 1997 (Continued)
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised. All participants com-
pleted the trial
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied the
interventions, but was not otherwise in-
volved in the trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Jain 2013
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy
Age (median and range)
• Lactulose group 42 (15 to 70) years
• Control group 41 (17 to 68) years
Proportion of men
• Lactulose group 66.7%
• Control group 63.3%
Aetiology of cirrhosis
• Alcohol 58.3%
• Hepatitis B 18.3%
• Hepatitis C 15.0%
Interventions Lactulose syrup versus no intervention for 3 months
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Arterial blood ammonia
• Psychometric Hepatic Encephalopathy Score (PHES) comprising:
i) Number Connection Tests A and B
ii) Digit symbol test
iii) Serial dotting test
iv) Line drawing test
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Jain 2013 (Continued)
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 3 months
Inclusion period October 2011 to February 2012
Country of origin India
Notes • The investigators used the Psychometric Hepatic Encephalopathy Score to
diagnose minimal hepatic encephalopathy.
• The paper also includes follow-up data on 20 participants who did not have
evidence of minimal hepatic encephalopathy.
• The median (range) Model of End-stage Liver Disease score at inclusion was 19
(14 to 34) for the lactulose and 20 (14 to 32) for the control group.
• The paper also describes plasma cytokines and cerebral magnetic resonance
spectroscopy, which are not included in our analyses.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. This trial is registered on clin-
icaltrials.gov as placebo-controlled, but is
conducted and reported as an open trial in
which the control group received no inter-
vention.Noblinding of participants or per-
sonnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk No blinding of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators account for all partici-
pants randomised. 2 participants were lost
to follow-up and excluded from the analy-
ses
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Jain 2013 (Continued)
Selective reporting (reporting bias) High risk In the trial registration, the primary out-
come measure was ’improvement of min-
imal hepatic encephalopathy’. In the pub-
lished report the primary outcome was the
change in arterial blood ammonia, inflam-
matory mediators, serum endotoxins, and
cerebral magnetic resonance spectroscopy.
The published report describes “improve-
ment in minimal hepatic encephalopathy”
as a secondary outcome measure (reported
for participants receiving lactulose)
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Jankovic 1996
Methods Open, parallel-arm, single-centre, inpatient trial
Participants The trial includes 16 participants with cirrhosis admittedwith an acute episode of hepatic
encephalopathy. Participant characteristics not reported
Interventions Lactulose syrup versus lactitol for 5 to 7 days
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Number Connection Test A
• Electroencephalography
Outcomes included in meta-analyses Mortality and adverse events assessed after 5 to 7 days and 13 days after the end of
treatment (see notes)
Inclusion period Not reported
Country of origin Serbia
Notes • The authors reported the intervention effect on the mean values for the measured
variables, but did not report the number with (or without) overall improvement in
hepatic encephalopathy. We were therefore unable to include the data in our analysis
for the outcome hepatic encephalopathy.
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Jankovic 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants with missing outcome data are
not described and the analyses do not ac-
count for participants with missing out-
come data
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Li 1999
Methods Open, parallel-arm, multicentre, outpatient trial
Participants The trial includes 86 participants with cirrhosis and minimal hepatic encephalopathy
(see notes)
Age (mean ± SD)
• Lactulose group 47.6 ± 10.9 years
• Control group 41.5 ± 13.0 years
Proportion of men
• Lactulose group 77.1%
• Control group 89.5%
Aetiology of cirrhosis not reported
Interventions Lactulose syrup versus no intervention for 30 days
Outcomes Neuropsychiatric assessment
• Number Connection Test A
• Digit Symbol Test
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 30 days
Inclusion period January 1997 to January 1998
Country of origin China
Notes • Published in Chinese
• The participants had minimal hepatic encephalopathy diagnosed on the basis of
impaired performance on the Number Connection Test results or Digit Symbol Test
• The proportion of participants with Child’s Grades B/C in the lactulose group
was 79.2% and in the control group 84.2%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
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Li 1999 (Continued)
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised. All participants com-
pleted the trial
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
McClain 1984
Methods Double-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 32 participants with cirrhosis and minimal hepatic encephalopathy
(see notes)
Age (mean ± SD)
• Lactulose group 55 ± 6.5 years
• Control group 54.0 ± 9.1 years
Proportion of men
• Both groups 96.9%
Aetiology of cirrhosis
• Alcohol 100%
Interventions Lactulose syrup versus placebo (sucrose) for 3 months
Outcomes Neuropsychiatric assessment
• Number Connection Tests A and B
• Digit Symbol Test
• Speed of writing words
• Speed of writing numbers
Outcomes included in meta-analyses Adverse events assessed after 3 months (see notes)
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McClain 1984 (Continued)
Inclusion period Not reported
Country of origin USA
Notes • All included participants had minimal hepatic encephalopathy (psychometric
testing shows impaired cognitive function).
• The report describes the characteristics of participants who completed the trial
(lactulose 10 participants, placebo 12).
• The investigators assessed the quality of life based on the Katz social functioning
score. The publication does not include quantitative data, but the authors comment
that they saw no changes in the Katz score in response to treatment.
• We were unable to gather data on the number with (or without) improvement in
hepatic encephalopathy because the results are expressed as percentage change over
baseline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Central independent unit
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The paper does not account for participants
whodidnot complete the trial and the anal-
yses exclude participants with missing out-
come data
Selective reporting (reporting bias) Low risk Predefined outcomes reported
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McClain 1984 (Continued)
For-profit funding High risk A pharmaceutical company supplied the
interventions, but was not otherwise in-
volved in the trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Mittal 2011
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 80 participants with cirrhosis and minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 43.9 ± 10.9 years
• Control group 41.2 ± 11.9 years
Proportion of men
• Lactulose group 80%
• Control group 75%
Aetiology of cirrhosis
• Alcohol 37.5%
• Hepatitis B/C 35.0%
Interventions Lactulose syrup versus no intervention for 3 months
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Picture Completion Test
• Block Design Test
• Arterial blood ammonia
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, quality of life, and blood ammonia
concentration assessed after 3 months
Inclusion period October 2007 to October 2009
Country of origin India
Notes • The trial includes 160 participants randomised to lactulose (n = 40), probiotics (n
= 40), L-ornithine L-aspartate (n = 40), or no treatment (n = 40). The L-ornithine L-
aspartate and probiotic groups are not included in our analyses.
• The investigators based the diagnosis of minimal hepatic encephalopathy on the
presence of at least 2 abnormal psychometric tests. They expressed the psychometric
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Mittal 2011 (Continued)
test results as a Z score equating to the difference between the observed result and the
population norm. They defined a Z score of <-2 as abnormal.
• The investigators assessed quality of life with the Sickness Impact Profile
questionnaire, which assessed the influence of disease and treatment on daily
functioning. The questionnaire consists of 136 items, which are grouped into 12 scales
such as sleep and rest, eating, work, and home management. Scores range from 0 (best
score) to 100 (worst score). Changes in the score were calculated. The scores were
comparable at baseline. After treatment, the score was lower in the lactulose group
compared with controls.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handlemissing data in the anal-
yses of clinical outcomes (but not in the
analyses of surrogate outcomes). Missing
outcome data are unlikely to affect the anal-
yses or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
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Mittal 2011 (Continued)
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Morgan 1987a
Methods Double-blind, parallel-arm, single-centre, inpatient trial
Participants The trial includes 25 participants with cirrhosis and acute hepatic encephalopathy (see
notes)
Age (mean ± SD)
• Lactulose group 48.3 ± 15.8 years
• Lactitol group 48.4 ± 12.5 years
Proportion of men
• Lactulose group 46.7%
• Lactitol group 61.5%
Aetiology of cirrhosis
• Alcohol 53.7%
• Hepatitis B/C 0%
Interventions Lactulose versus lactitol as identically presented liquids for 5 days
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results
assessed after 5 days (end of treatment). Additional information retrieved for clinical
outcomes 1 month after the end of treatment (see notes)
Inclusion period July 1984 to December 1985
Country of origin United Kingdom
Notes • Initially, the investigators evaluated 27 potentially eligible participants, but
excluded 2 with fulminant hepatic failure before treatment. The investigators
randomised 25 participants, who experienced between them 28 episodes of hepatic
encephalopathy.
• 3 participants discontinued treatment with lactitol because they developed severe
nausea (n = 1), profuse gastrointestinal bleeding (n = 1), or ileus (n = 1). All 3
participants died after the end of treatment.
• None of the participants died during the trial. Participants who died after the
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Morgan 1987a (Continued)
completion of the trial had severely decompensated cirrhosis.
• The investigators reported that the time to improved manifestations of hepatic
encephalopathy was shorter in the group of participants allocated to lactitol.
• Participants with autoimmune hepatitis made up 23.1% of the lactulose group
and 13.3% of the lactitol group.
• All participants had Child’s Grade B/C cirrhosis.
• One of the review authors (Marsha Y Morgan) was the primary investigator on
the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Central independent unit
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind trial with administration of
the interventions as identically appearing
solutions. Blinding of participants and per-
sonnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Blinding of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised. There are no post-ran-
domisation exclusions (follow-up assess-
ments and clinical monitoring continued
for all participants, including those who
discontinued the interventions)
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied lacti-
tol, but was not otherwise involved in the
trial
Other bias Low risk No other biases
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Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Morgan 1987b
Methods Double-blind, cross-over, single-centre, outpatient trial
Participants The trial includes 12 participants with cirrhosis and chronic hepatic encephalopathy
Age (mean ± SD)
• Both groups 57.3 ± 11.5 years
Proportion of men
• Both groups 55.6%
Aetiology of cirrhosis
• Alcohol 44%
• Hepatitis B/C 0%
Interventions Lactulose versus lactitol as identically presented liquids for 3 months
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental status (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and
blood ammonia concentrations assessed after 3 months
Inclusion period November 1985 to February 1986
Country of origin United Kingdom
Notes • 3 of 9 participants had surgical portal-systemic shunts.
• In total, 56% of participants had cryptogenic cirrhosis.
• 3 of 12 participants did not complete the trial because they died (n = 1) or began
to abuse alcohol and were non-compliant in the early phase of the first treatment
period (n = 2). Data on all participants are included in our analyses.
• One of the review authors (Marsha Y Morgan) was primary investigator on the
trial.
Risk of bias
Bias Authors’ judgement Support for judgement
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Morgan 1987b (Continued)
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Central independent unit
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind trial with administration of
the interventions as identically appearing
solutions. Blinding of participants and per-
sonnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Blinding of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and there are no missing
outcome data
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied lacti-
tol, but was not otherwise involved in the
trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Morgan 1989
Methods Single-blind, cross-over, single-centre, outpatient trial
Participants The trial includes 20 participants with cirrhosis, minimal hepatic encephalopathy, and
no history of previous overt hepatic encephalopathy (see notes)
Age (mean and range)
• Both groups 52.0 (37 to 66) years
Proportion of men
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Morgan 1989 (Continued)
• Both groups 78.6%
Aetiology of cirrhosis
• Alcohol 100%
Interventions Lactulose syrup versus lactitol for 2 months.
Outcomes Neuropsychiatric assessment
• Mental status (Modified Conn Score)
• Number Connection Tests A and B
• Digit Symbol Test
• Digit Copying Test
• Computer-based visual reaction time
• Computer-based perceptual maze test
• Electroencephalography
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and Number Connection Test results
assessed after 2 months
Inclusion period October 1986 to April 1988
Country of origin United Kingdom
Notes • All participants were abstinent from alcohol.
• 6 of the initially randomised participants did not complete 2 weeks of treatment
because of non-serious adverse events (lactitol n = 1) or for reasons unrelated to the
trial (lactulose: n = 2; lactitol: n = 3). 14 participants completed the trial. None died.
We included data on all randomised participants in our analyses.
• One of the review authors (Marsha Y Morgan) was the primary investigator on
the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Numbered, opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open, single-blind trial. No blinding of
participants or personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
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Morgan 1989 (Continued)
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open, single-blind trial. Blinding of out-
come assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and there are no missing
outcome data
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied lacti-
tol, but was not otherwise involved in the
trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Pai 1995
Methods Single-blind, parallel-arm, single-centre, inpatient trial
Participants The trial includes 41 participants with cirrhosis and acute hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 65.9 ± 9.8 years
• Lactitol group 67.5 ± 4.9 years
Proportion of men
• Lactulose group 75.0%
• Lactitol group 95.0%
Aetiology of cirrhosis
• Alcohol 18%.
• Hepatitis B/C 69%
Interventions Lactulose syrup versus lactitol for 5 days
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
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v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 5 days
Inclusion period April 1993 to April 1994
Country of origin Taiwan
Notes All participants had Child’s Grade B/C cirrhosis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open, single-blind trial. No blinding of
participants or personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open, single-blind trial. Blinding of out-
come assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators account for all partici-
pants randomised, but do not include par-
ticipants who died or dropped out in the
reported analyses
Selective reporting (reporting bias) High risk The trial report does not include informa-
tion about the allocation group of partici-
pants who died within the first 5 days after
randomisation
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
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Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Prasad 2007
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 61 participants with cirrhosis and minimal hepatic encephalopathy
(see notes)
Age (mean and range)
• Lactulose group 48.3 (38.4 to 58.2) years
• Control group 50.6 (39.1 to 62.1) years
Proportion of men
• Lactulose group 87.1%
• Control group 93.3%
Aetiology of cirrhosis
• Alcohol 65%
• Hepatitis B/C 30%
Interventions Lactulose syrup versus no intervention for 3 months
Outcomes Neuropsychiatric assessment
• Mini Mental State Examination
• Mental status (West Haven Criteria)
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Picture Completion Test
• Block Design Test
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and quality of life assessed after 3
months
Inclusion period January 2004 to March 2005
Country of origin India
Notes • The investigators based the diagnosis of minimal hepatic encephalopathy on the
presence of at least 2 abnormal psychometric tests. They expressed the psychometric
test results as a Z score equating to the difference between the observed result and the
population norm. They defined a Z score of <-2 as abnormal. The investigators
calculated a mean Z score (mZS) for each patient and referred to changes in the
number of abnormal tests AbnNP and the mZS at the end of treatment or follow-up as
1AbnNP and 1mZS
• The proportion with Child’s Grade B/C was 66.7% in the lactulose group and 55.
2% in the control group.
• The investigators describe 29 participants who were neuropsychiatrically
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Prasad 2007 (Continued)
unimpaired and followed them for 3 months in the same way as the participants in the
randomised clinical trial.
• The investigators assessed the quality of life based on the Sickness Impact Profile.
They defined the change in the total score after follow-up as the estimated change in
the overall quality of life. At baseline, participants with minimal hepatic
encephalopathy had impairment in 11 of the 12 scales in the score (in particular the
social interaction, alertness, emotional behaviour, sleep, work, home management,
recreation and pastime).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handlemissing data in the anal-
yses of clinical outcomes. 5 participants in
the control group and none in the lactulose
group were lost to follow-up. Missing out-
come data are unlikely to affect the analyses
or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
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Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Quero 1997
Methods Double-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 40 participants with cirrhosis and minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 51.9 ± 13.0 years
• Control group 49.7 ± 12 years
Proportion of men
• Lactulose group 73.7%
• Control group 71.4%
Aetiology of cirrhosis
• Alcohol 27.5%
• Hepatitis B/C 30.0%
Interventions Crystalline lactulose versus placebo (lactose) for 6 months
Outcomes Neuropsychiatric assessment
• Mental status (criteria not specified)
• Number Connection Test A
• Symbol Digit Test
• Electroencephalogram
• Arterial ammonia concentration
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and quality of life assessed after a
maximum of 9 months (3 months after the end of therapy)
Inclusion period October 1992 to September 1994
Country of origin Holland
Notes • The investigators diagnosed participants with at least 2 abnormal psychometric
tests scores as having minimal hepatic encephalopathy.
• All participants had elevated blood ammonia levels.
• Proportion with Child’s Grade B/C was 21.0% in the lactulose group and 9.5%
in the control group.
• The investigators assessed quality of life using the Sickness Impact Profile and
defined the change in the total score after follow-up as the estimated change in the
overall quality of life. At baseline, participants with minimal hepatic encephalopathy
had impairment in 11 of the 12 scales in the score (in particular social interaction,
alertness, emotional behaviour, sleep, work, home management, recreation and
pastime).
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Centrally prepared, numbered drug con-
tainers
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators account for all partici-
pants randomised, but the trial report ex-
cludes participants with missing outcomes
(2 fromboth intervention groups) from the
analyses
Selective reporting (reporting bias) Low risk Predefined outcomes not reported
For-profit funding High risk The trial received funding from a pharma-
ceutical company
Other bias Low risk No other biases identified
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
76Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Raza 2004
Methods Open, parallel-arm, single-centre, inpatient trial
Participants The trial includes 31 participants with cirrhosis experiencing an acute episode of hepatic
encephalopathy
Age (mean)
• Lactulose group 55.1 years
• Control group 52.4 years
Proportion of men
• Lactulose group 27.8%.
• Control group 46.2%.
Aetiology of cirrhosis
• Hepatitis B/C 100%
Interventions Lactulose enemata versus tap water enemata administered for a mean of 4.5 days de-
pending on clinical response
Outcomes Neuropsychiatric assessment
• Clinical scoring (Jones and Gammal)
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Digit Symbol Test (replacing Number Connection Test A)
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality and hepatic encephalopathy assessed after a mean duration of 4.5 days
Inclusion period Not reported
Country of origin Pakistan
Notes • The primary outcome was the time to improvement.
• The investigators made the assessments at 48 hours and then at the end of
treatment, which was on average 4.5 days.
• Both allocation groups also received oral lactulose syrup.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The investigators described the allocation
as 1:1, but the allocation sequence genera-
tion is unclear
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
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Raza 2004 (Continued)
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of the outcome
assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants who were excluded or lost to
follow-up are not described. The handling
of participants with missing outcomes is
unclear
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied the
drug, but was not otherwise involved in the
trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Riggio 1989
Methods Single-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 31 participants with cirrhosis who had undergone portal-systemic
shunt surgery and evaluates the prevention of hepatic encephalopathy. In total, 46.7%
in the lactulose group and 37.5% in the lactitol group had experienced at least 1 episode
of hepatic encephalopathy within 1 year of inclusion of the trial.
Age (mean ± SD)
• Lactulose group 49 ± 13 years
• Lactitol group 59 ± 6 years
Proportion of men
• Lactulose group 73.3%
• Lactitol group 68.8%
Aetiology of cirrhosis
• Alcohol 19%
• Hepatitis B/C 19%
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Riggio 1989 (Continued)
Interventions Lactulose syrup versus lactitol for 6 months
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 6 months
Inclusion period Not described
Country of origin Italy
Notes • The proportion of participants with Grade B/C cirrhosis was 13.3% in the
lactulose and 12.5% in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Numbered, opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open, single-blind trial. No blinding of
participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open, single-blind trial. Blinding of out-
come assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised; there are nomissing out-
come data and all participants are included
in the analyses
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Riggio 1989 (Continued)
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied the
lactitol, but was not otherwise involved in
the trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Riggio 2005
Methods Single-blind, parallel-arm, single-centre, inpatient/outpatient trial
Participants The trial includes 50 participants with cirrhosis randomised immediately after tran-
sjugular intrahepatic portosystemic shunt (TIPS) placement. 15% (8% in the lactitol
group and 24% in the control group) had experienced a previous episode of hepatic
encephalopathy
Age (mean ± SD)
• Lactitol group 60.6 ± 9.0 years
• Control group 54.9 ± 11.7 years
Proportion of men
• Lactitol group 56%
• Control group 84%
Aetiology of cirrhosis
• Alcohol 34%
• Hepatitis B/C not reported.
Interventions Lactitol versus no intervention for 6 months
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, and blood ammonia concentrations
assessed after 6 months
Inclusion period November 1998 to September 2003
Country of origin Italy
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Notes • The trial includes 75 participants randomised to no treatment (n = 25), lactitol (n
= 25), or rifaximin (n = 25). The rifaximin group is not included in our analyses.
• The proportion of participants with Child’s B/C cirrhosis was 76% in the lactitol
group and 64% in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Numbered, opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants and
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open, single-blind trial. Blinding of out-
come assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handle missing data. Missing
outcome data are unlikely to affect the anal-
yses or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Methods Double-blind, cross-over, single-centre, outpatient trial
Participants The trial includes 6 participants with cirrhosis and chronic hepatic encephalopathy. 3
are described in detail
Age (mean)
• Both groups: 65 years
Proportion of men
• Both groups: 66%
Aetiology of cirrhosis not reported
Interventions Lactulose syrup versus placebo (sorbitol) (see notes)
Outcomes Neuropsychiatric assessment
• Clinical grading (criteria not described)
• Blood ammonia
• Electroencephalography
Outcomes included in meta-analyses None (see notes)
Inclusion period 1967 to 1970
Country of origin USA
Notes • The investigators randomised 6 participants to treatment with lactulose or placebo
(sorbitol) alternatively for 2-month periods. The paper describes 3 of these participants
in detail. We were unable to extract quantitative data from the trial publication.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Centrally prepared, numbered drug con-
tainers
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
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Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators donot account for all par-
ticipants randomised in the trial report or
analysis
Selective reporting (reporting bias) High risk Predefined outcomes not reported
For-profit funding High risk A pharmaceutical company supported the
trial with a grant and supplied the drug and
placebo
Other bias Low risk No other biases identified
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Sharma 2009
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 140 participants with cirrhosis who had recovered from an episode of
overt hepatic encephalopathy. The trial evaluates secondary prevention. In total, 57% of
included participants had minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 48.2 ± 8.4 years
• Control group 44.9 ± 10.2 years
Proportion of men
• Lactulose group 77.1%
• Control group 71.4%
Aetiology of cirrhosis
• Alcohol 39.2%
• Hepatitis B/C 39.2%
Interventions Lactulose syrup versus no intervention for 12 months
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Digit Symbol Test
• Object Assembly Test
• Critical flicker frequency
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Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 12 months
Inclusion period January 2006 to June 2008
Country of origin India
Notes • The investigators defined the primary endpoint as the development of an episode
of overt hepatic encephalopathy 6 months after randomisation.
• The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion
was 21.8 ± 3.4 in the lactulose group and 20.6 ± 2.4 in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. The investigators describe the
trial as placebo-controlled, but the placebo
intervention is not described in the meth-
ods section describes the trial as open. No
blinding of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Open trial. The investigators describe the
trial as placebo-controlled in the trial reg-
istry, but the placebo intervention is not
mentioned in the methods section of the
published RCT. No blinding of outcome
assessment
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
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Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Sharma 2011
Methods Open, parallel-arm, single-centre, inpatient trial
Participants The trial includes 70 participants with cirrhosis who were stable after an acute variceal
bleed. In total, the trial included 16% with a previous episode of hepatic encephalopathy
(17.1% in the lactulose group and 14.3% in the control group). The trial evaluates
prevention of hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 41.6 ± 12.9 years
• Control group 37.2 ± 16.0 years
Proportion of men
• Lactulose group 86%
• Control group 80%
Aetiology of cirrhosis
• Alcohol 47%
• Hepatitis B/C 37%
Interventions Lactulose syrup versus no intervention for 120 hours
Outcomes Neuropsychiatric assessment
• Mental state (West Haven Criteria)
• Arterial blood ammonia
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 120 hours
Inclusion period December 2008 to January 2010
Country of origin India
Notes • The trial report describes the blood ammonia concentrations for participants who
did not did not develop hepatic encephalopathy, but not the values for participants in
the 2 allocation groups.
• The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion
was 16.7 ± 5.7 in the lactulose group and 15.8 ± 3.8 in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Serially numbered, opaque, sealed en-
velopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partic-
ipants randomised. There are no partic-
ipants with post-randomisation missing
outcome data
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Sharma 2012
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 120 participants with cirrhosis and no history of overt hepatic en-
cephalopathy. Of these, 57% had minimal hepatic encephalopathy at inclusion. The
trial evaluates prevention of hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 43.4 ± 12.5 years
• Control group 42.2 ± 11.5 years
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Sharma 2012 (Continued)
Proportion of men
• Lactulose group 80.0%
• Control group 88.3%
Aetiology of cirrhosis
• Alcohol 30.8%
• Hepatitis B 30.0%
• Hepatitis C 12.5%
Interventions Lactulose syrup versus no intervention for 12 months
Outcomes Neuropsychiatric assessment
• Mental status (West Haven Criteria)
• Number Connection Tests A and B
• Figure Connection Tests A and B
• Picture Completion Test
• Digit Symbol Test
• Serial Dotting Test
• Line Tracing Test
• Critical flicker frequency
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 12 months
Inclusion period January 2008 to September 2009
Country of origin India
Notes • The investigators based the diagnosis of minimal hepatic encephalopathy on the
finding of 2 or more abnormal psychometric tests.
• The investigators switched 4 participants from the control to the intervention
group. These participants are included in their original allocation group in our analyses.
• The Model for End-Stage Liver Disease (MELD) score (mean ± SD) at inclusion
was 13.4 ± 4.8 in the lactulose group and 12.3 ± 4.8 in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
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Sharma 2012 (Continued)
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handle missing data. Missing
outcome data are unlikely to affect the anal-
yses or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes are reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) Low risk Low risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Shi 1997
Methods Double-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 31 participants with cirrhosis and minimal hepatic encephalopathy
Mean age
• Both groups 54 years
Proportion of men
• Both groups 87%
Aetiology of cirrhosis
• Alcohol 0%
• Hepatitis B/C not described
Interventions Lactitol versus placebo (glucose) for 2 weeks
Outcomes Neuropsychiatric assessment
• Number Connection Test
• Digit Symbol Test
• Somatosensory evoked potentials
• Blood ammonia
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Shi 1997 (Continued)
Outcomes included in meta-analyses No outcomes (see notes)
Inclusion period Not reported
Country of origin China
Notes • The authors do not describe the criteria used to diagnose minimal hepatic
encephalopathy.
• No numerical data are provided.
• Published in Chinese.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Administration of coded, identical drug
containers
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Patient with missing outcome data are not
described and the handling of participants
with missing outcomes in the analyses is
unclear
Selective reporting (reporting bias) High risk Predefined outcomes not reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
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Shi 1997 (Continued)
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Simmons 1970
Methods Double-blind, parallel-arm, single-centre, inpatient trial
Participants The trial includes 26 participants with cirrhosis and acute hepatic encephalopathy
Age (mean ± SD)
Lactulose group 50.4 ± 7.6 years
Control group 51.8 ± 6.7 years
Proportion of men
• Both groups 100%
Aetiology of cirrhosis
• Alcohol 100%
Interventions Lactulose syrup versus placebo (glucose) for 10 days
Outcomes Neuropsychiatric assessment
• Mental function tests (Sherlock)
• Venous blood ammonia
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 10 days
Inclusion period Not reported
Country of origin USA
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
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Simmons 1970 (Continued)
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised. There are no missing
outcomes and all participants are included
in the analyses
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk A pharmaceutical company supplied lactu-
lose, but was not otherwise involved in the
trial
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Uribe 1987a
Methods Double-blind, cross-over, single-centre, inpatient trial
Participants The trial includes 37 participants with cirrhosis and acute hepatic encephalopathy
Participant characteristics not reported
Interventions Rectal lactitol enemata versus rectal placebo enemata (lactose or tap water) for 4 days
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and
blood ammonia concentrations assessed after 4 days
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Uribe 1987a (Continued)
Inclusion period Not reported
Country of origin Mexico
Notes • The trial includes 37 participants with cirrhosis experiencing 45 episodes of acute
overt hepatic encephalopathy.
• The investigators undertook a pre-agreed group sequential analysis of response
after randomisation of the first 20 participants to enemata of lactitol (n = 10), lactose
(n = 5), or tap water (n = 5). The investigators discontinued the tap water arm because
the mortality rate was high; the trial continued with the randomisation of participants
to lactitol or lactose.
• In our analyses, we combined participants randomised to the tap water and
lactose groups (n = 23).
• None of the participants in the trial was lactose intolerant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Blinded administration of coded drug con-
tainers
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all partici-
pants randomised and there are no missing
outcome data
Selective reporting (reporting bias) Low risk Predefined outcomes are described
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Uribe 1987a (Continued)
For-profit funding High risk One of the trial investigators was an em-
ployee of a pharmaceutical company,which
manufactured the trial drug
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Uribe 1987b
Methods Double-blind, cross-over, single-centre, outpatient trial
Participants The trial includes 20 participants with cirrhosis and chronic hepatic encephalopathy
Age (mean ± SD)
• Lactitol group 41.0 ± 1.5 years
• Control group 40.8 ± 2.5 years
Proportion of men
• Lactitol group 62.5%
• Control group 40.0%
Aetiology of cirrhosis
• Alcohol 44%
• Hepatitis B/C 55%
Interventions Lactitol versus placebo (lactose) for 2 weeks
Outcomes Neuropsychiatric assessment
• Portal Systemic Encephalopathy Sum and Index comprising:
i) Mental state (West Haven Criteria)
ii) Asterixis
iii) Number Connection Test A
iv) Venous blood ammonia
v) Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events, Number Connection Test results, and
blood ammonia concentrations assessed after 2 weeks
Inclusion period Not reported
Country of origin Mexico
Notes None of the participants in the control group was lactose intolerant
Risk of bias
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Uribe 1987b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Blinded administration of coded drug con-
tainers
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of participants and personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Double-blind, placebo-controlled. Blind-
ing of outcome assessment
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators account for all partici-
pants randomised. There are no missing
data for clinical outcomes, but trial au-
thors exclude 2 participants from the re-
ported analyses. The 2 participants devel-
oped complications requiring antibiotics
and never received the trial medication
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding High risk One of the trial investigators was an em-
ployee of a pharmaceutical company,which
manufactured the trial drug
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
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Watanabe 1997
Methods Open, parallel-arm, multicentre, outpatient trial
Participants The trial includes 75 participants with cirrhosis and previous overt hepatic encephalopa-
thy. In total, 48% hadminimal hepatic encephalopathy and 52%were unimpaired based
on neuropsychiatric assessment
Age (mean ± SD)
• Lactulose group (unimpaired) 56.7 ± 9.5 years
• Control group (unimpaired) 58.6 ± 6.2 years
• Lactulose group (minimal hepatic encephalopathy) 62.0 ± 7.3 years
• Control group (minimal hepatic encephalopathy) 65.6 ± 7.1 years
Proportion of men
• Lactulose and control group (unimpaired) 62%
• Lactulose and control group (minimal hepatic encephalopathy) 47%
Aetiology of cirrhosis
• Alcohol 11%
• Hepatitis B/C 78%
Interventions Lactulose syrup versus no intervention for 8 weeks (see notes)
Outcomes Neuropsychiatric assessment
• Mental state (Conn)
• Number Connection Test part A
• Symbol Digit Test
• Block Design Test
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events assessed after 8 weeks (see notes)
Inclusion period Not reported
Country of origin Japan
Notes • The primary publication (full paper article) does not describe quality of life, but
an earlier published abstract, reporting the same trial, states that the investigators
assessed quality of life “quantitatively according to the reported criteria” without
information about the specific method. The abstract reports that participants
randomised to lactulose had improved quality of life (general fatigue and abdominal
distension) although no quantitative data are provided.
• The investigators diagnosed 39 participants as neuropsychiatrically unimpaired
and 36 participants as having minimal hepatic encephalopathy on the basis of
psychometric testing. We combined the outcomes for the 2 groups in our primary
analysis.
• The investigators followed 62 of the 75 participants for 6 months after the trial
and registered that 18 participants with minimal hepatic encephalopathy and 11
participants diagnosed as unimpaired continued lactulose. 5 participants with minimal
hepatic encephalopathy and 4 participants who were unimpaired started de novo
lactulose after completing the trial.
Risk of bias
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Watanabe 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Numbered, opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants with missing outcome data are
excluded from the analyses. The authors
do not include information about the allo-
cation group for participants with missing
outcomes
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Wen 2013
Methods Open, parallel-arm, single-centre, inpatient trial
Participants The trial includes 130 participants with cirrhosis experiencing an acute upper gastroin-
testinal haemorrhage. None had overt or minimal hepatic encephalopathy at inclusion.
The trial evaluates prevention of hepatic encephalopathy
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Wen 2013 (Continued)
Age (mean ± SD)
• Lactulose group 53.0 ± 13.3 years
• Control group 50,4 ± 10.2 years
Proportion of men
• Lactulose group 48.4%
• Control group 51.5%
Aetiology of cirrhosis
• Alcohol 8%
• Hepatitis B/C 75%
Interventions Lactulose syrup versus no intervention for 7 days
Outcomes Neuropsychiatric assessment
• Mental state (West Haven Criteria)
• Number Connection Test
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 7 days
Inclusion period May 2007 to July 2011
Country of origin China
Notes • The proportion of participants with Child’s B/C was 39.7% in the lactulose
group and 49.2% in the control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open trial. Blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
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Wen 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk The investigators account for all partici-
pants randomised. There are no missing
clinical outcomes, but the trial authors ex-
clude 2 participants who were intolerant to
lactulose from the reported analyses
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Xing 2003
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 45 participants with cirrhosis and minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 33.6 ± 9.6 years
• Control group 38.5 ± 6.8 years
Proportion of men
• Lactulose group 66.7%
• Control group 58.3%
Aetiology of cirrhosis
• Alcohol 20.0%
• Hepatitis B/C 68.9%
Interventions Lactulose syrup versus no intervention for 4 weeks
Outcomes Neuropsychiatric assessment
• Number Connection Test
• Verbal and Performance Intelligence Quotient tests
• Blood ammonia
• Electroencephalogram
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 4 weeks
Inclusion period February 2000 to March 2002
Country of origin China
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Xing 2003 (Continued)
Notes • Published in Chinese.
• The method used to diagnose minimal hepatic encephalopathy is not described.
• Participants in the intervention and control group also received vitamin B and
silymarin.
• Of the 48 participants randomised, 3 (1 assigned to lactulose and 2 to no
intervention) did not complete the trial according to the protocol. The outcome of
these participants is described in the publication.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handle missing data. Missing
outcome data are unlikely to affect the anal-
yses or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
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Xing 2003 (Continued)
Overall assessment (non-mortality out-
comes)
High risk High risk
Yao 2014
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 40 participants with cirrhosis and minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 45.52 ± 6.34 years
• Control group 45.23 ± 7.46 years
Proportion of men
• Lactulose and control group 67.5%
Aetiology of cirrhosis
• Alcohol not described
• Hepatitis not described
Interventions Lactulose syrup versus no intervention for 4 weeks
Outcomes Neuropsychiatric assessment
• Number Connection Test
• Digit Symbol Test
• Mini Mental State Examination
Outcomes included in meta-analyses Mortality and Number Connection Test results assessed after 15 days
Inclusion period May 2011 to July 2013
Country of origin China
Notes The trial report describes the effects on lactulose using surrogate outcomes and does
not include information about the number of participants with (or without) an overall
improvement of hepatic encephalopathy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk The authors specify that allocation was
concealed, but do no specify the method of
concealment
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
Unclear risk Open trial. No blinding of participants or
personnel.
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Yao 2014 (Continued)
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Unclear risk Open trial. No blinding of outcome assess-
ment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants are described and there are
no missing outcome data
Selective reporting (reporting bias) Low risk Predefined outcomes are reported (see
notes).
For-profit funding Unclear risk Funding not described
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk of bias
Overall assessment (non-mortality out-
comes)
High risk High risk of bias
Zeng 2003
Methods Open, parallel-arm, single-centre, outpatient trial
Participants The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy
with no previous history of overt hepatic encephalopathy
Age (mean ± SD)
• Short -term lactulose 50 ± 16 years
• Long-term lactulose 49 ± 17 years
• Control 49 ± 13 years
Proportion of men
• All groups 85%
Aetiology of cirrhosis
• Alcohol 17%
• Hepatitis B/C 63%
Interventions Lactulose syrup versus no intervention for eight or 24 weeks (see notes)
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Zeng 2003 (Continued)
Outcomes Neuropsychiatric assessment
• Number Connection Test
• Digit Symbol Test
• Electroencephalography
• Venous blood ammonia
• Sensory Evoked Potentials
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, adverse events assessed after a maximum of 24 weeks
(see notes)
Inclusion period July 1998 to March 2002
Country of origin China
Notes • The investigators assess quality of life using the World Health Organization
quality of life BREF (WHOQOL-BREF) including the domains physical health,
psychological health, social relationships, and environment.
• The method for diagnosing minimal hepatic encephalopathy is not specified.
• The trial includes the following 3 allocation arms: lactulose for 8 weeks, lactulose
for 24 weeks, and no intervention. We combined the results of the 2 lactulose arms in
our analyses.
• All participants in the intervention and control groups also received vitamin B
and silymarin.
• The proportion of participants with Child’s B/C cirrhosis was 75% in the short-
term lactulose arm, 60% in the long-term lactulose arm, and 60% in the control arm.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open trial. No blinding of participants or
personnel.
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
High risk Open trial. No blinding of the outcome
assessment.
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Zeng 2003 (Continued)
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk The investigators account for all par-
ticipants randomised and used sufficient
methods to handle missing data. Missing
outcome data are unlikely to affect the anal-
yses or to be associated with the outcome
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
Ziada 2013
Methods Single-blind, parallel-arm, single-centre, outpatient trial
Participants The trial includes 60 participants with cirrhosis and minimal hepatic encephalopathy
Age (mean ± SD)
• Lactulose group 48.8 ± 8.2 years
• Control group 51.2 ± 7.5 years
Proportion of men
• Lactulose group 75.0%
• Control group 72.0%
Aetiology of cirrhosis
• Not reported
Interventions Lactulose syrup versus no intervention for 4 weeks
Outcomes Neuropsychiatric assessment
• Mental status (West-Haven Criteria)
• Number Connection Test A
• Block Design Test
• Digit Symbol Test
• Serial-dotting test
• Line tracing test
• Blood ammonia
• Cerebral magnetic resonance spectroscopy
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Ziada 2013 (Continued)
Outcomes included in meta-analyses Mortality, hepatic encephalopathy, and adverse events assessed after 4 weeks
Inclusion period March 2010 to January 2012
Country of origin Egypt
Notes • The trial includes 90 participants randomised to lactulose (n = 30), a probiotic (n
= 30), or to no treatment (n = 30). We did not include the probiotics group in our
analyses.
• The investigators based the diagnosis of minimal hepatic encephalopathy on the
finding of at least 2 abnormal psychometric tests.
• The proportion of participants with Child’s B/C cirrhosis was 91.7% in the
lactulose group and 88.0% in the control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Non-mortality outcomes
High risk Open, single-blind trial. No blinding of
participants or personnel
Blinding of participants and personnel
(performance bias)
Mortality
Low risk Performance bias unlikely to influence the
outcome
Blinding of outcome assessment (detection
bias)
Non-mortality outcomes
Low risk Open, single-blind trial. Blinding of out-
come assessment.
Blinding of outcome assessment (detection
bias)
Mortality
Low risk Detection bias unlikely to influence the
outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants with missing outcomes are ex-
cluded from the analyses
Selective reporting (reporting bias) Low risk Predefined outcomes reported
For-profit funding Low risk No for-profit funding
Other bias Low risk No other biases
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Ziada 2013 (Continued)
Overall assessment (mortality) High risk High risk
Overall assessment (non-mortality out-
comes)
High risk High risk
RCT: randomised clinical trial
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bajaj 2010a Observational study. Retrospective reviewof participantswith cirrhosismaintained on lactulose following an index
episode of hepatic encephalopathy. The outcomes included recurrence of hepatic encephalopathy, precipitating
factors, and compliance with lactulose treatment. The analyses compared participants with/without a recurrence
of hepatic encephalopathy and identified the predictors of recurrence
Bircher 1971 Case series reporting the effects of protein intake, lactulose, and neomycin on clinical grading, electroencephalog-
raphy, and blood ammonia levels in 6 participants with cirrhosis and chronic hepatic encephalopathy
Brown 1970 Case series reporting neuropsychiatric status and associated variables in 4 participants with cirrhosis and post-
shunt hepatic encephalopathy during alternating periods of treatment with lactulose and sorbitol
James 1971 Observational study. Careful documentation of the effects of treatment with lactulose over 10 days on cerebral
blood flow and metabolism in 6 participants with cirrhosis and chronic hepatic encephalopathy
Lanthier 1985 Observational cross-over study comparing the effects of 3 months of treatment with lactulose and lactitol on
mental status, psychometric performance, venous blood ammonia levels, electroencephalography mean cycle
frequency, and cerebral blood flow and metabolism in 5 participants with chronic hepatic encephalopathy
Merli 1992 Observational study on the effects of treatment with lactulose or lactitol on faecal fat excretion in 18 participants
with cirrhosis
Patil 1987 Observational study detailing the differential effects of lactulose and lactitol on (i) an in vitro faecal incubation
system and (ii) on terminal ileal and colonic pH in 6 normal participants using radiotelemetry
Piotraschke 1996 Observational open study published in abstract form describing the non-comparative effect of lactulose on
preventing hepatic encephalopathy in participants with cirrhosis following insertion of a transjugular intrahepatic
portosystemic shunt
Pockros 2009 Randomised clinical trial of lactulose versus AST-120 (spherical carbon adsorbent). The trial includes 47 partic-
ipants with cirrhosis and overt hepatic encephalopathy. The trial did not include a placebo or no intervention
group
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(Continued)
Quinton 1982 Randomised clinical trial of mannitol lavage versus a combination of lactulose and the antibiotic kanamycin for
the prevention of hepatic encephalopathy following gastrointestinal haemorrhage in participants with cirrhosis.
The trial did not include a placebo/no intervention group
Rahimi 2014 Randomised clinical trial on lactulose versus polyethylene glycol for the treatment of acute hepatic encephalopathy.
The trial did not include a placebo/no intervention group
Riggio 1990 Observational study comparing the effect of lactulose or lactitol on the faecal flora of 21 participants with cirrhosis
and no evidence of hepatic encephalopathy
Rorsman 1970 Case series reporting the responses of 3 participants with cirrhosis and post-shunt hepatic encephalopathy to
treatment with lactulose
Salerno 1994 Observational study on the differential effects of 2 different doses of lactitol on neuropsychiatric status in
participants with cirrhosis
Schomerus 1993 A field study documenting the prevalence of minimal hepatic encephalopathy in ambulatory participants with
cirrhosis
Sharma 2008 Randomised trial of lactulose versus probiotics for the treatment of minimal hepatic encephalopathy. The trial
does not include a placebo or no intervention group
Sharma 2009a Observational study to identify the predictors of minimal hepatic encephalopathy in participants with cirrhosis
Sharma 2010 Observational study evaluating predictors of non-response to lactulose in participants with cirrhosis and overt
hepatic encephalopathy
Sharma 2010a Observational study evaluating the prevalence of abnormal psychometric tests and critical flicker frequency after
clinical recovery of overt hepatic encephalopathy
Sharma 2011a Retrospective review of the efficacy of lactulose for the treatment of hepatic encephalopathy in young people
with hepatic encephalopathy
Trovato 1995 Observational study of the effects of lactitol on clinical status and blood ammonium, atrial natriuretic peptide,
and amino acid concentrations in 10 participants with cirrhosis and hepatic encephalopathy
Vendemiale 1992 An open comparison of the effects of 10 days treatment with lactulose or no treatment on blood ammonia levels,
Number Connection Test results, and lymphocyte sub-populations in people with cirrhosis
Venturini 2005 Randomised clinical trial of the effect of rifaximin, lactulose, and placebo on circulating benzodiazepine-like
compounds in 18 participants with cirrhosis. None of the included participants had hepatic encephalopathy
Zeegen 1970 Case series describes the effects of treatment with lactulose in 5 participants with cirrhosis and overt hepatic
encephalopathy
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Characteristics of ongoing studies [ordered by study ID]
Salih 2007
Trial name or title Lactulose for the prevention of hepatic encephalopathy in participants with cirrhosis and upper gastroin-
testinal haemorrhage
Methods Randomised clinical trial
Participants Participants with cirrhosis
Interventions Lactulose versus placebo
Outcomes Hepatic encephalopathy
Starting date 2007
Contact information Aga Kahn University
Trial registration number NCT00553423
Notes Investigators contacted via email October 2014. No reply
Wang 2012
Trial name or title Impact of lactulose treatment on cognition, assessment of quality of life and changes of intestinal flora
in minimal hepatic encephalopathy participants: a multicentre, randomised, open-label and controlled
clinical study
Methods Randomised clinical trial
Participants Cirrhosis and minimal hepatic encephalopathy
Interventions Lactulose versus no intervention
Outcomes Recovery from minimal hepatic encephalopathy
Starting date 2012
Contact information Zhong Shan Hospital, Shanghai, China
Trial registration number ChiCTR-TRC-12002342
Notes Investigators contacted via email October 2014 and reported that the final analyses will take place in
October 2014
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D A T A A N D A N A L Y S E S
Comparison 1. Non-absorbable disaccharides versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 24 1487 Risk Ratio (IV, Random, 95% CI) 0.59 [0.40, 0.87]
2 Mortality in trials with a low risk
of bias
8 705 Risk Ratio (IV, Random, 95% CI) 0.63 [0.41, 0.97]
3 Hepatic encephalopathy 22 1415 Risk Ratio (IV, Random, 95% CI) 0.58 [0.50, 0.69]
4 Serious adverse events 24 1487 Risk Ratio (IV, Random, 95% CI) 0.47 [0.36, 0.60]
5 Quality of life: sickness impact
profile
3 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Change from baseline 2 120 Mean Difference (IV, Random, 95% CI) 7.18 [5.28, 9.07]
5.2 End of treatment 1 40 Mean Difference (IV, Random, 95% CI) 0.90 [-4.13, 5.93]
6 Non-serious adverse events 9 Risk Ratio (IV, Random, 95% CI) Subtotals only
6.1 Overall 9 739 Risk Ratio (IV, Random, 95% CI) 2.47 [1.24, 4.93]
6.2 Diarrhoea 7 634 Risk Ratio (IV, Random, 95% CI) 6.41 [1.84, 22.40]
6.3 Bloating 6 563 Risk Ratio (IV, Random, 95% CI) 4.50 [1.17, 17.27]
6.4 Nausea 1 60 Risk Ratio (IV, Random, 95% CI) 11.00 [0.64, 190.53]
6.5 Constipation 2 298 Risk Ratio (IV, Random, 95% CI) 0.04 [0.01, 0.29]
6.6 Hyponatraemia 1 45 Risk Ratio (IV, Random, 95% CI) 0.35 [0.01, 8.11]
6.7 Anal fissure 1 45 Risk Ratio (IV, Random, 95% CI) 0.35 [0.01, 8.11]
6.8 Hyperglycaemia 1 45 Risk Ratio (IV, Random, 95% CI) 0.35 [0.01, 8.11]
7 Number connection test, end of
treatment
6 275 Mean Difference (IV, Random, 95% CI) -5.56 [-11.59, 0.47]
8 Ammonia end of treatment 6 374 Mean Difference (IV, Random, 95% CI) -11.64 [-21.14, -2.
14]
8.1 Venous 5 216 Mean Difference (IV, Random, 95% CI) -15.66 [-27.79, -3.
53]
8.2 Arterial 1 158 Mean Difference (IV, Random, 95% CI) -2.23 [-6.89, 2.43]
9 Ammonia change from baseline 3 155 Mean Difference (IV, Random, 95% CI) 18.97 [8.86, 29.09]
9.1 Arterial 2 134 Mean Difference (IV, Random, 95% CI) 10.45 [5.60, 15.31]
9.2 Venous 1 21 Mean Difference (IV, Random, 95% CI) 44.0 [32.34, 55.66]
10 Mortality in worst-case scenario
analyses
24 Risk Ratio (IV, Random, 95% CI) Subtotals only
10.1 Worst-case scenario 24 1487 Risk Ratio (IV, Random, 95% CI) 0.61 [0.42, 0.88]
10.2 Extreme worst-case
scenario analysis
24 1487 Risk Ratio (IV, Random, 95% CI) 0.64 [0.44, 0.94]
11 Hepatic encephalopathy
worst-case scenario analysis
22 2830 Risk Ratio (IV, Random, 95% CI) 0.60 [0.54, 0.66]
11.1 Worst-case scenario 22 1415 Risk Ratio (IV, Random, 95% CI) 0.59 [0.50, 0.69]
11.2 Extreme worst-case
scenario
22 1415 Risk Ratio (IV, Random, 95% CI) 0.60 [0.51, 0.70]
12 Serious adverse events
worst-case scenario analysis
24 2974 Risk Ratio (IV, Random, 95% CI) 0.48 [0.41, 0.57]
12.1 Worst-case scenario
analysis
24 1487 Risk Ratio (IV, Random, 95% CI) 0.47 [0.37, 0.61]
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12.2 Extreme worst-case
scenario analysis
24 1487 Risk Ratio (IV, Random, 95% CI) 0.49 [0.38, 0.62]
Comparison 2. Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 6 668 Risk Ratio (IV, Random, 95% CI) 0.63 [0.40, 0.98]
1.1 Primary 4 370 Risk Ratio (IV, Random, 95% CI) 0.56 [0.27, 1.17]
1.2 Secondary 2 298 Risk Ratio (IV, Random, 95% CI) 0.67 [0.39, 1.16]
2 Mortality and bias control 6 668 Risk Ratio (IV, Random, 95% CI) 0.63 [0.40, 0.98]
2.1 Low risk of bias 5 538 Risk Ratio (IV, Random, 95% CI) 0.64 [0.41, 0.99]
2.2 High risk of bias 1 130 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.03]
3 Hepatic encephalopathy 6 668 Risk Ratio (IV, Random, 95% CI) 0.47 [0.33, 0.68]
3.1 Primary 4 370 Risk Ratio (IV, Random, 95% CI) 0.48 [0.23, 0.98]
3.2 Secondary 2 298 Risk Ratio (IV, Random, 95% CI) 0.44 [0.31, 0.64]
4 Serious adverse events 6 668 Risk Ratio (IV, Random, 95% CI) 0.48 [0.33, 0.70]
4.1 Primary prevention 4 370 Risk Ratio (IV, Random, 95% CI) 0.50 [0.24, 1.03]
4.2 Secondary prevention 2 298 Risk Ratio (IV, Random, 95% CI) 0.44 [0.31, 0.64]
5 Non-serious adverse events 4 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 3. Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 18 819 Risk Ratio (IV, Random, 95% CI) 0.49 [0.23, 1.05]
1.1 Overt 6 172 Risk Ratio (IV, Random, 95% CI) 0.36 [0.14, 0.94]
1.2 Minimal 12 647 Risk Ratio (IV, Random, 95% CI) 0.82 [0.24, 2.86]
2 Mortality in trials with a low risk
of bias
18 819 Risk Ratio (IV, Random, 95% CI) 0.49 [0.23, 1.05]
2.1 Low risk of bias 3 167 Risk Ratio (IV, Random, 95% CI) 0.56 [0.12, 2.68]
2.2 High risk of bias 15 652 Risk Ratio (IV, Random, 95% CI) 0.47 [0.20, 1.13]
3 Mortality in acute or chronic
hepatic encephalopathy
6 172 Risk Ratio (IV, Random, 95% CI) 0.36 [0.14, 0.94]
3.1 Acute 3 102 Risk Ratio (IV, Random, 95% CI) 0.36 [0.14, 0.94]
3.2 Chronic 3 70 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Hepatic encephalopathy 16 747 Risk Ratio (IV, Random, 95% CI) 0.63 [0.53, 0.74]
4.1 Overt 5 140 Risk Ratio (IV, Random, 95% CI) 0.62 [0.39, 0.99]
4.2 Minimal 11 607 Risk Ratio (IV, Random, 95% CI) 0.63 [0.52, 0.76]
5 Acute or chronic hepatic
encephalopathy
5 140 Risk Ratio (IV, Random, 95% CI) 0.62 [0.39, 0.99]
5.1 Acute 3 102 Risk Ratio (IV, Random, 95% CI) 0.59 [0.34, 1.00]
5.2 Chronic 2 38 Risk Ratio (IV, Random, 95% CI) 0.55 [0.07, 4.10]
6 Serious adverse events 18 819 Risk Ratio (IV, Random, 95% CI) 0.42 [0.26, 0.69]
6.1 Overt 6 172 Risk Ratio (IV, Random, 95% CI) 0.40 [0.16, 1.02]
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6.2 Minimal 12 647 Risk Ratio (IV, Random, 95% CI) 0.43 [0.24, 0.78]
7 Serious adverse events in acute or
chronic hepatic encephalopathy
6 172 Risk Ratio (IV, Random, 95% CI) 0.40 [0.16, 1.02]
7.1 Acute 3 102 Risk Ratio (IV, Random, 95% CI) 0.40 [0.16, 1.02]
7.2 Chronic 3 70 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Non-serious adverse events 5 191 Risk Ratio (IV, Random, 95% CI) 2.12 [0.62, 7.28]
Comparison 4. Lactulose versus lactitol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 8 225 Risk Ratio (IV, Random, 95% CI) 1.30 [0.59, 2.85]
1.1 Overt hepatic
encephalopathy
6 174 Risk Ratio (IV, Random, 95% CI) 1.30 [0.59, 2.85]
1.2 Minimal hepatic
encephalopathy
1 20 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Prevention of hepatic
encephalopathy
1 31 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Hepatic encephalopathy 7 194 Risk Ratio (IV, Random, 95% CI) 1.00 [0.84, 1.19]
2.1 Overt hepatic
encephalopathy
5 162 Risk Ratio (IV, Random, 95% CI) 1.08 [0.60, 1.96]
2.2 Minimal hepatic
encephalopathy
1 20 Risk Ratio (IV, Random, 95% CI) 1.0 [0.83, 1.20]
2.3 Prevention hepatic
encephalopathy
1 12 Risk Ratio (IV, Random, 95% CI) 0.20 [0.01, 3.46]
3 Serious adverse events 9 245 Risk Ratio (IV, Random, 95% CI) 1.56 [0.84, 2.88]
4 Non-serious adverse events 6 Risk Ratio (IV, Random, 95% CI) Subtotals only
4.1 Overall 6 169 Risk Ratio (IV, Random, 95% CI) 1.55 [0.88, 2.74]
4.2 Diarrhoea 3 61 Risk Ratio (IV, Random, 95% CI) 0.80 [0.39, 1.64]
4.3 Bloating and flatulence 4 128 Risk Ratio (IV, Random, 95% CI) 2.20 [1.06, 4.54]
4.4 Nausea 4 104 Risk Ratio (IV, Random, 95% CI) 3.20 [0.76, 13.43]
4.5 Hyponatraemia 1 25 Risk Ratio (IV, Random, 95% CI) 3.23 [0.14, 72.46]
4.6 Abdominal pain 3 91 Risk Ratio (IV, Random, 95% CI) 0.95 [0.47, 1.91]
4.7 Asthenia 1 31 Risk Ratio (IV, Random, 95% CI) 0.35 [0.02, 8.08]
5 Number Connection Test: end
of treatment
4 84 Mean Difference (IV, Random, 95% CI) -4.22 [-16.12, 7.68]
6 Number Connection Test:
change from baseline
1 25 Mean Difference (IV, Random, 95% CI) 0.20 [-0.54, 0.94]
7 Venous blood ammonia: end of
treatment
3 72 Mean Difference (IV, Random, 95% CI) 6.47 [-8.36, 21.29]
8 Venous blood ammonia: change
from baseline
1 25 Mean Difference (IV, Random, 95% CI) -0.20 [-0.80, 0.40]
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Analysis 1.1. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 1
Mortality.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 1 Mortality
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Agrawal 2012 13/80 16/78 33.4 % 0.79 [ 0.41, 1.54 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 1/12 2.8 % 1.71 [ 0.18, 16.65 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 2.0 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 0/40 1/40 1.5 % 0.33 [ 0.01, 7.95 ]
Prasad 2007 0/31 3/30 1.7 % 0.14 [ 0.01, 2.57 ]
Quero 1997 1/20 0/20 1.5 % 3.00 [ 0.13, 69.52 ]
Raza 2004 1/18 2/13 2.8 % 0.36 [ 0.04, 3.57 ]
Riggio 2005 2/25 1/25 2.7 % 2.00 [ 0.19, 20.67 ]
Sharma 2009 5/70 11/70 14.5 % 0.45 [ 0.17, 1.24 ]
Sharma 2011 3/35 6/35 8.6 % 0.50 [ 0.14, 1.84 ]
Sharma 2012 5/60 10/60 14.3 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 11.0 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 1.8 % 0.12 [ 0.01, 2.04 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 0/65 1/65 1.4 % 0.33 [ 0.01, 8.03 ]
Xing 2003 0/23 0/22 Not estimable
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 0/40 0/20 Not estimable
Ziada 2013 0/30 0/30 Not estimable
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 768 719 100.0 % 0.59 [ 0.40, 0.87 ]
Total events: 36 (Disaccharide), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.16, df = 13 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 2
Mortality in trials with a low risk of bias.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 2 Mortality in trials with a low risk of bias
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Sharma 2011 3/35 6/35 10.8 % 0.50 [ 0.14, 1.84 ]
Dhiman 2000 2/14 1/12 3.6 % 1.71 [ 0.18, 16.65 ]
Sharma 2012 5/60 10/60 18.0 % 0.50 [ 0.18, 1.38 ]
Mittal 2011 0/40 1/40 1.8 % 0.33 [ 0.01, 7.95 ]
Sharma 2009 5/70 11/70 18.3 % 0.45 [ 0.17, 1.24 ]
Riggio 2005 2/25 1/25 3.4 % 2.00 [ 0.19, 20.67 ]
Prasad 2007 0/31 3/30 2.2 % 0.14 [ 0.01, 2.57 ]
Agrawal 2012 13/80 16/78 42.0 % 0.79 [ 0.41, 1.54 ]
Total (95% CI) 355 350 100.0 % 0.63 [ 0.41, 0.97 ]
Total events: 30 (Disaccharide), 49 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.06, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 3
Hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 3 Hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Agrawal 2012 18/80 37/78 7.2 % 0.47 [ 0.30, 0.76 ]
Dhiman 2000 6/14 12/12 5.3 % 0.45 [ 0.25, 0.81 ]
Germain 1973 4/9 3/9 1.7 % 1.33 [ 0.41, 4.33 ]
Horsmans 1997 6/7 6/7 8.0 % 1.00 [ 0.65, 1.53 ]
Jain 2013 2/30 2/30 0.7 % 1.00 [ 0.15, 6.64 ]
Li 1999 22/48 28/38 9.4 % 0.62 [ 0.43, 0.89 ]
Mittal 2011 21/40 36/40 10.7 % 0.58 [ 0.43, 0.80 ]
Prasad 2007 6/31 20/30 3.6 % 0.29 [ 0.14, 0.62 ]
Quero 1997 0/20 1/20 0.3 % 0.33 [ 0.01, 7.72 ]
Raza 2004 7/18 8/13 4.0 % 0.63 [ 0.31, 1.30 ]
Riggio 2005 9/25 8/25 3.6 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 5.4 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 2.7 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 6/60 14/60 2.8 % 0.43 [ 0.18, 1.04 ]
Simmons 1970 4/14 5/12 2.1 % 0.69 [ 0.24, 1.99 ]
Uribe 1987a 3/22 8/23 1.7 % 0.39 [ 0.12, 1.29 ]
Uribe 1987b 1/10 6/10 0.7 % 0.17 [ 0.02, 1.14 ]
Watanabe 1997 13/41 12/34 4.8 % 0.90 [ 0.47, 1.70 ]
Wen 2013 2/65 11/65 1.2 % 0.18 [ 0.04, 0.79 ]
Xing 2003 11/23 22/22 8.1 % 0.49 [ 0.32, 0.75 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Zeng 2003 7/40 8/20 3.0 % 0.44 [ 0.18, 1.03 ]
Ziada 2013 22/30 29/30 13.1 % 0.76 [ 0.61, 0.95 ]
Total (95% CI) 732 683 100.0 % 0.58 [ 0.50, 0.69 ]
Total events: 187 (Disaccharide), 320 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 30.96, df = 21 (P = 0.07); I2 =32%
Test for overall effect: Z = 6.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 4
Serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 4 Serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Agrawal 2012 18/80 37/78 28.6 % 0.47 [ 0.30, 0.76 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 3/12 2.4 % 0.57 [ 0.11, 2.87 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 0.8 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 1/40 4/40 1.4 % 0.25 [ 0.03, 2.14 ]
Prasad 2007 1/31 5/30 1.4 % 0.19 [ 0.02, 1.56 ]
Quero 1997 1/20 0/20 0.6 % 3.00 [ 0.13, 69.52 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Raza 2004 1/18 2/13 1.2 % 0.36 [ 0.04, 3.57 ]
Riggio 2005 9/25 8/25 10.5 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 18.6 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 7.6 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 5/60 10/60 6.1 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 4.7 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 1/22 3/23 1.3 % 0.35 [ 0.04, 3.10 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 2/65 11/65 2.9 % 0.18 [ 0.04, 0.79 ]
Xing 2003 0/23 2/22 0.7 % 0.19 [ 0.01, 3.78 ]
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 7/40 8/20 8.5 % 0.44 [ 0.18, 1.03 ]
Ziada 2013 2/30 5/30 2.6 % 0.40 [ 0.08, 1.90 ]
Total (95% CI) 768 719 100.0 % 0.47 [ 0.36, 0.60 ]
Total events: 71 (Disaccharide), 149 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.43, df = 16 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 5.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 5
Quality of life: sickness impact profile.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 5 Quality of life: sickness impact profile
Study or subgroup Disaccharide Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Change from baseline
Mittal 2011 35 11.64 (5.5) 31 2.87 (6.5) 26.8 % 8.77 [ 5.84, 11.70 ]
Prasad 2007 25 6.81 (0.8) 29 0.22 (0.15) 73.2 % 6.59 [ 6.27, 6.91 ]
Subtotal (95% CI) 60 60 100.0 % 7.18 [ 5.28, 9.07 ]
Heterogeneity: Tau2 = 1.25; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 7.43 (P < 0.00001)
2 End of treatment
Quero 1997 19 8.3 (9) 21 7.4 (7) 100.0 % 0.90 [ -4.13, 5.93 ]
Subtotal (95% CI) 19 21 100.0 % 0.90 [ -4.13, 5.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
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Analysis 1.6. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 6 Non-
serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 6 Non-serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overall
Agrawal 2012 29/80 10/78 20.3 % 2.83 [ 1.48, 5.40 ]
Horsmans 1997 3/7 0/7 4.9 % 7.00 [ 0.43, 114.70 ]
McClain 1984 4/16 1/16 7.6 % 4.00 [ 0.50, 31.98 ]
Quero 1997 13/20 14/20 22.6 % 0.93 [ 0.60, 1.43 ]
Sharma 2009 20/70 10/70 19.9 % 2.00 [ 1.01, 3.96 ]
Sharma 2012 16/60 0/60 4.9 % 33.00 [ 2.02, 537.82 ]
Uribe 1987a 1/22 3/23 7.1 % 0.35 [ 0.04, 3.10 ]
Wen 2013 2/65 0/65 4.3 % 5.00 [ 0.24, 102.16 ]
Ziada 2013 12/30 1/30 8.2 % 12.00 [ 1.66, 86.59 ]
Subtotal (95% CI) 370 369 100.0 % 2.47 [ 1.24, 4.93 ]
Total events: 100 (Disaccharide), 39 (Control)
Heterogeneity: Tau2 = 0.50; Chi2 = 22.24, df = 8 (P = 0.004); I2 =64%
Test for overall effect: Z = 2.56 (P = 0.010)
2 Diarrhoea
Agrawal 2012 18/80 0/78 12.0 % 36.09 [ 2.21, 588.62 ]
Horsmans 1997 3/7 0/7 12.0 % 7.00 [ 0.43, 114.70 ]
McClain 1984 4/16 1/16 16.4 % 4.00 [ 0.50, 31.98 ]
Quero 1997 5/20 5/20 24.6 % 1.00 [ 0.34, 2.93 ]
Sharma 2009 14/70 0/70 12.0 % 29.00 [ 1.76, 476.86 ]
Sharma 2012 12/60 0/60 12.0 % 25.00 [ 1.51, 412.90 ]
Wen 2013 2/65 0/65 10.9 % 5.00 [ 0.24, 102.16 ]
Subtotal (95% CI) 318 316 100.0 % 6.41 [ 1.84, 22.40 ]
Total events: 58 (Disaccharide), 6 (Control)
Heterogeneity: Tau2 = 1.35; Chi2 = 12.27, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 2.91 (P = 0.0036)
3 Bloating
Agrawal 2012 11/80 0/78 13.4 % 22.43 [ 1.34, 374.24 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Quero 1997 8/20 9/20 29.9 % 0.89 [ 0.43, 1.83 ]
Sharma 2009 6/70 0/70 13.2 % 13.00 [ 0.75, 226.45 ]
Sharma 2012 4/60 0/60 13.0 % 9.00 [ 0.50, 163.58 ]
Uribe 1987a 1/22 0/23 11.7 % 3.13 [ 0.13, 72.99 ]
Ziada 2013 7/30 1/30 18.7 % 7.00 [ 0.92, 53.47 ]
Subtotal (95% CI) 282 281 100.0 % 4.50 [ 1.17, 17.27 ]
Total events: 37 (Disaccharide), 10 (Control)
Heterogeneity: Tau2 = 1.44; Chi2 = 11.53, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 2.19 (P = 0.028)
4 Nausea
Ziada 2013 5/30 0/30 100.0 % 11.00 [ 0.64, 190.53 ]
Subtotal (95% CI) 30 30 100.0 % 11.00 [ 0.64, 190.53 ]
Total events: 5 (Disaccharide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
5 Constipation
Agrawal 2012 0/80 14/78 50.3 % 0.03 [ 0.00, 0.55 ]
Sharma 2009 0/70 10/70 49.7 % 0.05 [ 0.00, 0.80 ]
Subtotal (95% CI) 150 148 100.0 % 0.04 [ 0.01, 0.29 ]
Total events: 0 (Disaccharide), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
6 Hyponatraemia
Uribe 1987a 0/22 1/23 100.0 % 0.35 [ 0.01, 8.11 ]
Subtotal (95% CI) 22 23 100.0 % 0.35 [ 0.01, 8.11 ]
Total events: 0 (Disaccharide), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
7 Anal fissure
Uribe 1987a 0/22 1/23 100.0 % 0.35 [ 0.01, 8.11 ]
Subtotal (95% CI) 22 23 100.0 % 0.35 [ 0.01, 8.11 ]
Total events: 0 (Disaccharide), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
8 Hyperglycaemia
Uribe 1987a 0/22 1/23 100.0 % 0.35 [ 0.01, 8.11 ]
Subtotal (95% CI) 22 23 100.0 % 0.35 [ 0.01, 8.11 ]
Total events: 0 (Disaccharide), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 1.7. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 7
Number connection test, end of treatment.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 7 Number connection test, end of treatment
Study or subgroup Disaccharide Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Horsmans 1997 7 3.81 (0.94) 7 5.14 (3.21) 36.6 % -1.33 [ -3.81, 1.15 ]
Quero 1997 19 28.3 (11) 21 30 (4.8) 29.8 % -1.70 [ -7.06, 3.66 ]
Sharma 2012 57 47.7 (25.2) 56 58.4 (32.1) 17.6 % -10.70 [ -21.35, -0.05 ]
Uribe 1987a 5 114 (56) 23 154 (60) 1.2 % -40.00 [ -94.87, 14.87 ]
Yao 2014 20 88.55 (21.27) 20 95.65 (24.34) 12.4 % -7.10 [ -21.27, 7.07 ]
Zeng 2003 20 59 (37) 20 112 (75) 2.5 % -53.00 [ -89.65, -16.35 ]
Total (95% CI) 128 147 100.0 % -5.56 [ -11.59, 0.47 ]
Heterogeneity: Tau2 = 24.28; Chi2 = 12.61, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 1.81 (P = 0.071)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 8
Ammonia end of treatment.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 8 Ammonia end of treatment
Study or subgroup Disaccharide Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Venous
Corazza 1982 16 62.12 (8.99) 16 77.31 (6.11) 25.8 % -15.19 [ -20.52, -9.86 ]
Riggio 2005 25 125 (12.7) 25 126.4 (17.8) 22.9 % -1.40 [ -9.97, 7.17 ]
Uribe 1987a 22 146 (54) 23 170 (73) 5.2 % -24.00 [ -61.41, 13.41 ]
Zeng 2003 20 121 (61) 20 208 (110) 2.7 % -87.00 [ -142.13, -31.87 ]
Ziada 2013 24 55.64 (28.1) 25 74.54 (23.33) 17.0 % -18.90 [ -33.39, -4.41 ]
Subtotal (95% CI) 107 109 73.7 % -15.66 [ -27.79, -3.53 ]
Heterogeneity: Tau2 = 106.89; Chi2 = 15.55, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Arterial
Agrawal 2012 80 82.97 (12.9) 78 85.2 (16.7) 26.3 % -2.23 [ -6.89, 2.43 ]
Subtotal (95% CI) 80 78 26.3 % -2.23 [ -6.89, 2.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 187 187 100.0 % -11.64 [ -21.14, -2.14 ]
Heterogeneity: Tau2 = 83.49; Chi2 = 25.92, df = 5 (P = 0.00009); I2 =81%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 4.10, df = 1 (P = 0.04), I2 =76%
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Analysis 1.9. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 9
Ammonia change from baseline.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 9 Ammonia change from baseline
Study or subgroup Disaccharide Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Arterial
Jain 2013 27 26 (6.95) 27 13.1 (2.75) 37.4 % 12.90 [ 10.08, 15.72 ]
Mittal 2011 40 8.47 (5.8) 40 0.52 (7.8) 37.2 % 7.95 [ 4.94, 10.96 ]
Subtotal (95% CI) 67 67 74.5 % 10.45 [ 5.60, 15.31 ]
Heterogeneity: Tau2 = 10.04; Chi2 = 5.53, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 Venous
Simmons 1970 11 55 (6.7) 10 11 (17.7) 25.5 % 44.00 [ 32.34, 55.66 ]
Subtotal (95% CI) 11 10 25.5 % 44.00 [ 32.34, 55.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.39 (P < 0.00001)
Total (95% CI) 78 77 100.0 % 18.97 [ 8.86, 29.09 ]
Heterogeneity: Tau2 = 69.24; Chi2 = 36.10, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Chi2 = 27.09, df = 1 (P = 0.00), I2 =96%
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Analysis 1.10. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 10
Mortality in worst-case scenario analyses.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 10 Mortality in worst-case scenario analyses
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Worst-case scenario
Agrawal 2012 13/80 16/78 30.6 % 0.79 [ 0.41, 1.54 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 1/12 2.6 % 1.71 [ 0.18, 16.65 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 1.8 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 0/40 1/40 1.3 % 0.33 [ 0.01, 7.95 ]
Prasad 2007 0/31 3/30 1.6 % 0.14 [ 0.01, 2.57 ]
Quero 1997 1/20 0/20 1.4 % 3.00 [ 0.13, 69.52 ]
Raza 2004 2/18 3/13 5.0 % 0.48 [ 0.09, 2.48 ]
Riggio 2005 2/25 1/25 2.5 % 2.00 [ 0.19, 20.67 ]
Sharma 2009 5/70 11/70 13.3 % 0.45 [ 0.17, 1.24 ]
Sharma 2011 3/35 6/35 7.9 % 0.50 [ 0.14, 1.84 ]
Sharma 2012 5/60 10/60 13.1 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 10.1 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 1.6 % 0.12 [ 0.01, 2.04 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 3/65 3/65 5.5 % 1.00 [ 0.21, 4.77 ]
Xing 2003 0/23 0/22 Not estimable
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 1/40 1/20 1.8 % 0.50 [ 0.03, 7.59 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ziada 2013 0/30 0/30 Not estimable
Subtotal (95% CI) 768 719 100.0 % 0.61 [ 0.42, 0.88 ]
Total events: 41 (Disaccharide), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.33, df = 14 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
2 Extreme worst-case scenario analysis
Agrawal 2012 13/80 16/78 31.9 % 0.79 [ 0.41, 1.54 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 1/12 2.7 % 1.71 [ 0.18, 16.65 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 1.9 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 0/40 1/40 1.4 % 0.33 [ 0.01, 7.95 ]
Prasad 2007 0/31 3/30 1.6 % 0.14 [ 0.01, 2.57 ]
Quero 1997 1/20 0/20 1.4 % 3.00 [ 0.13, 69.52 ]
Raza 2004 2/18 2/13 4.2 % 0.72 [ 0.12, 4.48 ]
Riggio 2005 2/25 1/25 2.6 % 2.00 [ 0.19, 20.67 ]
Sharma 2009 5/70 11/70 13.9 % 0.45 [ 0.17, 1.24 ]
Sharma 2011 3/35 6/35 8.2 % 0.50 [ 0.14, 1.84 ]
Sharma 2012 5/60 10/60 13.7 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 10.6 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 1.7 % 0.12 [ 0.01, 2.04 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 3/65 1/65 2.8 % 3.00 [ 0.32, 28.09 ]
Xing 2003 0/23 0/22 Not estimable
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 1/40 0/20 1.4 % 1.54 [ 0.07, 36.11 ]
Ziada 2013 0/30 0/30 Not estimable
Subtotal (95% CI) 768 719 100.0 % 0.64 [ 0.44, 0.94 ]
Total events: 41 (Disaccharide), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.07, df = 14 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 1.11. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 11
Hepatic encephalopathy worst-case scenario analysis.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 11 Hepatic encephalopathy worst-case scenario analysis
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Worst-case scenario
Agrawal 2012 18/80 37/78 3.5 % 0.47 [ 0.30, 0.76 ]
Dhiman 2000 6/14 12/12 2.5 % 0.45 [ 0.25, 0.81 ]
Germain 1973 4/9 3/9 0.8 % 1.33 [ 0.41, 4.33 ]
Horsmans 1997 6/7 6/7 3.9 % 1.00 [ 0.65, 1.53 ]
Jain 2013 2/30 2/30 0.3 % 1.00 [ 0.15, 6.64 ]
Li 1999 22/48 28/38 4.8 % 0.62 [ 0.43, 0.89 ]
Mittal 2011 21/40 36/40 5.6 % 0.58 [ 0.43, 0.80 ]
Prasad 2007 6/31 20/30 1.7 % 0.29 [ 0.14, 0.62 ]
Quero 1997 0/20 1/20 0.1 % 0.33 [ 0.01, 7.72 ]
Raza 2004 8/18 9/13 2.3 % 0.64 [ 0.34, 1.21 ]
Riggio 2005 9/25 8/25 1.6 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 2.6 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 1.2 % 0.36 [ 0.14, 0.88 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Sharma 2012 6/60 14/60 1.3 % 0.43 [ 0.18, 1.04 ]
Simmons 1970 4/14 5/12 0.9 % 0.69 [ 0.24, 1.99 ]
Uribe 1987a 3/22 8/23 0.7 % 0.39 [ 0.12, 1.29 ]
Uribe 1987b 1/10 6/10 0.3 % 0.17 [ 0.02, 1.14 ]
Watanabe 1997 13/41 12/34 2.2 % 0.90 [ 0.47, 1.70 ]
Wen 2013 5/65 13/65 1.1 % 0.38 [ 0.15, 1.02 ]
Xing 2003 11/23 22/22 4.0 % 0.49 [ 0.32, 0.75 ]
Zeng 2003 8/40 9/20 1.6 % 0.44 [ 0.20, 0.98 ]
Ziada 2013 22/30 29/30 7.3 % 0.76 [ 0.61, 0.95 ]
Subtotal (95% CI) 732 683 50.2 % 0.59 [ 0.50, 0.69 ]
Total events: 192 (Disaccharide), 324 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 29.27, df = 21 (P = 0.11); I2 =28%
Test for overall effect: Z = 6.68 (P < 0.00001)
2 Extreme worst-case scenario
Agrawal 2012 18/80 37/78 3.5 % 0.47 [ 0.30, 0.76 ]
Dhiman 2000 6/14 12/12 2.5 % 0.45 [ 0.25, 0.81 ]
Germain 1973 4/9 3/9 0.8 % 1.33 [ 0.41, 4.33 ]
Horsmans 1997 6/7 6/7 3.9 % 1.00 [ 0.65, 1.53 ]
Jain 2013 2/30 2/30 0.3 % 1.00 [ 0.15, 6.64 ]
Li 1999 22/48 28/38 4.8 % 0.62 [ 0.43, 0.89 ]
Mittal 2011 21/40 36/40 5.6 % 0.58 [ 0.43, 0.80 ]
Prasad 2007 6/31 20/30 1.7 % 0.29 [ 0.14, 0.62 ]
Quero 1997 0/20 1/20 0.1 % 0.33 [ 0.01, 7.72 ]
Raza 2004 8/18 8/13 2.0 % 0.72 [ 0.37, 1.41 ]
Riggio 2005 9/25 8/25 1.6 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 2.6 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 1.2 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 6/60 14/60 1.3 % 0.43 [ 0.18, 1.04 ]
Simmons 1970 4/14 5/12 0.9 % 0.69 [ 0.24, 1.99 ]
Uribe 1987a 3/22 8/23 0.7 % 0.39 [ 0.12, 1.29 ]
Uribe 1987b 1/10 6/10 0.3 % 0.17 [ 0.02, 1.14 ]
Watanabe 1997 13/41 12/34 2.2 % 0.90 [ 0.47, 1.70 ]
Wen 2013 5/65 11/65 1.0 % 0.45 [ 0.17, 1.24 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Xing 2003 11/23 22/22 4.0 % 0.49 [ 0.32, 0.75 ]
Zeng 2003 8/40 8/20 1.5 % 0.50 [ 0.22, 1.14 ]
Ziada 2013 22/30 29/30 7.3 % 0.76 [ 0.61, 0.95 ]
Subtotal (95% CI) 732 683 49.8 % 0.60 [ 0.51, 0.70 ]
Total events: 192 (Disaccharide), 320 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 28.47, df = 21 (P = 0.13); I2 =26%
Test for overall effect: Z = 6.59 (P < 0.00001)
Total (95% CI) 1464 1366 100.0 % 0.60 [ 0.54, 0.66 ]
Total events: 384 (Disaccharide), 644 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 57.75, df = 43 (P = 0.07); I2 =26%
Test for overall effect: Z = 9.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.12. Comparison 1 Non-absorbable disaccharides versus placebo/no intervention, Outcome 12
Serious adverse events worst-case scenario analysis.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 1 Non-absorbable disaccharides versus placebo/no intervention
Outcome: 12 Serious adverse events worst-case scenario analysis
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Worst-case scenario analysis
Agrawal 2012 18/80 37/78 13.5 % 0.47 [ 0.30, 0.76 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 3/12 1.1 % 0.57 [ 0.11, 2.87 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 0.4 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 1/40 4/40 0.6 % 0.25 [ 0.03, 2.14 ]
Prasad 2007 1/31 5/30 0.7 % 0.19 [ 0.02, 1.56 ]
Quero 1997 1/20 0/20 0.3 % 3.00 [ 0.13, 69.52 ]
Raza 2004 2/18 3/13 1.1 % 0.48 [ 0.09, 2.48 ]
Riggio 2005 9/25 8/25 5.0 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 8.8 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 3.6 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 5/60 10/60 2.9 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 2.2 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 1/22 3/23 0.6 % 0.35 [ 0.04, 3.10 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 5/65 13/65 3.1 % 0.38 [ 0.15, 1.02 ]
Xing 2003 0/23 2/22 0.3 % 0.19 [ 0.01, 3.78 ]
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 8/40 9/20 4.8 % 0.44 [ 0.20, 0.98 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ziada 2013 2/30 5/30 1.2 % 0.40 [ 0.08, 1.90 ]
Subtotal (95% CI) 768 719 50.4 % 0.47 [ 0.37, 0.61 ]
Total events: 76 (Disaccharide), 153 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.92, df = 16 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 6.01 (P < 0.00001)
2 Extreme worst-case scenario analysis
Agrawal 2012 18/80 37/78 13.5 % 0.47 [ 0.30, 0.76 ]
Corazza 1982 0/16 0/16 Not estimable
Dhiman 2000 2/14 3/12 1.1 % 0.57 [ 0.11, 2.87 ]
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 0.4 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 1/40 4/40 0.6 % 0.25 [ 0.03, 2.14 ]
Prasad 2007 1/31 5/30 0.7 % 0.19 [ 0.02, 1.56 ]
Quero 1997 1/20 0/20 0.3 % 3.00 [ 0.13, 69.52 ]
Raza 2004 2/18 2/13 0.9 % 0.72 [ 0.12, 4.48 ]
Riggio 2005 9/25 8/25 5.0 % 1.13 [ 0.52, 2.44 ]
Sharma 2009 12/70 30/70 8.8 % 0.40 [ 0.22, 0.72 ]
Sharma 2011 5/35 14/35 3.6 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 5/60 10/60 2.9 % 0.50 [ 0.18, 1.38 ]
Simmons 1970 3/14 6/12 2.2 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 1/22 3/23 0.6 % 0.35 [ 0.04, 3.10 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Wen 2013 5/65 11/65 3.0 % 0.45 [ 0.17, 1.24 ]
Xing 2003 0/23 2/22 0.3 % 0.19 [ 0.01, 3.78 ]
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 8/40 8/20 4.4 % 0.50 [ 0.22, 1.14 ]
Ziada 2013 2/30 5/30 1.2 % 0.40 [ 0.08, 1.90 ]
Subtotal (95% CI) 768 719 49.6 % 0.49 [ 0.38, 0.62 ]
Total events: 76 (Disaccharide), 149 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.88, df = 16 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 1536 1438 100.0 % 0.48 [ 0.41, 0.57 ]
Total events: 152 (Disaccharide), 302 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.82, df = 33 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 8.30 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 2.1. Comparison 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 1 Mortality.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 1 Mortality
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Primary
Sharma 2011 3/35 6/35 11.5 % 0.50 [ 0.14, 1.84 ]
Sharma 2012 5/60 10/60 19.1 % 0.50 [ 0.18, 1.38 ]
Riggio 2005 2/25 1/25 3.6 % 2.00 [ 0.19, 20.67 ]
Wen 2013 0/65 1/65 1.9 % 0.33 [ 0.01, 8.03 ]
Subtotal (95% CI) 185 185 36.1 % 0.56 [ 0.27, 1.17 ]
Total events: 10 (Disaccharide), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Secondary
Sharma 2009 5/70 11/70 19.4 % 0.45 [ 0.17, 1.24 ]
Agrawal 2012 13/80 16/78 44.6 % 0.79 [ 0.41, 1.54 ]
Subtotal (95% CI) 150 148 63.9 % 0.67 [ 0.39, 1.16 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 18 (Disaccharide), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Total (95% CI) 335 333 100.0 % 0.63 [ 0.40, 0.98 ]
Total events: 28 (Disaccharide), 45 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.28, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 2.2. Comparison 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 2 Mortality and bias control.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 2 Mortality and bias control
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Sharma 2012 5/60 10/60 19.1 % 0.50 [ 0.18, 1.38 ]
Riggio 2005 2/25 1/25 3.6 % 2.00 [ 0.19, 20.67 ]
Sharma 2009 5/70 11/70 19.4 % 0.45 [ 0.17, 1.24 ]
Sharma 2011 3/35 6/35 11.5 % 0.50 [ 0.14, 1.84 ]
Agrawal 2012 13/80 16/78 44.6 % 0.79 [ 0.41, 1.54 ]
Subtotal (95% CI) 270 268 98.1 % 0.64 [ 0.41, 0.99 ]
Total events: 28 (Disaccharide), 44 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.12, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
2 High risk of bias
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Wen 2013 0/65 1/65 1.9 % 0.33 [ 0.01, 8.03 ]
Subtotal (95% CI) 65 65 1.9 % 0.33 [ 0.01, 8.03 ]
Total events: 0 (Disaccharide), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 335 333 100.0 % 0.63 [ 0.40, 0.98 ]
Total events: 28 (Disaccharide), 45 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.28, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.3. Comparison 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 3 Hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 3 Hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Primary
Riggio 2005 9/25 8/25 16.0 % 1.13 [ 0.52, 2.44 ]
Sharma 2011 5/35 14/35 12.6 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 6/60 14/60 13.1 % 0.43 [ 0.18, 1.04 ]
Wen 2013 2/65 11/65 5.6 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 185 185 47.4 % 0.48 [ 0.23, 0.98 ]
Total events: 22 (Disaccharide), 47 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 6.62, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 2.02 (P = 0.043)
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
2 Secondary
Agrawal 2012 18/80 37/78 29.3 % 0.47 [ 0.30, 0.76 ]
Sharma 2009 12/70 30/70 23.3 % 0.40 [ 0.22, 0.72 ]
Subtotal (95% CI) 150 148 52.6 % 0.44 [ 0.31, 0.64 ]
Total events: 30 (Disaccharide), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
Total (95% CI) 335 333 100.0 % 0.47 [ 0.33, 0.68 ]
Total events: 52 (Disaccharide), 114 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.18, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 4.02 (P = 0.000059)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 2.4. Comparison 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 4 Serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 4 Serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Riggio 2005 9/25 8/25 16.4 % 1.13 [ 0.52, 2.44 ]
Sharma 2011 5/35 14/35 13.0 % 0.36 [ 0.14, 0.88 ]
Sharma 2012 5/60 10/60 10.9 % 0.50 [ 0.18, 1.38 ]
Wen 2013 2/65 11/65 5.8 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 185 185 46.1 % 0.50 [ 0.24, 1.03 ]
Total events: 21 (Disaccharide), 43 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 6.37, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 1.88 (P = 0.060)
2 Secondary prevention
Agrawal 2012 18/80 37/78 30.0 % 0.47 [ 0.30, 0.76 ]
Sharma 2009 12/70 30/70 23.9 % 0.40 [ 0.22, 0.72 ]
Subtotal (95% CI) 150 148 53.9 % 0.44 [ 0.31, 0.64 ]
Total events: 30 (Disaccharide), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
Total (95% CI) 335 333 100.0 % 0.48 [ 0.33, 0.70 ]
Total events: 51 (Disaccharide), 110 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.12, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 3.86 (P = 0.00011)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 2.5. Comparison 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 5 Non-serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 2 Prevention trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 5 Non-serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Agrawal 2012 29/80 10/78 2.83 [ 1.48, 5.40 ]
Sharma 2009 20/70 10/70 2.00 [ 1.01, 3.96 ]
Sharma 2012 16/60 0/60 33.00 [ 2.02, 537.82 ]
Wen 2013 2/65 0/65 5.00 [ 0.24, 102.16 ]
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Analysis 3.1. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 1 Mortality.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 1 Mortality
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overt
Corazza 1982 0/16 0/16 Not estimable
Germain 1973 0/9 0/9 Not estimable
Raza 2004 1/18 2/13 11.1 % 0.36 [ 0.04, 3.57 ]
Simmons 1970 3/14 6/12 44.0 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 7.1 % 0.12 [ 0.01, 2.04 ]
Uribe 1987b 0/10 0/10 Not estimable
Subtotal (95% CI) 89 83 62.3 % 0.36 [ 0.14, 0.94 ]
Total events: 4 (Disaccharide), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Minimal
Dhiman 2000 2/14 1/12 11.3 % 1.71 [ 0.18, 16.65 ]
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 7.9 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 0/40 1/40 5.8 % 0.33 [ 0.01, 7.95 ]
Prasad 2007 0/31 3/30 6.8 % 0.14 [ 0.01, 2.57 ]
Quero 1997 1/20 0/20 5.9 % 3.00 [ 0.13, 69.52 ]
Watanabe 1997 0/41 0/34 Not estimable
Xing 2003 0/23 0/22 Not estimable
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 0/40 0/20 Not estimable
Ziada 2013 0/30 0/30 Not estimable
Subtotal (95% CI) 344 303 37.7 % 0.82 [ 0.24, 2.86 ]
Total events: 4 (Disaccharide), 6 (Control)
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 433 386 100.0 % 0.49 [ 0.23, 1.05 ]
Total events: 8 (Disaccharide), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.57, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Chi2 = 1.07, df = 1 (P = 0.30), I2 =7%
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Analysis 3.2. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 2 Mortality in trials with a low risk of bias.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 2 Mortality in trials with a low risk of bias
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Dhiman 2000 2/14 1/12 11.3 % 1.71 [ 0.18, 16.65 ]
Mittal 2011 0/40 1/40 5.8 % 0.33 [ 0.01, 7.95 ]
Prasad 2007 0/31 3/30 6.8 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 85 82 24.0 % 0.56 [ 0.12, 2.68 ]
Total events: 2 (Disaccharide), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 High risk of bias
Corazza 1982 0/16 0/16 Not estimable
Germain 1973 0/9 0/9 Not estimable
Horsmans 1997 0/7 0/7 Not estimable
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Jain 2013 1/30 1/30 7.9 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Quero 1997 1/20 0/20 5.9 % 3.00 [ 0.13, 69.52 ]
Raza 2004 1/18 2/13 11.1 % 0.36 [ 0.04, 3.57 ]
Simmons 1970 3/14 6/12 44.0 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 7.1 % 0.12 [ 0.01, 2.04 ]
Uribe 1987b 0/10 0/10 Not estimable
Watanabe 1997 0/41 0/34 Not estimable
Xing 2003 0/23 0/22 Not estimable
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 0/40 0/20 Not estimable
Ziada 2013 0/30 0/30 Not estimable
Subtotal (95% CI) 348 304 76.0 % 0.47 [ 0.20, 1.13 ]
Total events: 6 (Disaccharide), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Total (95% CI) 433 386 100.0 % 0.49 [ 0.23, 1.05 ]
Total events: 8 (Disaccharide), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.57, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 3.3. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 3 Mortality in acute or chronic hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 3 Mortality in acute or chronic hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute
Raza 2004 1/18 2/13 17.9 % 0.36 [ 0.04, 3.57 ]
Simmons 1970 3/14 6/12 70.7 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 0/22 4/23 11.4 % 0.12 [ 0.01, 2.04 ]
Subtotal (95% CI) 54 48 100.0 % 0.36 [ 0.14, 0.94 ]
Total events: 4 (Disaccharide), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Chronic
Corazza 1982 0/16 0/16 Not estimable
Germain 1973 0/9 0/9 Not estimable
Uribe 1987b 0/10 0/10 Not estimable
Subtotal (95% CI) 35 35 Not estimable
Total events: 0 (Disaccharide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 89 83 100.0 % 0.36 [ 0.14, 0.94 ]
Total events: 4 (Disaccharide), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 4 Hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 4 Hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overt
Germain 1973 4/9 3/9 1.9 % 1.33 [ 0.41, 4.33 ]
Raza 2004 7/18 8/13 4.6 % 0.63 [ 0.31, 1.30 ]
Simmons 1970 4/14 5/12 2.3 % 0.69 [ 0.24, 1.99 ]
Uribe 1987a 3/22 8/23 1.9 % 0.39 [ 0.12, 1.29 ]
Uribe 1987b 1/10 6/10 0.8 % 0.17 [ 0.02, 1.14 ]
Subtotal (95% CI) 73 67 11.5 % 0.62 [ 0.39, 0.99 ]
Total events: 19 (Disaccharide), 30 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.01, df = 4 (P = 0.40); I2 =0%
Test for overall effect: Z = 1.98 (P = 0.047)
2 Minimal
Dhiman 2000 6/14 12/12 6.5 % 0.45 [ 0.25, 0.81 ]
Horsmans 1997 6/7 6/7 10.3 % 1.00 [ 0.65, 1.53 ]
Jain 2013 2/30 2/30 0.8 % 1.00 [ 0.15, 6.64 ]
Li 1999 22/48 28/38 12.6 % 0.62 [ 0.43, 0.89 ]
Mittal 2011 21/40 36/40 14.8 % 0.58 [ 0.43, 0.80 ]
Prasad 2007 6/31 20/30 4.2 % 0.29 [ 0.14, 0.62 ]
Quero 1997 0/20 1/20 0.3 % 0.33 [ 0.01, 7.72 ]
Watanabe 1997 13/41 12/34 5.7 % 0.90 [ 0.47, 1.70 ]
Xing 2003 11/23 22/22 10.5 % 0.49 [ 0.32, 0.75 ]
Zeng 2003 7/40 8/20 3.4 % 0.44 [ 0.18, 1.03 ]
Ziada 2013 22/30 29/30 19.5 % 0.76 [ 0.61, 0.95 ]
Subtotal (95% CI) 324 283 88.5 % 0.63 [ 0.52, 0.76 ]
Total events: 116 (Disaccharide), 176 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 15.90, df = 10 (P = 0.10); I2 =37%
Test for overall effect: Z = 4.81 (P < 0.00001)
Total (95% CI) 397 350 100.0 % 0.63 [ 0.53, 0.74 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 135 (Disaccharide), 206 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 19.95, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 3.5. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 5 Acute or chronic hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 5 Acute or chronic hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute
Raza 2004 7/18 8/13 42.6 % 0.63 [ 0.31, 1.30 ]
Simmons 1970 4/14 5/12 19.6 % 0.69 [ 0.24, 1.99 ]
Uribe 1987a 3/22 8/23 15.7 % 0.39 [ 0.12, 1.29 ]
Subtotal (95% CI) 54 48 77.9 % 0.59 [ 0.34, 1.00 ]
Total events: 14 (Disaccharide), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Chronic
Germain 1973 4/9 3/9 16.1 % 1.33 [ 0.41, 4.33 ]
Uribe 1987b 1/10 6/10 6.0 % 0.17 [ 0.02, 1.14 ]
Subtotal (95% CI) 19 19 22.1 % 0.55 [ 0.07, 4.10 ]
Total events: 5 (Disaccharide), 9 (Control)
Heterogeneity: Tau2 = 1.50; Chi2 = 3.26, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.59 (P = 0.56)
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 73 67 100.0 % 0.62 [ 0.39, 0.99 ]
Total events: 19 (Disaccharide), 30 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.01, df = 4 (P = 0.40); I2 =0%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 3.6. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 6 Serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 6 Serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overt
Corazza 1982 0/16 0/16 Not estimable
Germain 1973 0/9 0/9 Not estimable
Raza 2004 1/18 2/13 4.7 % 0.36 [ 0.04, 3.57 ]
Simmons 1970 3/14 6/12 18.4 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 1/22 3/23 5.1 % 0.35 [ 0.04, 3.10 ]
Uribe 1987b 0/10 0/10 Not estimable
Subtotal (95% CI) 89 83 28.2 % 0.40 [ 0.16, 1.02 ]
Total events: 5 (Disaccharide), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
2 Minimal
Dhiman 2000 2/14 3/12 9.4 % 0.57 [ 0.11, 2.87 ]
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Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Horsmans 1997 0/7 0/7 Not estimable
Jain 2013 1/30 1/30 3.3 % 1.00 [ 0.07, 15.26 ]
Li 1999 0/48 0/38 Not estimable
Mittal 2011 1/40 4/40 5.3 % 0.25 [ 0.03, 2.14 ]
Prasad 2007 1/31 5/30 5.6 % 0.19 [ 0.02, 1.56 ]
Quero 1997 1/20 0/20 2.5 % 3.00 [ 0.13, 69.52 ]
Watanabe 1997 0/41 0/34 Not estimable
Xing 2003 0/23 2/22 2.7 % 0.19 [ 0.01, 3.78 ]
Yao 2014 0/20 0/20 Not estimable
Zeng 2003 7/40 8/20 33.0 % 0.44 [ 0.18, 1.03 ]
Ziada 2013 2/30 5/30 10.0 % 0.40 [ 0.08, 1.90 ]
Subtotal (95% CI) 344 303 71.8 % 0.43 [ 0.24, 0.78 ]
Total events: 15 (Disaccharide), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.05, df = 7 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0049)
Total (95% CI) 433 386 100.0 % 0.42 [ 0.26, 0.69 ]
Total events: 20 (Disaccharide), 39 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.11, df = 10 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 3.7. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 7 Serious adverse events in acute or chronic hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 7 Serious adverse events in acute or chronic hepatic encephalopathy
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute
Raza 2004 1/18 2/13 16.5 % 0.36 [ 0.04, 3.57 ]
Simmons 1970 3/14 6/12 65.4 % 0.43 [ 0.14, 1.36 ]
Uribe 1987a 1/22 3/23 18.1 % 0.35 [ 0.04, 3.10 ]
Subtotal (95% CI) 54 48 100.0 % 0.40 [ 0.16, 1.02 ]
Total events: 5 (Disaccharide), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
2 Chronic
Corazza 1982 0/16 0/16 Not estimable
Germain 1973 0/9 0/9 Not estimable
Uribe 1987b 0/10 0/10 Not estimable
Subtotal (95% CI) 35 35 Not estimable
Total events: 0 (Disaccharide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 89 83 100.0 % 0.40 [ 0.16, 1.02 ]
Total events: 5 (Disaccharide), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention,
Outcome 8 Non-serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 3 Treatment trials: non-absorbable disaccharides versus placebo/no intervention
Outcome: 8 Non-serious adverse events
Study or subgroup Disaccharide Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Horsmans 1997 3/7 0/7 12.6 % 7.00 [ 0.43, 114.70 ]
McClain 1984 4/16 1/16 17.7 % 4.00 [ 0.50, 31.98 ]
Quero 1997 13/20 14/20 34.2 % 0.93 [ 0.60, 1.43 ]
Uribe 1987a 1/22 3/23 16.8 % 0.35 [ 0.04, 3.10 ]
Ziada 2013 12/30 1/30 18.6 % 12.00 [ 1.66, 86.59 ]
Total (95% CI) 95 96 100.0 % 2.12 [ 0.62, 7.28 ]
Total events: 33 (Disaccharide), 19 (Control)
Heterogeneity: Tau2 = 1.11; Chi2 = 10.44, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Lactulose versus lactitol, Outcome 1 Mortality.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 1 Mortality
Study or subgroup Lactulose Lactitol Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overt hepatic encephalopathy
Grandi 1991 0/20 0/20 Not estimable
Heredia 1987 4/20 3/20 33.2 % 1.33 [ 0.34, 5.21 ]
Jankovic 1996 2/9 1/7 12.9 % 1.56 [ 0.17, 13.87 ]
Morgan 1987a 4/12 4/13 47.2 % 1.08 [ 0.35, 3.40 ]
Morgan 1987b 1/6 0/6 6.7 % 3.00 [ 0.15, 61.74 ]
Pai 1995 0/20 0/21 Not estimable
Subtotal (95% CI) 87 87 100.0 % 1.30 [ 0.59, 2.85 ]
Total events: 11 (Lactulose), 8 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Minimal hepatic encephalopathy
Morgan 1989 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Lactulose), 0 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Prevention of hepatic encephalopathy
Riggio 1989 0/15 0/16 Not estimable
Subtotal (95% CI) 15 16 Not estimable
Total events: 0 (Lactulose), 0 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 112 113 100.0 % 1.30 [ 0.59, 2.85 ]
Total events: 11 (Lactulose), 8 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Lactulose versus lactitol, Outcome 2 Hepatic encephalopathy.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 2 Hepatic encephalopathy
Study or subgroup Lactulose Lactitol Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overt hepatic encephalopathy
Grandi 1991 5/20 4/20 2.3 % 1.25 [ 0.39, 3.99 ]
Heredia 1987 4/20 3/20 1.6 % 1.33 [ 0.34, 5.21 ]
Morgan 1987a 4/12 5/13 2.7 % 0.87 [ 0.30, 2.49 ]
Morgan 1987b 0/6 0/6 Not estimable
Pai 1995 4/22 4/23 1.9 % 1.05 [ 0.30, 3.67 ]
Subtotal (95% CI) 80 82 8.5 % 1.08 [ 0.60, 1.96 ]
Total events: 17 (Lactulose), 16 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
2 Minimal hepatic encephalopathy
Morgan 1989 10/10 10/10 91.1 % 1.00 [ 0.83, 1.20 ]
Subtotal (95% CI) 10 10 91.1 % 1.00 [ 0.83, 1.20 ]
Total events: 10 (Lactulose), 10 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Prevention hepatic encephalopathy
Riggio 1989 0/6 2/6 0.4 % 0.20 [ 0.01, 3.46 ]
Subtotal (95% CI) 6 6 0.4 % 0.20 [ 0.01, 3.46 ]
Total events: 0 (Lactulose), 2 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 96 98 100.0 % 1.00 [ 0.84, 1.19 ]
Total events: 27 (Lactulose), 28 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.61, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 1.29, df = 2 (P = 0.52), I2 =0.0%
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Analysis 4.3. Comparison 4 Lactulose versus lactitol, Outcome 3 Serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 3 Serious adverse events
Study or subgroup Lactulose Lactitol Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Grandi 1991 0/20 0/20 Not estimable
Heredia 1987 4/20 3/20 20.3 % 1.33 [ 0.34, 5.21 ]
Heredia 1988 0/10 0/10 Not estimable
Jankovic 1996 2/9 1/7 7.9 % 1.56 [ 0.17, 13.87 ]
Morgan 1987a 4/12 1/13 9.0 % 4.33 [ 0.56, 33.53 ]
Morgan 1987b 1/6 0/6 4.1 % 3.00 [ 0.15, 61.74 ]
Morgan 1989 0/10 0/10 Not estimable
Pai 1995 4/20 4/21 24.4 % 1.05 [ 0.30, 3.64 ]
Riggio 1989 6/15 4/16 34.2 % 1.60 [ 0.56, 4.58 ]
Total (95% CI) 122 123 100.0 % 1.56 [ 0.84, 2.88 ]
Total events: 21 (Lactulose), 13 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.58, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Lactulose versus lactitol, Outcome 4 Non-serious adverse events.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 4 Non-serious adverse events
Study or subgroup Lactulose Lactitol Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Overall
Grandi 1991 7/20 7/20 24.4 % 1.00 [ 0.43, 2.33 ]
Jankovic 1996 2/9 1/7 6.0 % 1.56 [ 0.17, 13.87 ]
Morgan 1987a 4/12 6/13 20.2 % 0.72 [ 0.27, 1.95 ]
Morgan 1989 10/10 5/10 33.0 % 1.91 [ 1.04, 3.50 ]
Pai 1995 6/18 0/19 3.8 % 13.68 [ 0.83, 226.63 ]
Riggio 1989 7/15 2/16 12.5 % 3.73 [ 0.92, 15.21 ]
Subtotal (95% CI) 84 85 100.0 % 1.55 [ 0.88, 2.74 ]
Total events: 36 (Lactulose), 21 (Lactitol)
Heterogeneity: Tau2 = 0.16; Chi2 = 7.58, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Diarrhoea
Jankovic 1996 2/9 1/7 11.0 % 1.56 [ 0.17, 13.87 ]
Morgan 1987a 4/12 6/13 53.3 % 0.72 [ 0.27, 1.95 ]
Morgan 1989 3/10 4/10 35.7 % 0.75 [ 0.22, 2.52 ]
Subtotal (95% CI) 31 30 100.0 % 0.80 [ 0.39, 1.64 ]
Total events: 9 (Lactulose), 11 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
3 Bloating and flatulence
Grandi 1991 7/20 5/20 34.0 % 1.40 [ 0.53, 3.68 ]
Morgan 1989 10/10 5/10 53.6 % 1.91 [ 1.04, 3.50 ]
Pai 1995 6/18 0/19 6.2 % 13.68 [ 0.83, 226.63 ]
Riggio 1989 6/15 0/16 6.2 % 13.81 [ 0.84, 225.84 ]
Subtotal (95% CI) 63 65 100.0 % 2.20 [ 1.06, 4.54 ]
Total events: 29 (Lactulose), 10 (Lactitol)
Heterogeneity: Tau2 = 0.16; Chi2 = 4.19, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 2.13 (P = 0.033)
4 Nausea
Jankovic 1996 2/9 0/7 24.6 % 4.00 [ 0.22, 72.01 ]
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(. . . Continued)
Study or subgroup Lactulose Lactitol Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Morgan 1989 1/10 0/10 21.5 % 3.00 [ 0.14, 65.90 ]
Pai 1995 4/18 0/19 25.2 % 9.47 [ 0.55, 164.35 ]
Riggio 1989 1/15 1/16 28.6 % 1.07 [ 0.07, 15.57 ]
Subtotal (95% CI) 52 52 100.0 % 3.20 [ 0.76, 13.43 ]
Total events: 8 (Lactulose), 1 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
5 Hyponatraemia
Morgan 1987a 1/12 0/13 100.0 % 3.23 [ 0.14, 72.46 ]
Subtotal (95% CI) 12 13 100.0 % 3.23 [ 0.14, 72.46 ]
Total events: 1 (Lactulose), 0 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
6 Abdominal pain
Grandi 1991 7/20 7/20 68.0 % 1.00 [ 0.43, 2.33 ]
Morgan 1989 3/10 3/10 27.1 % 1.00 [ 0.26, 3.81 ]
Riggio 1989 0/15 1/16 5.0 % 0.35 [ 0.02, 8.08 ]
Subtotal (95% CI) 45 46 100.0 % 0.95 [ 0.47, 1.91 ]
Total events: 10 (Lactulose), 11 (Lactitol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.88)
7 Asthenia
Riggio 1989 0/15 1/16 100.0 % 0.35 [ 0.02, 8.08 ]
Subtotal (95% CI) 15 16 100.0 % 0.35 [ 0.02, 8.08 ]
Total events: 0 (Lactulose), 1 (Lactitol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
0.01 0.1 1 10 100
Favours lactulose Favours lactitol
149Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic
encephalopathy in people with cirrhosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 Lactulose versus lactitol, Outcome 5 Number Connection Test: end of
treatment.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 5 Number Connection Test: end of treatment
Study or subgroup Lactulose Lactitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heredia 1987 20 226 (161) 20 196 (139) 1.6 % 30.00 [ -63.22, 123.22 ]
Jankovic 1996 5 150 (60) 7 180 (40) 3.9 % -30.00 [ -90.36, 30.36 ]
Morgan 1987b 6 32.7 (13.1) 6 37.3 (18.1) 44.3 % -4.60 [ -22.48, 13.28 ]
Morgan 1989 10 33.9 (18.3) 10 36.9 (20) 50.2 % -3.00 [ -19.80, 13.80 ]
Total (95% CI) 41 43 100.0 % -4.22 [ -16.12, 7.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Lactulose versus lactitol, Outcome 6 Number Connection Test: change from
baseline.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 6 Number Connection Test: change from baseline
Study or subgroup Lactulose Lactitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Morgan 1987a 12 1.6 (0.9) 13 1.4 (1) 100.0 % 0.20 [ -0.54, 0.94 ]
Total (95% CI) 12 13 100.0 % 0.20 [ -0.54, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Lactulose versus lactitol, Outcome 7 Venous blood ammonia: end of treatment.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 7 Venous blood ammonia: end of treatment
Study or subgroup Lactulose Lactitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heredia 1987 20 155.4 (21) 20 149.7 (32) 78.1 % 5.70 [ -11.07, 22.47 ]
Heredia 1988 10 152.09 (141.76) 10 140.66 (200.65) 0.9 % 11.43 [ -140.84, 163.70 ]
Morgan 1987b 6 64.7 (26.6) 6 55.6 (30.5) 21.0 % 9.10 [ -23.28, 41.48 ]
Total (95% CI) 36 36 100.0 % 6.47 [ -8.36, 21.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Lactulose versus lactitol, Outcome 8 Venous blood ammonia: change from
baseline.
Review: Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people
with cirrhosis
Comparison: 4 Lactulose versus lactitol
Outcome: 8 Venous blood ammonia: change from baseline
Study or subgroup Lactulose Lactitol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Morgan 1987a 12 0.7 (0.6) 13 0.9 (0.9) 100.0 % -0.20 [ -0.80, 0.40 ]
Total (95% CI) 12 13 100.0 % -0.20 [ -0.80, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Definitions and assessment of overt hepatic encephalopathy with corresponding recommended definitions in the
EASL/AASLD guidelines
Trial Definition in trial publication Definition based on classification
in EASL/AASLD guidelines
Assessment of hepatic
encephalopathy
Elkington 1969 Chronic persistent hepatic
encephalopathy
Persistent Mental status assessed using Parsons-
Smith criteria
Arterial blood ammonia concentra-
tions
Electroencephalogram
Simmons 1970 Acute, acute remittent, and chronic
remittent hepatic encephalopathy
Episodic (81%)
Recurrent (19%)
Mental status assessed on a scale sim-
ilar to but more extensive than the
West Haven Criteria
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Table 1. Definitions and assessment of overt hepatic encephalopathy with corresponding recommended definitions in the
EASL/AASLD guidelines (Continued)
Venous blood ammonia concentra-
tions
Brown 1971 Chronic persistent hepatic
encephalopathy
Persistent Mental status
Blood ammonia concentrations
Electroencephalogram*
Germain 1973 Chronic persistent hepatic
encephalopathy
Persistent Mental status assessed using Parson-
Smith criteria
Psychometric tests
Venous blood ammonia concentra-
tions
Electroencephalogram
Rodgers 1973 Chronic persistent hepatic
encephalopathy
Persistent Clinical assessment of mental status
Blood ammonia concentrations
Electroencephalogram*
Corazza 1982 Chronic persistent hepatic
encephalopathy
Persistent Encephalopathy Intensity Score
Plasma ammonia concentrations
Heredia 1987 Acute hepatic encephalopathy Episodic/recurrent Conn score
Number Connection Test
Blood ammonia concentrations
Electroencephalogram
Morgan 1987a Acute hepatic encephalopathy Episodic Portal Systemic Encephalopathy
Sum and Index
Morgan 1987b Chronic persistent hepatic
encephalopathy
Persistent Portal Systemic Encephalopathy
Sum and Index
Uribe 1987a Acute hepatic encephalopathy Episodic Portal Systemic Encephalopathy
Sum and Index
Uribe 1987b Chronic persistent hepatic
encephalopathy
Persistent Portal Systemic Encephalopathy
Sum and Index
Heredia 1988 Chronic recurrent hepatic
encephalopathy
Persistent Portal Systemic Encephalopathy
Sum and Index*
Grandi 1991 Chronic hepatic encephalopathy Persistent Portal
Systemic Encephalopathy Sum and
Index modified by omitting the elec-
troencephalogram
Pai 1995 Acute hepatic encephalopathy Episodic Portal Systemic Encephalopathy
Sum and Index
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Table 1. Definitions and assessment of overt hepatic encephalopathy with corresponding recommended definitions in the
EASL/AASLD guidelines (Continued)
Jankovic 1996 Acute hepatic encephalopathy Episodic Mental status using West Haven cri-
teria
Number connection Test A
Electroencephalogram*
Raza 2004 Acute hepatic encephalopathy Episodic Clinical scoring
Modified Portal Systemic En-
cephalopathy Sum and Index with
electroencephalogram omitted and
Digit Symbol test replacing Number
Connection Test A
*The trial is not included in the analysis of hepatic encephalopathy, because we were unable to extract data on the number of participants
with (or without) an overall improvement.
Table 2. Liver-related serious adverse events
Event Non-absorbable disaccharides Placebo/no intervention
Variceal bleeding 19/438 (4%) 17/336 (5%)
Hepatorenal syndrome 10/196 (5%) 7/153 (5%)
Spontaneous bacterial peritonitis 10/140 (7%) 16/138 (12%)
Liver failure 9/189 (5%) 7/117 (6%)
The overall risk of serious adverse events is analysed as one of the primary outcomes.
Table 3. Quero 1996: Sickness Impact Profile selected subscores
End of treatment Control (n = 21) Lactulose (n = 19)
Mean Standard deviation Mean Standard deviation
Psychological subscore 8.0 11 10.9 14
Physical subscore 2.8 4 4.8 6
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Table 4. Prasad 2007: Sickness Impact Profile selected subscores
Change from baseline Control (n = 20) Lactulose (n = 25)
Mean Standard deviation Mean Standard deviation
Psychosocial scales
Social interactions 0.5 0.68 8.5 1.35
Alertness -0.75 1.13 10.43 1.73
Emotional behaviour 2.76 1.83 8.98 1.55
Communication 0.75 1.19 2.66 1.22
Total psychological sub-
score
0.77 0.41 8.47 0.98
Physical scales
Ambulation -1.89 1.12 3.67 0.80
Mobility 1.22 1.18 5.36 1.35
Body care and move-
ments
0.72 0.42 1.62 0.55
Total physical subscore 0.01 0.52 2.99 0.56
Independent scales
Sleep and rest 2.29 1.35 9.04 1.95
Work -0.06 1.44 15.83 4.45
Home management 0.94 1.19 12.64 2.71
Recreation and pastimes -0.28 1.11 11.59 1.97
Eating -0.56 1.31 3.88 1.21
Table 5. Mittal 2009: Sickness Impact Profile selected subscores
Change from baseline Control (n = 31) Lactulose (n = 35)
Mean Standard deviation Mean Standard deviation
Subscores
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Table 5. Mittal 2009: Sickness Impact Profile selected subscores (Continued)
Sleep and rest 2.87 6.5 11.64 5.5
Emotional behaviour 0.40 4.1 9.84 4.8
Body care and move-
ments
-0.38 1.9 3.20 2.4
Home management -0.25 5.7 6.34 5.20
Mobility 0.59 5.5 4.64 4.3
Social interaction 1.63 3.2 3.88 2.8
Alertness 0.18 2.4 3.63 2.2
Ambulation -0.18 2.9 5.10 4.2
Communication 0.80 3.3 2.07 5.1
Work 0.64 2.5 9.46 15.7
Recreation and pastime 3.06 4.4 7.74 5.7
Eating 1.12 3.1 2.48 3.1
Psychosocial 1.13 2.4 5.17 2.9
Physical -0.05 2.0 3.59 2.1
Table 6. Zeng 2003: WHO-Bref selected subscores
End of treat-
ment
Control (n = 20) Short term lactulose (n = 20) Long-term lactulose (n = 20)
Mean Standard devia-
tion
Mean Standard devia-
tion
Mean Standard devia-
tion
Physical health 28 19 37 18 54 19
Psychological
health
42 14 44 15 58 15
Social relation-
ships
38 16 42 15 60 17
Environment 51 18 53 15 51 13
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A P P E N D I C E S
Appendix 1. Search strategy
Database Time span Search terms
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
October 2015 (disaccharid* or lactulos* or lactitol*) AND (encephalopath*
OR liver disease* OR cirrho*)
Cochrane Central Register of Controlled
Trials (CENTRAL)
Issue 10 of 12, 2015 #1 MeSH descriptor: [Disaccharides] explode all trees
#2 MeSH descriptor: [Lactulose] explode all trees
#3 disaccharid* or lactulos* or lactitol*
#4 #1 or #2 or #3
#5 MeSH descriptor: [Hepatic Encephalopathy] explode all
trees
#6 MeSH descriptor: [Liver Diseases] explode all trees
#7 MeSH descriptor: [Fibrosis] explode all trees
#8 encephalopath* or liver disease* or cirrho*
#9 #5 or #6 or #7 or #8
#10 #4 and #9
MEDLINE (Ovid SP) 1946 to October 2015 1. exp Disaccharides/
2. exp Lactulose/
3. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, ab-
stract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary con-
cept, rare disease supplementary concept, unique identifier]
4. 1 or 2 or 3
5. exp Hepatic Encephalopathy/
6. exp Liver Diseases/
7. exp Fibrosis/
8. (encephalopath* or liver disease* or cirrho*).mp. [mp=ti-
tle, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplemen-
tary concept, rare disease supplementary concept, unique iden-
tifier]
9. 5 or 6 or 7 or 8
10. 4 and 9
11. (random* or blind* or placebo* or meta-analysis).mp.
[mp=title, abstract, original title, name of substance word, sub-
ject heading word, keyword heading word, protocol supple-
mentary concept, rare disease supplementary concept, unique
identifier]
12. 10 and 11
Embase (Ovid SP) 1974 to October 2015 1. exp disaccharide/
2. exp lactulose/
3. exp lactitol/
4. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, ab-
stract, subject headings, heading word, drug trade name, origi-
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(Continued)
nal title, device manufacturer, drug manufacturer, device trade
name, keyword]
5. 1 or 2 or 3 or 4
6. exp hepatic encephalopathy/
7. exp liver disease/
8. exp fibrosis/
9. (encephalopath* or liver disease* or cirrho*).mp. [mp=title,
abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device
trade name, keyword]
10. 6 or 7 or 8 or 9
11. 5 and 10
12. (random* or blind* or placebo* ormeta-analys*).mp. [mp=
title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer,
device trade name, keyword]
13. 11 and 12
Science Citation Index Expanded (Web of
Science)
1900 to October 2015 5 #4 AND #3
4 TS=(random* or blind* or placebo* or meta-analysis)
3 #2 AND #1
2 TS=(encephalopath* or liver disease* or cirrho*)
1 TS=(disaccharid* or lactulos* or lactitol*)
WH A T ’ S N E W
Last assessed as up-to-date: 19 October 2015.
Date Event Description
19 April 2016 Amended Reference Gluud 2016 added to Other published
versions of this review.
28 February 2016 Amended Changes to the ’Risk of bias’ assessment: We updated
the ’Risk of bias’ assessment included in the latest ver-
sion of the review. The change included the addition
of the domains ’for-profit funding’ and ’overall bias as-
sessment’. We made the updates following the recom-
mendations in the Cochrane Hepato-Biliary Group
module
30 September 2015 New search has been performed The first version of this review, published in 2000, in-
cluded 10 randomised clinical trials (RCTs) evaluating
non-absorbable disaccharides versus placebo/no inter-
vention and eight RCTs evaluating lactulose versus lac-
titol. An update in 2004 did not identify additional
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(Continued)
RCTs. This updated review includes 38RCTs (29 eval-
uating non-absorbable disaccharides versus placebo/
no intervention and nine evaluating lactulose versus
lactitol). The methods of the review have been up-
dated in accordance with the recommendations made
in the Cochrane Handbook for Systematic Reviews of In-
terventions and the Cochrane Hepato-Biliary Group
module. The changes include updated trial searches
(the searches now include several trial registries), as-
sessment of bias control and statistical analyses (regres-
sion analyses of small study effects, meta-regression
analyses and Trial Sequential Analyses). The review in-
cludes ’Summary of findings’ tables
26 February 2015 New citation required and conclusions have changed The updated review found evidence that lactulose and
lactitol are associated with beneficial effects onmortal-
ity, hepatic encephalopathy, and serious adverse events
26 February 2015 New search has been performed We excluded RCTs evaluating antibiotics for people
with hepatic encephalopathy to avoid overlap with
another planned review (Kimer 2015). Hence, we
changed the review title ’Nonabsorbable disaccharides
for hepatic encephalopathy’ (Als-Nielsen 2000; Als-
Nielsen 2004a; Als-Nielsen 2004b; Als-Nielsen 2005)
to ’Non-absorbable disaccharides versus placebo/no
intervention and lactulose versus lactitol for the pre-
vention and treatment of hepatic encephalopathy in
people with cirrhosis’
C O N T R I B U T I O N S O F A U T H O R S
LLGluud drafted the revised review, identified and selected RCTs, contributed to the data extraction, analyses, and interpretation of the
results, and revised the review. H Vilstrup identified and selected RCTs, contributed to the data extraction, analyses, and interpretation
of the results, and revised the review. MY Morgan identified and selected RCTs, contributed to the data extraction, analyses, and
interpretation of the results, and revised the review.
All authors agreed to the publication of the review.
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D E C L A R A T I O N S O F I N T E R E S T
Lise L Gluud received payment for presentations given at scientific meetings sponsored by Norgine.
All review authors have conducted previous reviews on hepatic encephalopathy and two authors (Hendrik Vilstrup andMarshaMorgan)
have conducted RCTs on hepatic encephalopathy. These previous research activities are an academic bias based on the definitions given
in the Cochrane Hepato-Biliary Group module.
S O U R C E S O F S U P P O R T
Internal sources
• No funding received, Other.
External sources
• No funding received, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have revised the methods used in the original protocol and the previous version of this review (Als-Nielsen 2000; Als-Nielsen 2004a;
Als-Nielsen 2004b; Als-Nielsen 2005) with:
• exclusion of RCTs assessing non-absorbable disaccharides versus antibiotics;
• redefinition of primary and secondary outcomes (serious adverse events was previously a secondary outcome and is now a
primary outcome);
• revised assessment of bias control based on the Cochrane Hepato-Biliary Group module (Gluud 2015). The changes include the
addition of the domains missing outcome data; outcome reporting bias; other bias; for-profit funding; overall bias assessment.
• additional statistical analyses including regression analyses of small study effects; trial sequential analyses; worst-case scenario
analyses; random-effects meta-regression.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Disaccharides [adverse effects; ∗therapeutic use]; Hepatic Encephalopathy [∗drug therapy; mortality; ∗prevention & control]; Lactulose
[∗therapeutic use]; Liver Cirrhosis [∗complications]; Neomycin [therapeutic use]; Randomized Controlled Trials as Topic; Sugar
Alcohols [∗therapeutic use]; Watchful Waiting
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MeSH check words
Humans
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